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2Abstract
Phosphatidyl D-myo-inositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3] contributes to the
activation of protein kinase B (PKB) by interacting with the PKB PH domain. PKB is
known to be up-regulated in several cancer cell types. Compounds that can display
selective inhibition of this kinase have promising chemotherapeutic potential, and
inhibition of the PH domain of PKB represents a realistic means by which to achieve
this. Analysis of the X-ray crystal structures of apo PKBαPH and PKBαPH bound to D-
myo-inositol 1,3,4,5-tetrakisphosphate [InsP4, the inositol head group of PtdIns(3,4,5)P3]
led to the design of PtdIns(3,4,5)P3 and InsP4 analogues as potential PKB PH domain
inhibitors. The synthesis of PtdIns(3,4,5)P3 analogues modified at the C-4 position was
investigated, but it was discovered that such compounds were prone to migration of the
1-position phosphate. Subsequently, a range of racemic InsP4 analogues, modified at
the C-1 or C-4 position, were successfully synthesised. Advanced progress has also
been made towards the synthesis of enantiomerically pure analogues of InsP4.
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10
PtdIns phosphatidylinositol
PtdIns(3)P phosphatidylinositol (3)-phosphate
PtdIns(3,4)P2 phosphatidylinositol (3,4)-bisphosphate
PtdIns(3,4,5)P3 phosphatidylinositol (3,4,5)-trisphosphate
PtdIns(4)P phosphatidylinositol (4)-phosphate
PtdIns(4,5)P2 phosphatidylinositol (4,5)-bisphosphate
PTEN phosphatase and tensin homologue
PX PHOX
RT room temperature
Ser serine
SGK serum/glucocorticoid regulated kinase
SHIP 1/2 Src homology 2-containing inositol 5'-phosphatase 1 or 2
TBAF tetrabutylammonium fluoride
TBAI tetrabutylammonium iodide
THF tetrahydrofuran
Thr threonine
TIPS triisopropylsilyl
TLC thin layer chromatography
TMS tetramethyl silane
4-TsOH·H2O 4-toluenesulfonic acid monohydrate
VL variable loop
11
1. INTRODUCTION
1.1 Inositols: Structure, nomenclature and natural occurrence
In 1850 Scherer isolated from heart muscle an optically inactive cyclitol possessing an
empirical formula of a carbohydrate [Cn(H2O)n].1 This compound was termed “inosit”
after the Greek root inos, meaning “muscle”, and became known in English as “inositol”.
It is now understood that this was one of nine possible stereoisomers of hexahydroxy
cyclohexane (Figure 1.1), and is currently known as myo-inositol 1.
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Figure 1.1. The nine inositol stereoisomers.
As Figure 1.1 depicts, the stereoisomers myo-, allo-, cis-, epi-, scyllo-, neo- and muco-
inositol 1-7 all contain internal elements of symmetry and are therefore optically inactive.
L-(-)-Chiro-inositol 8 and D-(+)-chiro-inositol 9 are unsymmetrical and form an
enantiomeric pair. myo-Inositol, a meso compound, is by far the most naturally
abundant of the series, and is synthesised in both plants and animals from D-glucose-6-
phosphate. Therefore, often the term “inositol”, without the prefix, refers to myo-inositol
whereas “inositols” refers to all of the nine diastereomers.
The large number of inositols and their derivatives has caused much confusion in the
scientific literature in relation to nomenclature. myo-Inositol 1 is represented in its more
thermodynamically stable chair form with five equatorial hydroxyl groups and one axial
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hydroxyl. The carbon bearing the axial hydroxyl is designated C-2 (Figure 1.2), and the
other carbons on the ring can be numbered from C-1 to C-6 starting from a C-1 atom
either side of C-2 and proceeding either clockwise or anti-clockwise around the ring.
According to convention, an anti-clockwise numbering in an asymmetrically substituted
inositol leads to the D-configuration, while a clockwise numbering gives a substituted
inositol with an L-prefix. The choice of prefix would be derived by giving preference to
the lowest numbering of substituents. However, complications arise in multiply
substituted derivatives and, in particular, when a biological pathway is traversed,
confusing changes in nomenclature can occur. Consequently, an IUPAC
recommendation allowing all biologically relevant compounds to be denoted as D-
derivatives was proposed in 1989.2 This convention has largely been adhered to in the
literature since, and is adopted in this thesis. It is the function of these biologically
significant phosphorylated derivatives of myo-inositol, in particular the phospholipids,
that this research project is focussed on.
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Figure 1.2. The numbering of myo-inositol.
1.2 History of the inositol phosphates
1.2.1. Phospholipids and the Phosphoinositide effect
The function and regulation of the inositol phosphates has been of long standing interest
to the biologist and biochemist alike.3 Although Scherer’s discovery of myo-inositol was
as early as 1850, it was not until 1942 that Folch reported the discovery of inositol-
containing phospholipids in the brain.4 In 1953 Lowell and Mabel Hokin established that
acetylcholine stimulates the turnover of inositol-containing phospholipids in the pancreas
and brain cortex slices.5 This type of stimulus-response coupling was subsequently
observed in a number of other systems exposed to agonist stimulation, and became
13
known as the phosphoinositide (or “PI”) effect. By the late 1950s, new analytical
techniques allowed the separation of inositol-containing phospholipids, permitting the
isolation of phosphatidylinositol (PtdIns) 10, phosphatidylinositol (4)-phosphate
[PtdIns(4)P] 11, and phosphatidylinositol (4,5)-bisphosphate [PtdIns(4,5)P2]6 12 (Figure
1.3). The chemical structures of these compounds were soon established by Ballou and
co-workers.7 The structures of these intracellular, membrane-bound molecules are
essentially defined by a myo-inositol core, bearing a “phosphatidyl” moiety (i.e. a
phosphate ester bearing glycerol-linked, fatty chains) at the 1-position of the ring.
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12 PtdIns(4,5)P2: R1=H, R2 = R3 = PO32-
13 PtdIns(3)P: R1 = PO32-, R2 = R3 = H
14 PtdIns(3,4)P2: R1= R2 = PO32-, R3 = H
15 PtdIns(3,4,5)P3: R1 = R2 = R3 = PO32-
Figure 1.3. The major phosphatidylinositols and InsP3.
1.2.2. Inositol (1,4,5)-trisphosphate and Ca2+ release
Despite the observation of the so-called “PI effect”, little progress had been made in
understanding the physiological significance of the stimulated turnover of
phosphoinositides until a key breakthrough in 1975. Michell realised a connection
between agonist-stimulated phospholipid turnover and increased intracellular Ca2+
levels.8 However, the chemical link between these events was not known until Berridge
and co-workers published their findings on a seminal breakthrough in 1983.9 1D-myo-
Inositol (1,4,5)-trisphosphate (InsP3) 16 was correctly proposed to mobilise Ca2+ from
intracellular stores. Phospholipase C (PLC) hydrolyses PtdIns(4,5)P2 leading to the
accumulation of InsP3 and diacylglycerol (DAG) following activation of G-protein coupled
receptors (Figure 1.4). The lipophilic DAG remains bound to the cell membrane and
effects signal transduction by the activation of protein kinase C (PKC). InsP3, which is
hydrophilic, acts as a second messenger by diffusing into the cytoplasm and binding to
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InsP3 receptors which, upon activation, promote Ca2+ release from intracellular Ca2+
stores. This discovery helped stimulate even greater interest in the role of inositol
phosphates in signal transduction. Gradually, this resulted in the mapping out of a
complex metabolic pathway involving a large number of different phosphorylated
inositols,10,11 including higher inositol phosphates such as InsP6 and even the
pyrophosphate-containing InsP7 and InsP8.12 However, some years following Berridge’s
discovery of InsP3 as a second messenger, it became evident that several lipid-bound
phosphoinositides themselves may be considered as second messengers in their own
right.
Figure 1.4. Schematic representation of the InsP3 signalling cascade.13
1.2.3. PI3-Kinase and D3-phosphorylated inositol lipids
In 1988 Whitman et al. observed the phosphorylation of PtdIns 10 at the D3-position by a
phosphoinositide 3-kinase to give the novel phospholipid phosphatidylinositol (3)-
phosphate (PtdIns(3)P) 13.14 In the same year, Traynor-Kaplin et al. reported the
appearance of a novel phosphoinositide that contained four phosphates (a
phosphatidylinositol trisphosphate), which was found only in activated, and not in
unstimulated, human neutrophils.15 It was shown that in such neutrophils N-
formylmethionylleucylphenylanaline (FMLP) causes the rapid accumulation of the
trisphosphate, as well as a novel phospholipid bisphosphate. These compounds were
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thought to be phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3] 15 and
phosphatidylinositol (3,4)-bisphosphate [PtdIns(3,4)P2] 14 respectively; products of the
action of the phosphoinositide 3-kinase (PI3-K). Indeed, the enzyme responsible for
producing these lipids was later purified and shown to phosphorylate PtdIns(4)P and
PtdIns(4,5)P2 to produce PtdIns(3,4)P2 and PtdIns(3,4,5)P3 respectively, with the
structures of these products having finally been characterised.16 Given the discovery
that these compounds were virtually absent in unstimulated cells, and accumulated
rapidly after agonist induced stimulation, there was a clear indication that these
phosphoinositides act as intracellular second messengers.
Eventually, it was established that three classes of PI3-K exist in mammalian cells, types
I, II and III, the former two consisting of multiple isoforms.17 These different classes
display varying substrate preferences, contributing towards a multifaceted regulation
cycle for phosphoinositides. Class I PI3-Ks are recognised as the most important in the
phosphorylation of PtdIns(4,5)P2 and hence the production of PtdIns(3,4,5)P3.18 It also
emerged that the phospholipid products of Class I PI3-Ks do indeed act as important
second messenger signalling molecules following PI3-K activation, recruiting a range of
proteins to the cell membrane.19 It is this pathway that has generated most interest while
extensive research attempts to decipher the diverse roles that phosphoinositides play in
cellular processes.
1.3. Metabolism and activity of D3-phosphorylated phosphoinositides
1.3.1. Phosphoinositide Regulation
Metabolic regulation of the known phosphoinositides has proved to be highly complex.
As well as the existence of kinase driven phosphorylation of such species at the D3-, D4-
and D5-positions, phosphatases that can specifically remove the phosphates at each of
these positions have also been discovered (Figure 1.5).20 Furthermore, these enzymes
are often expressed as more than one class and/or isoform (such as PI3-Ks) and have
been shown to be prevalent in distinct intracellular locations. Consequently, the
phosphoinositide products of their action also exhibit characteristic subcellular
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distribution patterns. For instance, PtdIns(4,5)P2 and PtdIns(3,4,5)P3 are found mainly in
the plasma membrane, whereas PtdIns(3)P, PtdIns(4)P and PtdIns(5)P are mainly
present in endosomes, Golgi and nuclei respectively.21-23 Figure 1.5 demonstrates how
different phosphoinositide species can be reversibly interconverted through tightly
regulated kinase/phosphatase processes. This can result in short-term alterations of the
protein-binding properties and function of a given membrane domain. Such plastic
properties render phosphoinositides ideally suited to integrating cell signalling events
and membrane trafficking.24-26
Figure 1.5. The phosphorylation/dephosphorylation cycles of the known phosphoinositides.25
1.3.2. Regulation of PtdIns(3,4,5)P3 and PtdIns(3,4)P2
The regulation of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 within the cell appears to
demonstrate the significance of these type of complex
phosphorylation/dephosphorylation cycles. Their metabolism clearly demonstrates that,
during cell activation, both positive and negative regulatory signalling processes are vital
for homeostasis. For instance, while PtdIns(3,4)P2 can be formed by the action of a PI3-
K on PtdIns(4)P as outlined above, the action of Src homology domain 2-containing
inositol 5'-phosphatases (SHIP) on PtdIns(3,4,5)P3 also results in PtdIns(3,4)P2
production (Figure 1.5).27 Cellular concentration of PtdIns(3,4)P2 appears to be lower
than the concentration of PtdIns(3,4,5)P3, and it is currently thought that SHIP
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phosphatase action on PtdIns(3,4,5)P3 is the dominant mechanism by which
PtdIns(3,4)P2 is formed.28 SHIP mediates an important negative feedback mechanism in
lymphocytes. Loss of SHIP results in an unbalanced immune response, potentially
leading to autoimmunity.29,30 Phosphatase and tensin homolog deleted on chromosome
10 (PTEN) catalyses the dephosphorylation of both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 at
the 3-position.31 Cells lacking PTEN have elevated levels of these two
phosphoinositides. The significance of such negative feedback regulation is
demonstrated by the fact that PTEN is known to act as a tumour suppressor that is
mutated/deleted in a variety of different human tumours.32 The importance of elevated
PtdIns(3,4,5)P3 levels in relation to human malignancy is discussed later. Suffice to say,
at this early stage of discussion it is clear how vital these D-3 phosphoinositides and the
proteins with which they interact are to fundamental cellular processes. The implication
is that proteins exist within the cell that selectively recognise and interact with these
phosphoinositides in a highly regulated manner.
1.3.3. The targets for D3 phosphoinositides
For a given protein to bind to a membrane-bound phosphoinositide, a particular
recognition domain is required through which the enzyme can interact with the
phospholipid. The number of domains or modules known to bind to phosphoinositides
has increased dramatically in recent years.33 Figure 1.6 indicates the major binding
domains that the most studied phosphoinositides are known to interact with, including
some of the relevant proteins. The selectivity of such domains and how they bind is
variable. Those that target only the rare D3-phosphorylated phosphoinositides must bind
with very high affinity and selectivity. In the case of certain pleckstrin homology (PH)
domains which bind PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2, this is achieved almost solely
via the inositol headgroup interactions.34 Although, as indicated, monophosphorylated
phosphatidylinositols (e.g. PtdIns(3)P) have also been reported to bind PH domains, at
least in vitro, this is achieved with reduced affinity, and the physiological relevance of
such interactions is unclear. In the case of FYVE35 and phox36,37 homology domains,
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which bind PtdIns(3)P preferentially, high affinity interactions are achieved via a
membrane insertion and/or oligomerisation component in addition to head group
interaction.33 Domains that target PtdIns(4,5)P2, which is more abundant by some 25-
fold, do not seem to require the same stringent affinity and specificity characteristics,
and tend to be more structurally diverse. Some of these domains, such as the PH
domain of PLCδ1, do bind PtdIns(4,5)P2 strongly and selectively, although this is
possibly more of an exception rather than the rule. Such high affinity PH domain binding
is generally reserved for PtdIns(3,4)P2 and PtdIns(3,4,5)P3.
Thus, variability between binding domain-types affords the targeting of different
phosphoinositides, while variability in preference and specificity within the domain types
allow for further differentiation of inositol lipid targeting. Therefore, the apparent range
that exists in phosphoinositide-substrate binding modes allows a large number of
proteins to be selectively recruited to specific membrane locations. Of all known
phosphoinositide recognition modules, the PH domain is the most thoroughly
characterised. By far the most common target for PH domains is PtdIns(3,4,5)P3.
Figure 1.6. Phosphinositide binding domains and associated proteins.26 BD = binding domain. Domains types: PX
(phox); FYVE (Fab1, YOTB/ZK632.12, Vac1, EEA1); PH (pleckstrin homology); TUBBY; ENTH (Epsin N-terminal
homology).
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1.3.4. PtdIns(3,4,5)P3 and the PH domain
As noted, PtdIns(3,4,5)P3 is the major product of agonist-stimulated PI3-kinases, and its
concentration increases by more than 40-fold within seconds of cell stimulation. Thus,
proteins containing a domain capable of specific and preferential PtdIns(3,4,5)P3
binding, such as certain PH domains, can be recruited rapidly to the plasma membrane
of agonist-treated cells, in a PI3-K dependent manner. PH domains are composed of
approximately 120 amino acid residues and, although sequence homology between
different PH domain family members is relatively low, all contain a common β-sandwich
fold.38 Since the discovery of this domain in 1993,39 it has been found in some 250+
human proteins. In fact, those that are highly selective for PtdIns(3,4,5)P3 are rather few,
and several also bind PtdIns(3,4)P2 with appreciable affinity.40,41 Prominent examples
are protein kinase B (PKB, also known as Akt), phosphoinositide-dependent protein
kinase 1 (PDK1), Bruton’s tyrosine kinase (Btk), the general receptor for
phosphoinositides-1 (Grp1) and the dual adaptor for phosphotyrosine and 3-
phosphoinositides-1 (DAPP1).33,34,38,40,42 Of these, only Btk and Grp1 are considered
highly selective for PtdIns(3,4,5)P3.
Of the PH domain-containing proteins mentioned, PKB in particular, a serine/threonine
kinase belonging to the ‘AGC’ superfamily of protein kinases, has aroused significant
interest in recent years due to the crucial role it plays in a range of fundamental cellular
processes (‘AGC’ stands for protein kinases A, G and C).43 PKB’s PH domain binds
selectively to PtdIns(3,4)P2 and PtdIns(3,4,5)P3 with similar affinity, and its activation is
therefore PI3-kinase driven. This PI3-K/PKB pathway, as it has become known, is now
recognised as one of the most crucial signal transduction pathways in cellular
metabolism, with the second messenger activity of the two aforementioned
phosphoinositides at its core. An overview of this signalling cascade serves to highlight
this fact.
20
1.4. PI3-K/PKB signalling pathway overview
PI3-kinases are activated by a host of stimulants including growth factors, cytokines, and
insulin.44 They consist of a p110 catalytic subunit and a regulatory adaptor subunit p85,
which binds to specific tyrosine-phosphorylated sequences within the cytoplasmic tail of
the receptor (see Figure 1.7).45 This binding process of the p85 subunit recruits the p110
catalytic subunit to the plasma membrane where it can phosphorylate PtdIns(4,5)P2
thereby generating PtdIns(3,4,5)P3. As discussed, this phosphoinositide then binds to
the PH domain of several proteins, in this case PKB, PDK1 and PDK2, thus recruiting
them to the cell membrane. The tandem translocation of these proteins may be crucial
as it brings them in close proximity to one another, facilitating their interaction.
Fig.1.7. An overview of the phosphoinositide 3-kinase (PI3-K) signalling pathway. The diagram shows how the
activation of PI3-K from extracellular stimuli leads to the accumulation of PtdIns(3,4,5)P3 at the cell membrane. The
binding of PtdIns(3,4,5)P3 to PKB, PDK1 and PDK2 brings these proteins together to allow the phosphorylation of
PKB. PKB then phosphorylates a number of proteins downstream of the signalling cascade.
PKB is fully activated by phosphorylation at two specific sites by PDK1 and PDK2,
following which it disperses into the cytoplasm and the nucleus, phosphorylating a
number of proteins downstream of the signalling cascade.46 Identifying the target
substrates for PKB has been a major challenge in the study of the PI3-K pathway, and
several have been determined.43,47 One such example is the mammalian target of
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rapamycin (mTOR),48 a major effector in cell growth and translation, which PKB
activates through at least two mechanisms. PKB is also recognised to phosphorylate
several proteins that mediate apoptosis. 43 For instance, it inhibits the proteins BAD and
FKHR which are activators of apoptosis. Also, it activates NF-κB, a protein known to 
inhibit apoptosis. Thus, PKB activity promotes cell growth and survival. Also, PKBβ is
highly expressed in insulin responsive tissue such as adipose tissue,49 and is believed to
be heavily involved in glucose metabolism via the inactivation of glycogen synthase
kinase 3β (GSK3β). Clearly, deregulation of the PI3-K/PKB signalling pathway would
have profound effects on cellular function.
1.5 PKB structure and activation
1.5.1. A structural overview
Given the crucial role that PKB plays in such fundamental cellular processes, it is
unsurprising that the precise structure and activation mechanism of this protein has
commanded great interest in recent years. Consequently, it has been well studied,
although its mechanism of activation is complex and remains somewhat controversial.50
Three isoforms of PKB (α, β and γ) are known to exist in mammals, each consisting of 
three conserved domains: the N-terminal PH domain, a central kinase catalytic domain
and a C-terminal extension containing a regulatory hydrophobic motif (HM) (Figure
1.8.A).51 Among the PKB isoforms, the PH domains are ~80 % identical and the kinase
domains ~90 % identical. The kinase domain is structurally similar to other members of
the AGC kinase family and is closely related to the PKC, PKA and SGK subfamilies. The
linker (LINK) region is poorly conserved and the structure of the 25 residue gap between
the PH and kinase domains is currently unknown.
Figure 1.8 shows a composite of the crystal structures of the PH (yellow) and CAT (blue)
domains, with the PH domain positioned arbitrarily with respect to the kinase domain
and connected by a modelled linking peptide.51 The crystal structure of the kinase
domain for PKBβ in activated and unactivated forms have been solved.52,53 Crystal
structures of PKB PH bound to naturally occurring PtdIns(3,4,5)P3 or shortened glyceryl-
chain analogues of PtdIns(3,4,5)P3 have not been obtained. However, a crystal structure
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of the inositol head group of PtdIns(3,4,5)P3, inositol(1,3,4,5)tetrakisphosphate (InsP4
17, which has a similar affinity for PKB), bound to the PH domain of PKBα has been
solved and was reported in 2003 by van Aalten and co-workers.54 Analysis of the
binding of InsP4 revealed several interesting features. For instance, as Figure 1.8.B
shows, the 1-, 3- and 4- position phosphates of InsP4 interact strongly with the binding
site, while the 5-position phosphate is largely solvent exposed. This explains the similar
affinity that PtdIns(3,4)P2 and PtdIns(3,4,5)P3 have for PKB. Furthermore, on
comparison with the InsP4 bound structure and the uncomplexed apo structure, it was
observed that such binding induced a large conformational change in PKBα PH, not
previously observed in PH domain–phosphoinositide interactions.
A B
Figure 1.8. A. A composite of the crystal structure of the PKBαPH (yellow) and PKBβ kinase (CAT, blue) domains.51
B. PyMOL representation of the crystal structure of InsP4 bound to PKBαPH.54 The 3- and 4-position phosphates
interact strongly with the binding site residues, while the 5-position phosphate is significantly solvent exposed.
5-position
phosphate
1-position
phosphate
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1.5.2. The binding of the PtdIns(3,4,5)P3 head group to PKB PH produces a
conformational change
Prior to the report of van Aalten, it had been postulated that the binding of
PtdIns(3,4,5)P3 to PKB PH did not only serve to co-localise the protein with PDK1 at the
cell membrane. It had been speculated that such binding also induced an activating
conformational change in PKB, supported by the observation that PDK1 is unable to
phosphorylate wild-type PKB under conditions where it does efficiently phosphorylate a
mutant form of PKB that lacks its PH domain.55,56 Van Aalten’s study provided the first
direct structural evidence that a conformational change does indeed occur.
Fig.1.9. PyMOL representations of the crystal structure of PKBαPH in the apo form (left) and as the InsP4
complex (right). Variable loops VL1 and VL3 move towards the charged phosphates of the inositol
substrate. VL2 also undergoes a conformational change, forming an acidic α-helix in the process.54
The ribbon representations of the structures determined in the study are presented in
Figure 1.9. As expected, the apo PKBα PH possessed the standard PH domain fold,
together with three loops (VL1, VL2 and VL3), that are variable in both length and
sequence in all known PH domains.38,40 In the case of PKBα PH, these loops help form
a highly basic pocket into which the head groups of PtdIns(3,4)P2 and PtdIns(3,4,5)P3
bind. Significantly, conformational changes in all three variable loops were observed
upon InsP4 binding. For instance, the VL3 loop was positioned up to 7.4 Å away from the
apo InsP4 bound
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phosphoinositide binding pocket in the apo structure compared to its position in the
InsP4 complex. The most dramatic difference, however, was observed by the absence of
the short acidic α-helix of VL2 in the apo structure, present in the complex. The VL2 loop
was not well defined in the apo structure, suggesting that in this form the loop is flexible.
However, it was evident that VL2 did not assume ordered secondary structure, such as
the α-helix observed in the InsP4 complex. According to the analysis, in order to achieve
the formation of the α-helix, VL2 must undergo a 7.6 Å shift upon InsP4 binding. The
formation of this helix is defined by the clustering of 3-4 negative charges (Asp-44, Asp-
46, Glu-49 and to a lesser extent Glu-40), forming an acidic patch facing the solvent.
It has been proposed that a consequence of these conformational changes observed in
VL2 and/or VL3 could be to effect interactions of these loops with the PKB kinase
domain, and in doing so expose one of the protein’s sites of phosphorylation by either
PDK1 or PDK2. So far, this kind of ligand-induced conformational change for PH
domains appears to be unique to PKB. Such changes in other PH domains bound to
InsP4 are limited to movement of VL1, typically to accommodate the D5-phosphate
group.57-59
1.5.3. The Activation cycle of PKB
The binding of PKB PH to PtdIns(3,4,5)P3 is merely the initial step in a complex
activation process for PKB. The precise mechanism of activation is, in fact, far more
complicated than that implied in the simplified PI3-K/PKB pathway overview presented in
Figure 1.7. The protein is phosphorylated at a threonine residue in the activation T loop
(Thr308 in PKBα) on the kinase domain, which stimulates enzymatic activity by at least
100-fold, and is essential for activity.60 Mutation of Thr308 to non-phosphorylatable
alanine greatly reduces activity.61 Evidence suggests that PDK1 is responsible for this
phosphorylation. PDK1 is a ‘master kinase’ responsible for the phosphorylation of
numerous AGC kinases. Over-expression of PDK1 leads to elevated Thr308
phosphorylation in the absence of natural agonists.62 Also, phosphorylation of Thr308 is
lost in cells where PDK1 has been genetically disrupted, and PKB is unresponsive to
mitogenic stimulation as a result.63 PDK1 appears to phosphorylate several of its
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substrates in a non-regulated manner. However, when translocated to the cell
membrane by phosphoinositide binding, the targets it phosphorylates at this location are
PI3-K signal-dependent. Thus, PDK1 only encounters some of its kinase substrates at
the cell membrane, and PKB is one of these.64
The second point of PKB activation occurs via the phosphorylation of a serine residue
(Ser473 in PKBα) located on the C-terminal hydrophobic motif (HM). This process
increases PKB activity by another 10-fold. However, the means by which this occurs
remains unknown. The existence of a “PDK2” which performs this phosphorylation has
been inferred, but so far it has not yet been discovered. In fact, a number of enzymes
responsible for this modification have been touted. These include PDK1 (when in a
complex with the kinase PRK2),65 PKCα,66 PKCβII,67 DNA-dependent kinase,68 and the
rictor-mTOR complex.69 It has even been suggested that PDK2 may not exist at all, and
that activation occurs via autophosphorylation.70
The role that the phosphorylated HM plays in PKB activation is also not certain. It has
been suggested that phosphorylation of the HM stabilises the interaction between PKB
and PDK for the crucial T-loop phosphorylation.71 The HM present in PKB is found in
many other AGC kinases, and is believed to act as a docking site for PDK1.72 PDK1, like
many AGC kinases, contains what has been termed the ‘PKC related kinase 2
interacting factor pocket’ or ‘PIF pocket’, to which HM binds. PDK1 has a PIF pocket, but
no HM. On the other hand, the HM of PKB binds with lower affinity to PDK1 PIF than the
HM of several other AGC kinases do. Evidence suggests that this type of PIF pocket
binding is more important for the PDK1-induced activation of kinases not bearing a PH
domain (and therefore not PI3-K dependent).73 Thus, the assumption is that co-
localisation at the cell membrane itself, as well as the conformational change that lipid
binding induces, does contribute significantly to an effective interaction of PDK1 with
PKB. Again, the significance of phosphoinositide binding is highlighted. Perhaps the
tenfold increase in PKB activity seen by HM phosphorylation may well be related to the
association of HM with its own PIF pocket following Thr308 activation (Figure 1.10).
This, it has been postulated, may further stabilise PKB, resulting in its release from the
cell membrane to then diffuse into the cytoplasm.
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Figure 1.10. Proposed activation cycle of PKB. A. PKB is cytosolic and inactive, and PDK1 has low
activity for PKB phosphorylation. PI3-K-produced PtdIns(3,4,5)P2 and PtdIns(3,4)P2 recruit PKB and PDK1
to the plasma membrane. B. PKB undergoes Ser473 phosphorylation by an unknown mechanism,
increasing affinity of HM for PDK1. C. PDK1 phosphorylates PKB onThr308. D. The HM of PKB
associates with and stabilises its kinase domain. Fully active PKB then phosphorylates cytosolic and
nuclear targets.
The precise mechanism of PKB activation remains uncertain. The order in which Ser473
and Thr308 are phosphorylated has not been confirmed, nor has the means by which
Ser473 phosphorylation occurs. However, both phosphorylation processes appear to be
dependent on PI3-K activation. What is clear is that the process of PKB activation lies at
a crucial juncture in a complex and critically important signalling cascade.
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1.6. The PI3-K/PKB pathway in human cancer
The discussion so far has presented how an intricate and tightly regulated activation
process of PKB is essential for cell growth, proliferation, glucose metabolism and protein
synthesis. The fact that upregulation of this pathway is now strongly associated with
malignancy is, therefore, not surprising. In fact, the PI3-K/PKB pathway is one of the
most frequently hyperactivated signalling pathways in human cancer.74,75 A crucial
feature of this pathway is the role of the second messenger phosphoinositides produced
by PI3-K. As alluded to earlier, one frequent route of overactivity is derived directly from
phosphoinositide deregulation. PTEN dephosphorylates PtdIns(3,4,5)P3 and
PtdIns(3,4)P2 at the D3-position, preventing them from binding to PH domain-containing
proteins such as PKB.76 Thus, loss of PTEN leads to constitutive signalling of the PI3-K
pathway, resulting in uncontrolled cell growth, survival and proliferation.77 It is now
known that a major path through which PTEN acts as a tumour suppressor is by
negatively regulating PKB activity specifically. PTEN was originally isolated as a tumour
suppressor gene in breast cancer and glioblastomas78 and has subsequently been
implicated in various human cancers (Table 1). Reintroduction of wild-type PTEN into
tumour cells that are mutant for PTEN have resulted in inhibition of PKB activation
leading to either cell cycle arrest or apoptosis.79-81
Several oncogenic mutations are associated with PI3-K itself, and PI3-K is constitutively
active in a number of human malignancies.74 Mutations have been observed in both the
p110 and p85 subunits of PI3-K. Again, the immediate result of such hyperactivity is the
increased levels of PtdIns(3,4,5)P3, leading to constitutive phosphoinositide signalling
through PKB activity.
PKB was originally identified as a retroviral oncogene product,82 and amplification and
overexpression of PKB was subsequently observed in several cancer types including
ovarian, breast and pancreatic cancer.83,84 Site mutations in PKB are rare, although a
recent report did describe a Glu→Lys mutation at amino acid 17 of the PH domain of
PKBα.85 The crystal structures of this mutant PH domain in apo form and bound to the
PtdIns(3,4,5)P3 head group InsP4 were obtained, revealing enhanced interaction of the
binding site with the 6-OH and 5-phosphate groups of InsP4. Thus, the mutation is
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believed to result in increased binding efficacy of the PH domain to PtdIns(3,4,5)P3. This
led to pathological localisation of PKBα to the plasma membrane, thus stimulating
downstream signalling and induced leukaemia in mice.85
Target Alteration in PI3-K/PKBpathway Type of cancer References
Mutation or deletion Brain, bladder, breast, prostate andendometrial cancers, glioblastoma 76, 86-90
PTEN
Epigenetic silencing
NSCLC, endometrial and gastric
cancer, prostate, ovarian and
melanocytic tumours
91-94
Amplification of PIK3CA
(encodes p110α) Ovarian and cervical cancers 95-97
Mutation in PIK3CA
Colorectal, gastric, breast, ovarian
cancers, glioblastoma and
hepatocellular carcinoma
97-100PI3-K
Mutation in p85α Colon and ovarian cancers 101
PKBα amplification Gastric adenocarcinoma 102
PKBβ amplification Ovarian, breast and pancreaticcancers 83, 103, 104
PKB
PKBγ amplification 
Hormone-independent breast and
prostate 84
Table 1. Genetic alterations resulting in activation of the PI3-K/PKB pathway and their associated human
malignancies.105
Importantly, the alterations in the PI3-K/PKB pathway, such as those described in Table
1, are frequently associated with advanced disease, and are often features of a poor
prognostic factor in many cancers.106,107 Hyperactivation of the pathway has also been
linked with resistance to chemotherapeutic drugs in cancer treatment. Inhibition of the
pathway by biochemical or genetic means increases the efficacy of chemotherapy
and/or radiation both in vivo and in vitro.108,109 All such factors provide strong justification
and rationale for the development of compounds that potently and directly inhibit the
PI3-K/PKB signalling pathway for use in the treatment of cancer.
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1.7. Targeting PKB inhibition for cancer therapy
Inhibition of the PI3-K/PKB pathway can theoretically be achieved at several junctures
along the signalling cascade. Indeed, in the search for effective chemotherapeutic
agents, this is exactly what has taken place in recent years, with varying success.110 As
well as PKB itself, targets have included the tyrosine receptor kinases (TRKs), PI3-K,
PDK1 and downstream targets such as mTOR. The synthesis of targets upstream of
PKB, such as PI3-K, which are selective and exhibit acceptable toxicity profiles, has met
with very limited success. Some older compounds, such as wortmannin, are well
characterised and target the p110 subunit of PI3-K.111 Wortmannin has displayed
effective inhibition of tumour cell growth in vivo and in vitro,112 but poor solubility and
high toxicity have limited its clinical application.113 The inhibition of PDK1 appears more
encouraging, given the decent potency and reduced toxicity of most of the available
inhibitors compared with the available PI3-K inhibitors.105 However, as noted earlier,
PDK1 also activates a number of other kinases that regulate cell survival and
proliferation. Thus, although potentially advantageous from a therapeutic standpoint,
establishing such compounds as inhibitors specifically of the PKB pathway has become
complicated, given that their anti-tumour effects may be related to an alternative
pathway.
mTOR is a downstream target of PKB which plays a role in protein synthesis,
angiogenesis and cell cycle progression. Studies have shown that mTOR inhibitors,
rapamycin and its derivatives CCI-779 and RAD001, induce cell cycle arrest and/or
apoptosis in tumours exhibiting activation of PKB.114,115 However, inhibition of PKB itself
may be considered preferable as this would be expected to inhibit most, if not all, PKB
substrates. Not all PKB substrates have been identified and the “critical substrates” can
vary with cell type, therefore inhibition of individual downstream components may miss
key substrates involved in cancer cell survival and proliferation. Thus PKB inhibition may
offer greater efficacy, albeit at the expense of potential greater toxicity.
The last three years in particular have seen a number of structurally variable PKB
inhibitors reported. The mode of action of such compounds can generally be divided into
four categories: ATP-competitive, PH domain, allosteric and substrate-mimetic inhibitors.
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However, the precise nature of inhibition for some compounds has not been
conclusively determined.
ATP-competitive inhibitors
Several small molecule leads are being used as the basis for developing potent and
selective PKB inhibitors which target the ATP binding site. As there is a high degree of
homology between the ATP-binding pocket of PKB, PKA and PKC, achieving a high
degree of selectivity has proved challenging. However, several leads have been derived
from the modulation of PKA inhibitors which have been subjected to optimisation for
PKB selectivity. An example of such efforts led to the discovery of compound 18,
displaying potent inhibition of PKBα (IC50 20 nM) with enhanced selectivity against PKA
(IC50 1900 nM).116
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Figure 1.11. Representative ATP-competitive PKB inhibitors.
A hit from high throughput screening enabled the group from Abbott laboratories to
develop highly potent indole/indazole-pyridine based inhibitors 21 and 22.117 These
compounds slowed the growth of tumours when used alone or in combination with
paclitaxel or rapamycin. However, selectivity against PKA was very moderate and the
compounds displayed a narrow therapeutic window with significant toxicities observed.
Optimisation to provide more selective compounds from this series is still underway.118 A
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collaboration between Astex Therapeutics and the Institute of Cancer Research led to
the development of low molecular weight phenylpurine and phenylpyrazole ATP-binding
inhibitors 19 and 20, via fragment-based screening techniques.119,120 Again, however,
selectivity against PKA was somewhat low.
Allosteric inhibitors
Improved selectivity for PKB has been achieved in the synthesis of allosteric inhibitors
(Figure 1.12).121,122 These are in fact PKBα and PKBβ isoform selective and highly
selective against closely related kinases such as PKA. Such compounds do not
compete with ATP or peptide substrate. They are active only against the full-length
enzyme requiring the PH domain for full inhibition, but do not bind to this domain.
Interestingly, it was observed that inhibition of both the PKBα and PKBβ isoforms, using
dual inhibitor 25 or compounds 23 and 24 together, was required for maximal apoptotic
response in tumour cells when used in combination with chemotherapeutic agents. Also,
it was shown that inhibition of PKBα and PKBβ sensitised only tumour cells but not
normal cells to apoptotic stimuli. Unfortunately, these compounds have poor solubility
and pharmacokinetic properties that have precluded their evaluation in animal tumour
models.
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Figure 1.12. Allosteric inhibitors of PKB.
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Pseudosubstrate inhibitors
Substrate mimetic inhibitors of PKB have also been reported. These have included the
identification of a 14-mer peptide, AKTide-2T, which binds to the substrate binding
region of PKBα catalytic domain and inhibits the enzyme with a Ki of 12 μM.123
Subsequent manipulation resulted in a further 10-fold increase in potency (Ki 0.11 μM).
However, the size of this and other peptide-based inhibitors makes them poor leads for
development of small molecule inhibitors. Truncation of the peptide chains generally led
to reduced potency. A recent report has described the development of a small molecule,
substrate mimetic inhibitor derived from modification of the GSK3β substrate
sequence.124 Potency was rather moderate, though, with an IC50 of 14 μM. The cytotoxic
effects of such compounds have yet to be fully investigated.
PH domain inhibitors
Several examples now exist where the binding of the PKB PH domain to PtdIns(3,4,5)P3
is inhibited. It is understood that this process prevents membrane localisation and thus
activation of PKB. One example supporting this is the discovery of inositol(1,3,4,5,6)-
pentakisphosphate [Ins(1,3,4,5,6)P5] 26 as an inhibitor of PKB, which induced apoptosis
in ovarian, lung and breast cancer cells.125 Conversely, other inositol polyphosphates
such as Ins(1,4,5,6)P4, Ins(3,4,5,6)P4 and InsP6 had little or no effect on cell apoptosis.
Concentrations of synthetic Ins(1,3,4,5,6)P5 (20-50 μM) required for activity were higher
than concentrations normally found in mammalian cells (5-15 μM). However, the
biological role of indigenous Ins(1,3,4,5,6)P5 has not been well studied, and poor cellular
penetration may be a problem for extracellular Ins(1,3,4,5,6)P5.
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Figure 1.13. Inhibitors of PKB membrane localisation.
Several lipid-based inhibitors of PKB PH have also been synthesised. Perifosine 27 is
the best characterised of these. In vitro, perifosine is believed to inhibit membrane
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translocation of PKB.126 This is evidenced by the fact that perifosine-mediated inhibition
of PKB phosphorylation was substantially relieved by introduction of MYR-PKB, which
bypasses the requirement for PH domain-mediated membrane recruitment. Perifosine
inhibited the growth of melanoma, prostate, lung, colon and breast cancer cell lines in
vitro, and is currently in Phase II trials alone and in combination to treat multiple forms of
cancer. The precise mechanism of PKB inhibition for this drug could not be determined,
however. Modulation of PKB has not been assessed in clinical studies so far, and
perifosine is not specific for PKB, interacting with additional pathways downstream of
growth factors. Thus, it will be important to correlate its clinical effects with modulation of
PKB signalling, as with all such drugs.
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Figure 1.14. Phosphatidylinositol ether lipid analogues.
Another group of lipid-based PKB inhibitors are those developed by Kozikowski and co-
workers, known as phosphatidylinositol ether lipid analogues (PIAs).127-129 These were
designed to interact selectively with the PH domain of PKB, and five PIAs (28-32) were
observed to inhibit PKB with IC50s of between 2.5 and 5 μM.129 These compounds
inhibited PKB activation and phosphorylation of several downstream substrates of PKB
in tumour cells, without affecting the activities of upstream kinases PI3-K and PDK1. The
result was increased apoptosis 20-30-fold in cancer cell lines with high levels of PKB
activity, and only 4-5-fold in those with low levels of PKB activity. It is assumed that it is
the phosphorylated derivatives of such compounds that are active, if they are to
competitively interact with the highly charged PH domain binding site. However, their
phosphorylated versions were not obtained in order to ascertain this. Furthermore,
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selectivity against other PH domain-containing proteins was not well established, and in
vivo efficacy has yet to be presented.
To conclude, the PKB pathway appears to represent an attractive target for anticancer
drug discovery. The fact that there are several examples where apoptosis or cell cycle
arrest is observed selectively for PKB-upregulated cells suggests that there is an
acceptable therapeutic index to be exploited. Many challenges remain though, not least
the need for compounds which display genuine selectivity for the PI3-K pathway and, in
particular, for PKB inhibition. Even compounds which may not necessarily be suitable for
drug development, if highly selective for PKB, will also be of great use as biological tools
in the continuing effort to probe this complex pathway.
1.8. Summary
Over the many years during which inositol phosphates have been studied, it has
become evident that the controlled metabolism of phosphoinositides is fundamental for
signal transduction in eukaryotic cells. It has emerged that many of these inositol-
containing phospholipids act as second messengers in complex intracellular systems.
PtdIns(3,4,5)P3, a product of phosphoinositide-3 kinase, is one such lipid. Notably,
PtdIns(3,4,5)P3 recruits protein kinase B, among other proteins, to the cell membrane.
This process partially activates PKB, facilitating its phosphorylation. Once fully activated,
PKB proceeds to phosphorylate a number of other kinases involved in several crucial
processes such as cell growth and proliferation. Up-regulation of the PI3-K/PKB pathway
is a feature of numerous cancer cell lines. Thus, recent years have seen a drive towards
the synthesis of selective PKB inhibitors. Whilst potency has often been achieved,
selectivity has proved more challenging. Many of the reported inhibitors bind to the ATP
binding site of the PKB kinase domain. However, due to the high homology between the
kinase domains of AGC kinases, selectivity is often compromised. PH domain inhibitors
offer a potential advantage in terms of selectivity, given that there are far fewer PH
domain-containing proteins than proteins bearing an ATP binding site. Furthermore,
different PH domains possess different binding affinities towards different inositol
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phosphates. This increases the possibility of selectively inhibiting a particular
membrane-targeted protein.
The discussion has detailed how the binding of PtdIns(3,4,5)P3 to PKB PH recruits PKB
to the cell membrane and induces a conformational change in the protein, presumably
resulting in a conformation more active to subsequent phosphorylation. Inhibition of this
interaction can result in reduction of PKB activity, as suggested by the activity of PIAs
28-32. Further probing of the PKB PH domain with novel PtdIns(3,4,5)P3 analogues is
required to ascertain whether such compounds can demonstrate higher selectivity than
other types of the reported PKB inhibitors. It would be useful if such compounds could
demonstrate whether inhibition of membrane recruitment alone is sufficient for effective
inhibition, or if conformational changes in PKB PH are crucial. Thus, analysis of any
crystal structure data for active compounds bound to PKB PH would contribute greatly to
our understanding of PKB activity and activation.
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Chapter 2. Results and Discussion Part 1
2.1. Project Aims
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Figure 2.1. The structures of PtdIns(3,4,5)P3 15 and InsP4 17.
The aim of this project is to synthesise analogues of PtdIns(3,4,5)P3 15, and/or
analogues of its inositol head group InsP4 17, with the view to obtaining novel selective
inhibitors of the PKB PH domain. Furthermore, it will be desirable to obtain crystal
structures of such compounds bound to PKB PH. This would help to ascertain precisely
how modification of the inositol ring substituents affects substrate binding and how it
may affect PH domain conformation in PKB. Such a study would offer further insight into
the extent by which unnatural substrates are tolerated by PKB PH, and thus aid the
development of potent and selective inhibitors of the protein.
The crystal structure of InsP4 bound to PKBαPH, obtained by van Aalten and co-
workers, was compared with the apo PKBαPH structure.54 A complex hydrogen bonding
network exists in the binding site of the apo structure, involving several amino acid
residues and a number of water molecules. The binding of InsP4 disrupts this
arrangement, as the 1-, 3- and 4- phosphate groups interact with several of the proximal
basic amino acids, and in doing so form a new hydrogen bonded network (Figure 2.2).
Thus, upon InsP4 binding, Arg-86 moves 2.3 Å towards the 4-phosphate and Lys-14
moves 1.2 Å to interact with both the 3- and 4-position phosphates. Acidic Glu-17 is
repelled from the ligand binding site by the negatively charged phosphates. This
repulsion of Glu-17 away from the ligand binding pocket could enable the movement of
Arg-86 towards the 4-phosphate. Arg-86 is found at the base of the VL3 loop, and its
movement upon ligand binding could mediate the observed movement in this loop noted
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earlier, contributing to a significant conformational change. Furthermore, Arg-23 is
observed to move 6.2 Å inwards to make contact with the 1- and 3-position phosphates.
Meanwhile, Arg-25 is also seen to interact significantly with the 3-position phosphate.
Additionally, van Aalten and co-workers also obtained a third PKBαPH crystal structure
in the study, in which the ligand binding pocket contained an ordered sulfate molecule
rather than the expected inositol ligand. In this complex, the water-mediated hydrogen
bonding network present in the unbound apo structure was significantly disrupted by the
presence of the sulfate. The study also showed that the sulfate molecule was located
approximately 2.2 Å from the 4-phosphate of InsP4 in the complex structure, forming
similar interactions as InsP4 with Arg-86 and Asn-53. However, the disruption of the
hydrogen bonding network was apparently not sufficient to induce the major
conformational changes seen between the apo and InsP4 complex structures. For
instance, the VL1 and VL3 loops are found in the same positions in the PKBαPH-sulfate
structure as in the apo structure. The VL2 loop in the PKBαPH-sulfate complex is
disordered and possesses no detectable secondary structure.
Figure 2.2. PyMOL representation of the PKBαPH domain ligand binding site, crystallised with Ins(1,3,4,5)P4 17.54
Relevant binding site residues are labelled, and their phosphate interactions indicated. Water molecules are removed
for clarity. Colour coding: InsP4 C = green, O = red P = orange; PH domain binding site residues C = violet, N = blue,
O = red.
Together, such observations suggest that if the movement of particular binding site
residues is reduced or altered upon the binding of an analogue of the PtdIns(3,4,5)P3
head group, formation of the activating conformation of PKBαPH may be restricted. A
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compound which can achieve this and prevent the membrane translocation of PKB
should act as an effective PKB inhibitor. Potentially, suitable modification at either the 1-,
3- or 4-positions of the inositol ring of PtdIns(3,4,5)P3 could achieve this. Given that the
movement of Arg-86 towards the 4-position phosphate may be a major factor in
conformational change in VL3, the first objective of this project was to synthesise
analogues of the type displayed in Figure 2.3, which are modified at the 4-position of the
inositol ring. No 4-position analogues of PtdIns(3,4,5)P3 have been reported in the
literature to date.
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Figure 2.3. Initial target compounds 33-36 as 4-position modified PtdIns(3,4,5)P3 analogues.
With respect to 4-position modification, the primary aim was to synthesise the
dimethylphosphinate 33. The phosphinate moiety would approximate the tetrahedral
geometry of the phosphate group, but lack the H-bonding capacity to trigger the full
movements of Arg-86 and Lys-14 seen upon InsP4 binding. An acidic group alternative
to a phosphate could also be introduced at the 4-position, such as the
methylenecarboxylate 34. This type of acidic group may be necessary to maintain
affinity for the basic binding site whilst potentially offering an altered binding mode to the
parent phosphate. The introduction of other functionality via the synthesis of carbonates
or sulfonates 35 and 36 were also to be synthesised in order to further probe the binding
site, including the introduction of aromatic groups at the 4-position. Phe-55 lies in close
proximity to the 4-position phosphate of the InsP4-PKBαPH complex (Figure 2.2), and is
associated with an aromatic, hydrophobic pocket in the apo structure. Aromatic 4-
position analogues may be able to interact with this hydrophobic region leading to
altered conformation while maintaining binding affinity.
In the proposed compounds, the long-chain diester groups of the phosphoglyceryl unit of
PtdIns(3,4,5)P3 are truncated to simple diacyl groups for the rationally designed
analogues. The reason for this truncation is to increase the chances of obtaining crystal
structures of the active analogues bound to PKB PH. Lengthy diester-chains historically
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make co-crystallisation of the inositol with PH domain-containing proteins unlikely, and
are not considered crucial for PH domain binding. Once an effective inhibitor is
discovered, the phosphate groups could potentially be masked with suitable
bioactivatable protecting groups to provide cell-permeable derivatives,130 enhancing
their value as potential modulatory tools for cell biology.
2.2. Retrosynthesis
A number of syntheses of PtdIns(3,4,5)P3 have been reported in the literature.131-135
However, none of the approaches described are directly compatible with the synthesis
of 4-position analogues. A retrosynthesis of the primary target, the 4-
dimethylphosphinate analogue 33, is presented in Scheme 2.1. As outlined, the 1-
position phosphoglyceryl group is introduced as the penultimate step prior to global
deprotection, and is derived from compound 37. The mild conditions for PMB-
deprotection, required for compound 37, are known to be highly compatible with the
presence of phosphate functionality.136 It was envisaged that the 3,5-bisphosphate 37
could be obtained from intermediate (-)-38, which in turn could be derived from the
versatile alcohol (-)-39 via a phosphinylation reaction. Clearly, the synthesis of other 4-
position-modified PtdIns(3,4,5)P3 analogues could be achieved by the introduction of
other relevant groups at the 4-position at this stage. Compound (-)-39 itself was to be
synthesised via a selective allylation of the vicinal diol (-)-40. Many of the reported
syntheses of phosphorylated inositols involve a resolution step within the synthetic route
to obtain the optically active final product. It is this type of approach that was to be
adopted in the attempted synthesis of analogue 33. Thus, intermediate (-)-40 was to be
obtained from the resolution of racemic triol 42 using the camphor acetal
methodology.134 This serves to protect the 3,4-diol as well as producing enantiopure
material. Finally, the racemic triol can be synthesised in 6 steps from myo-inositol 1
using literature procedures.134
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Scheme 2.1. Proposed retrosynthesis of the 4-dimethylphosphinate PtdIns(3,4,5)P3 analogue 33.
It is clear that the synthesis of compounds such as analogue 33 requires a high degree
of protecting group orthogonality in order to achieve the sequential introduction of the
desired functionality. Although a compatible protecting group strategy was devised, the
reactivity of alkylphosphinates towards a range of reaction conditions is not well
established in the literature. Thus, it was anticipated that the success of the synthetic
approach outlined above may depend on the compatibility of the dimethylphosphinate
group with the conditions required for the synthesis of compound 33 from the 4-
dimethylphosphinate (-)-38.
2.3. Synthesis of the enantiopure 3,4 vicinal diol (-)-40
Following the chemistry developed by Holmes and co-workers,134 the synthesis of key
diastereomeric intermediate (-)-41 began with the formation of the inositol orthoformate
43 from myo-inositol (Scheme 2.2). Indeed, compound 43 has proved an effective
starting point for the synthesis of several phosphoinositides and associated
analogues.137 All starting materials are inexpensive and highly conducive to large scale
synthesis. Therefore, reacting myo-inositol with 2 equivalents of triethylorthoformate in
the presence of 4-toluenesulfonic acid monohydrate gave the desired orthoformate 43 in
71% yield. This process was regularly performed on a 40 g scale.
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Scheme 2.2. Synthesis of the camphor acetal (-)-41. Reagents and conditions: i. (EtO)3CH (3 equiv), TsOH·H2O (0.3
equiv.), DMF, 100 °C, 71% yield; ii. NaH (1.3 equiv), PMBCl (1.1equiv), DMF, 0 °C to RT, 85% yield; iii. NaH (2.5
equiv), BnBr (2.5 equiv), DMF, -5 °C to RT, 98% yield; iv. DIBAL-H (2.5 equiv), CH2Cl2, 0 °C to RT, 96% yield; v. NaH
(1.5 equiv), allyl bromide (1.5 equiv), imidazole (cat.), DMF, -5 °C to RT, 84% yield; vi. HCl, MeOH, reflux, 83% yield;
vii. a. (-)-(S)-Camphor dimethyl acetal (3.5 equiv), TsOH·H2O (0.3 equiv.) CH2Cl2, reflux, b. Silica gel column
chromatography diastereomeric resolution, 24% yield.
Regioselective protection of triol 43 at an axial hydroxyl upon treatment with 1.3
equivalents of sodium hydride and 1.1 equivalents of 4-(methoxy)benzyl chloride
(PMBCl) gave the diol 44 as a racemate (85% yield). Ensuring controlled reaction
conditions by adding the optimal amount of sodium hydride portionwise to a cooled
solution of compound 43 in N,N-dimethylformamide (DMF) allows the formation of a di-
axial sodium chelate complex (Scheme 2.3).138 Here, the sodium ion ionically bonded to
an axial alkoxide ion is able to chelate to the other axial hydroxyl group. This stabilises
the complex increasing the favourability of its formation over that of the equatorial
sodium alkoxide species. Further studies by Billington and co-workers138 confirmed this
experimental outcome, as a loss of regioselectivity is observed when either the counter-
ion or solvent are changed. The 1.3 equivalents of sodium hydride ensure complete
consumption of the triol 43 with minimal formation of di-protected product. Subsequent
reaction of the sodium chelate with PMBCl affords the PMB ether. Naturally, the sodium
hydride does not distinguish between the two axial alcohols, i.e. this desymmetrisation
procedure is not stereocontrolled and thus the enantiomer of compound 44 is also
produced. The formation of di-protected material is also observed, but can be removed
by silica gel column chromatography.
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Scheme 2.3. Mechanism for the regioselective protection of the axial hydroxyl group of 43.138
Dibenzylation of diol 44 proceeded in excellent yield (98%) to afford the fully protected
orthoformate 45. This compound was then treated with 2.5 equivalents of 1 M
diisobutylaluminium hydride (DIBAL-H) in hexane to give the nonane 46. The
mechanism of this regioselective reduction has been studied with deuterium labelling,
and is understood to occur as outlined in Scheme 2.4.13,139,140 The DIBAL-H acts as a
Lewis acid by coordinating to the least hindered orthoformate oxygen atom of the 5-
position, as the equatorial O-benzyl group hinders approach of the bulky DIBAL-H group
towards the 1- and 3-position oxygen atoms. Thus, the formation of intermediate 48 is
the more favourable, and spontaneous rearrangement to give an oxacarbenium species
occurs. This species is considered to be more stable in a boat conformer to avoid
unfavourable 1,3-diaxial interactions, and thus following a ring flip the intermediate 50
accepts a hydrogen from a second equivalent of DIBAL-H to give the desired compound
in excellent yield, without the need for chromatographic purification.
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Scheme 2.4. Mechanism for selective reduction of orthoformate 45.13,139,140
Allyl protection of the resulting alcohol by treatment with sodium hydride and allyl
bromide gave compound 47. Acid hydrolysis of this compound allowed removal of the
PMB group as well as hydrolysis of the acetal to give the racemic triol 42 in good yield.
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At this stage, resolution of the racemic mixture was performed by 1,2-diol protection of
the 3- and 4-position hydroxyl groups using the chiral auxiliary (1S)-(-)-camphor dimethyl
acetal (-)-52.135 This compound was prepared by stirring (1S)-(-)-camphor (-)-51 with
trimethylorthoformate in the presence of Montmorillonite® clay K-10 (Scheme 2.5). The
reaction afforded a crude mixture of 75% converted acetal (-)-52 and unreacted starting
material, as adjudged by 1H NMR analysis.
i
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Scheme 2.5. Synthesis of (S)-(-)-camphor dimethyl acetal (-)-52. Reagents and conditions: i. (MeO)3CH, K-10 clay,
hexane, RT, 75% yield.
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Scheme 2.6. Resolution of racemic triol 42. Reagent and conditions: i. a. Crude (-)-(S)-camphor dimethyl acetal (3.5
equiv), 4-TsOH·H2O (0.3 equiv.) CH2Cl2, reflux, b. silica gel column chromatography diastereomeric resolution, 24%
yield.
This crude mixture was reacted directly with triol 42 in the presence of 4-toluenesulfonic
acid monohydrate in dichloromethane under reflux, to give a mixture of the four possible
diastereomeric products (Scheme 2.5).134 Lengthy silica gel column chromatography
was required to obtain compound (-)-41, the only isolable diastereomer from the mixture.
The other three diastereomers 53, 54 and 55 were not separable from each other using
this technique, including the other desired product 53. This being the case, the desired
diastereomer (-)-41 was only acquired in 24% yield. The observed specific rotation for
camphor derivative (-)-41 ( 20D[α] -10.8) compared well with the literature value (
20
D[α]
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-11.7).6 It should be noted that the L-enantiomer can be synthesised at this point, simply
by using the (+)-R-camphor dimethyl acetal. This may potentially be desirable in order to
synthesise the opposite enantiomer of any active analogues, to use as a control in
biological testing, or simply to assess the activity of the alternative enantiomer.
2.4 Synthesis of the 3,5-diallyl protected intermediate (-)-39
Following chromatographic resolution, the alcohol (-)-41 was converted to the
enantiomeric 3,4-diol (-)-40 in two steps, in a manner similar to that reported by Lim et
al.141 PMB protection of alcohol (-)-41 under modified conditions provided intermediate
(-)-56 in good yield. Acidic methanolysis of the camphor acetal, using acetyl chloride in
methanol/dichloromethane, afforded the intermediate (-)-40 (82% yield).
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Scheme 2.7. Synthesis of enantiomeric diol (-)-40. Reagents and conditions: i. NaH, PMBCl, THF/N,N-
dimethylformamide, TBAI, 0 °C to RT, 83% yield; ii. AcCl, MeOH/CH2Cl2, RT, 82% yield;
The following crucial step in the synthesis involved selective allyl protection of the 3-
position alcohol over the 4-position alcohol (see Scheme 2.9). Selective protection of
this nature has been reported on compound (-)-40 within the group, and in the
literature,136,141 in good yield (72%) involving benzyl as opposed to allyl protection
(Scheme 2.8). According to the literature,136 the ratio of isomers formed in this
benzylation was approximately 5:1 in favour of the desired product. The structure of the
major isomer was determined by crystal structure analysis.136 The reaction conditions
involved heating under reflux a mixture of the diol, 1.1 equivalents of dibutyltin oxide, 4.8
equivalents of benzyl bromide and 1 equivalent of tetrabutylammonium iodide in
acetonitrile. Soxhlet apparatus filled with 3 Å molecular sieves served to remove water
generated during the reaction. Allyl protection of diol (-)-40 has not been previously
reported.
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Scheme 2.8. The reported selective benzylation of (-)-40. Reagents and conditions: i. Bu2SnO (1.1 equiv.), TBAI (1
equiv.), BnBr (4.8 equiv.), 3 Å mol. sieves, CH3CN, reflux, 72% yield.8
The analogous reaction using allyl bromide instead of benzyl bromide proved less
successful. Attempts to optimise this reaction are summarised in Table 1. Exposing diol
(-)-40 to the same conditions as above using allyl bromide (Table 1, Experiment 1) gave
only very low conversion of starting material into products after 48 h as indicated by TLC
analysis, even following the addition of further equivalents of allyl bromide. This was
possibly due to the loss of volatile allyl bromide at the temperature required for efficient
reflux of the reaction mixture (~100 °C).
In order to minimise the loss of allyl bromide it was decided that the desired allyl-
protection be carried out over two steps. The mechanism for dibutyltin oxide-based
protection, previously discussed in the literature,142,143 allows this to be performed. The
reaction proceeds via the initial formation of a stannylene acetal upon treatment of the
diol with dibutyltin oxide in a suitable solvent (Scheme 2.9). The intermediate 58 is
believed to form in polar solvents, where co-ordination of a solvent molecule to the tin
atom gives a trigonal bipyramidal stannylene complex. In this structure, the oxygen
atoms of the stannylene are in apical (the 3-position oxygen as depicted in compound
58), and equatorial positions. The bond between the apical oxygen atom and the tin is
longer than the equatorial tin-oxygen bond, and hence more reactive. This results in
increased reactivity of this oxygen towards the allyl bromide electrophile, resulting in
monosubstitution. Once formed via reflux of the diol with dibutyltin oxide, the stannylene
acetal is sufficiently stable to allow the reaction conditions to be altered to favour the
following allylation.
The first attempt at the two-step approach towards allyl protection (Table 1, Experiment
2) followed a procedure reported by Gigg,144 where the dibutyltin oxide and diol mixture
was heated under reflux in toluene using Dean Stark apparatus for the azeotropic
removal of water. The toluene was then removed in vacuo and replaced with DMF as
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Scheme 2.9. Mechanism for the dibutyltin oxide-based protection of (-)-40.
Table 1. Summary of reaction conditions attempted for the formation of compound (-)-39. For a given experiment, “a”
refers to the conditions used for the stannylene acetal-forming step, and “b” refers to the conditions of the following
alkylation step.
solvent. The allyl bromide was then added and the mixture heated to 50 °C. However,
consumption of the starting material was still extremely slow. It was clear that an additive
was required to promote efficient allylation. A number of analogous and highly selective
reactions reported in the literature have utilised caesium fluoride as an additive for tin-
mediated allyl protection.145 Thus, following the initial pre-formation of the stannylene
acetal as before, caesium fluoride was added in the allylation step and after 24 h almost
full consumption of the starting material was seen to have occurred by TLC analysis
(Experiment 3). However, analysis by 1H NMR of the crude product following work-up
Expt. Bu2SnO(equiv.)
AllBr
(equiv.) Salt Solvent
Reaction
progress
by TLC
Ratio of (-)-39:59
(crude)
1. 1.1 6.8 TBAI MeCN incomplete Not determined
2. a
b
1.1
-
-
8.0
-
-
Toluene
reflux
DMF 50 °C
incomplete 1.8 : 1
3. a
b
1.2
-
-
6.0
-
CsF
Toluene
reflux
DMF -20 °C
to RT
Almost
complete
1.6 : 1
36% yield (-)-39
4. a
b
2.0
-
-
8.0
-
CsF
Toluene
reflux
DMF < 0 °C
Almost
complete
1.5 : 1
36% yield (-)-39
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revealed poor selectivity for the allyl protection; the ratio of isomers being 1.6:1 in favour
of the desired compound (-)-39 (Figure 2.4). The compound structure was assigned on
the basis of characteristic proton NMR shifts of the hydroxyl groups for each of the
isomers. An attempt to see if selectivity could be increased by maintaining a low
temperature (< 0 °C) throughout the reaction (Table 1, Experiment 4) offered little
improvement. Further difficulty in separating the two isomers efficiently by silica gel
column chromatography resulted in a maximum isolated yield for the intermediate (-)-39
of 36% following successive separation attempts. The unwanted isomer 59 could not be
isolated by column chromatography without contaminants of (-)-39 present.
Figure 2.4. Partial 1H spectrum (300 MHz, CDCl3) of a crude mixture of compounds (-)-39 and 59 after the allyl
protection under the conditions in Table 2.1, Expt. 3.
The large difference in selectivity between allyl and benzyl protection for this step
suggests that the outcome of the reaction is at least in part dependent on steric
interactions. Benzyl bromide must be of sufficient size to afford significant steric clash
with the 5-O-allyl group upon reaction with the stannane acetal. The axial O-benzyl
group at the 2-position is believed to lie sufficiently far away from the 3-position oxygen
to provide only minimal steric hindrance. π-Stacking interactions of the 2-O-benzyl with
benzyl bromide may also contribute towards enhanced selectivity. Allyl bromide is
apparently too small to provide significant steric interaction with the 5-O-allyl group.
Integrals ratio 1.6:1
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2.5. Attempted synthesis of bisphosphate 37
Having obtained the di-allyl protected intermediate (-)-39, the introduction of the
dialkylphosphinate group at the 4-position, as indicated in the retrosynthesis, was now
required. One method by which this could be achieved was to react the alcohol with the
desired dialkylphosphinic chloride. The dimethylphosphinic chloride 62, although
commercially available in small quantities, can be prepared from inexpensive materials
in two steps using literature procedures (Scheme 2.10). The first step involved the
formation of tetramethyl biphosphine disulfide 61, a dimeric compound, from the reaction
of thiophosphoryl chloride with a suitable Grignard reagent.146 Although the yield for this
step was poor (23%), a sufficient amount of pure material was obtained to produce
significant quantities of the desired phosphinic chloride. Thus, dimethylphosphinic
chloride 62 was subsequently formed by reacting the tetramethyl biphosphine disulfide
with thionyl chloride.147 The dimethylphosphinic chloride was very moisture sensitive,
presumably undergoing hydrolysis to give the corresponding free acid. It was therefore
prepared fresh for use in any subsequent reaction. A range of dialklylphosphinic
chlorides can be prepared in a similar fashion by varying the Grignard reagent used for
the formation of the biphosphine disulfide.146
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Scheme 2.10. Preparation of the dimethylphosphinic chloride reagent 62.146,147 Reagents and conditions: i.
CH3MgBr, Et2O, 0 °C - 8 °C, reflux, 1 h, 23% yield; ii. SOCl2, toluene, -5 °C to RT, 30 min, reflux, 1 h, 57% yield.
Phosphinylation of alcohol (-)-39 was performed under similar conditions employed for
this type of reaction in the literature.136,148 Therefore, intermediate (-)-38 was obtained by
the addition of dimethylphosphinic chloride in DMF with 2,6-lutidine as a base, in high
yield (89%, Scheme 2.11). Allyl deprotection at the 3- and 5-positions was then required.
Conditions reported by Chen et al. resulted in allyl deprotection in high yields for several
inositol-based compounds bearing a PMB-ether as one of the substituents.149 According
to this procedure, the palladium catalyst would effect the isomerisation of the allyl
groups, followed by acidic cleavage of the resultant vinyl ether. However, employing
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such conditions for the allyl deprotection of (-)-38 by heating a mixture of (-)-39,
palladium on carbon and 4-toluenesulfonic acid in methanol/water under reflux afforded
diol 63 in a modest yield of 31%. PMB deprotection was also observed under such
conditions, owing to the low yield. A standard de-allylation procedure using Wilkinson’s
catalyst for the allyl isomerisation under reflux, followed by acidic cleavage of the vinyl
ether at room temperature also resulted in a poor yield (30%) and less pure product.
Despite this, sufficient material was obtained in order to attempt the next step, directly
following the de-allylation.
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Scheme 2.11. Attempted synthesis of intermediate 37. Reagents and conditions: i. a. nBu2SnO, toluene, reflux; b.
AllBr, CsF, N,N-dimethylformamide; 36% yield; ii. Dimethylphosphinic chloride, 2,6-lutidine, N,N-dimethylformamide,
89% yield; iii. Pd/C, 4-TsOH·H2O, MeOH/H2O, reflux, 31% yield; iv. a. bis(benzyloxy)-N,N-diisopropylamino
phosphine, 1H-tetrazole; b. mCPBA, inseparable mixture of products.
Phosphitylation at the 3- and 5-positions of the inositol ring was attempted. Standard
conditions for phosphitylation were employed. For the synthesis of benzyl protected
phosphates, such conditions require the synthesis of the phosphoramidite reagent
bis(benzyloxy)-N,N-diisopropylamino phosphine 65, which was derived from phosphorus
trichloride in two steps (Scheme 2.12).150 Addition of the diol 63 to a mixture of excess
phosphoramidite 65 and 1H-tetrazole in dichloromethane followed by oxidation by
mCPBA resulted in full consumption of the starting material. However, the desired di-
phosphorylated product 37 was not obtained. A mixture of two mono-phosphorylated
products, inseparable by silica gel column chromatography, were identified by 1H and
31P NMR. Mass spectrometric data of the product mixture revealed only one M+ ion,
suggesting that the products were regioisomers. There are two possible scenarios that
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could have led to this isomeric mixture. Firstly, the two compounds could have arisen
from two separate phosphitylation events at the 3- and 5-positions respectively, with a
second phosphitylation of both resultant intermediates proving unfavourable in the
chosen reaction conditions. A second possibility is that the phosphinate group migrated
following phosphitylation of one of the alcohols, again resulting in an isomeric mixture.
Incompatibility of the phosphinate moiety on the inositol ring with standard
phosphitylation conditions has proved not to be an isolated example, as this has since
been observed within the research group on a different substrate.
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Scheme 2.12. Synthesis of bis(benzyloxy)-N,N-diisopropylamino phosphine 65.150 Reagents and conditions: i. a.
Pyridine, diethyl ether, benzyl alcohol, -78 °C to RT; b. Diisopropylamine, diethyl ether, -5 °C to RT, 62% yield; ii. 1-H
tetrazole (0.43 M in CH3CN), benzyl alcohol, CH2Cl2, 71% yield.
2.6. Summary
Analysis of the crystal structure of InsP4 bound to PKBαPH,54 and comparison with the
apo PKBαPH structure, has enabled the rational design of novel PtdIns(3,4,5)P3
analogues. Such compounds are altered at the 4-position to prevent the formation of an
activating conformational change in the PH domain of PKB upon ligand binding, thus
potentially acting as selective inhibitors of this oncogenic protein. A synthetic strategy
towards the primary target, the dimethylphosphinate 33, was devised. Although
advanced intermediate 63, bearing the required phosphinate at the 4-position, was
successfully synthesised enantiomerically pure in 12 steps, phosphitylation of this
compound failed. It would appear that the dimethylphosphinate group is susceptible to
migration under the conditions for phosphitylation. In order to circumvent this problem,
an alternative synthetic approach was to be devised.
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Chapter 3. Results and Discussion Part 2
3.1. Second synthetic approach
The initial synthetic route towards the 4-dimethylphosphinate PtdIns(3,4,5)P3 analogue
33 presented a series of problems which undermined the viability of this route (see
chapter 2). It seemed necessary to introduce the phosphate groups prior to the
dimethylphosphinate to avoid migration of the phosphinate moiety. Thus, in order to
introduce the dimethylphosphinate group at a late stage in the synthesis, a route was
conceived whereby the 4-position hydroxyl is functionalised as the penultimate step,
prior to global debenzylation (Scheme 3.1). Although lengthier than the initial strategy,
this synthetic approach would facilitate the synthesis of a greater number of analogues.
Potentially, key intermediate 66 could be reacted with a range of electrophiles, enabling
the introduction of the type of functionality desired for probing the PKB PH domain,
followed by the final deprotection step. The phosphoglyceryl unit was to be introduced at
the 1-position of alcohol 67, synthesised from the 3,5-diol 68. Given the poor outcome of
the tin-mediated allyl protection of the 3-position of compound (-)-40 discussed in
chapter 2, an alternative protecting group would be employed for the selective protection
of intermediate 70. This compound could again be derived from the racemic triol 42.
OH
O
HO
O
O
O
P
P P
O-Na+
+Na-O
O
+Na-O O
-Na+
O
P
O
O-Na+
O
OAc
OAc
O 33
OBn
OAll
BnO
HO
OH
OTIPS
OBn
OAll
BnO
PgO
OH
OTIPS
OBn
OH
BnO
HO
OPMB
OTIPS
OBn
O
BnO
O
OH
O
P P
OBn
BnO
O
BnO OBn
O
P
O
OBn
O
OAc
OAc
OBn
O
BnO
O
OPMB
OH
P P
OBn
BnO
O
BnO OBn
O
66 67
686970
OBn
OAll
BnO
HO
OH
OH
42
selective
protection
Scheme 3.1. Retrosynthesis for the racemic PtdIns(3,4,5)P3 analogue 33.
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Given the low yield of the resolution step, the synthetic complexity of the target molecule
and the potential requirement for extensive optimisation of reaction conditions, it was
decided that the first series of the 4-position analogues using this route were to be
synthesised as a mixture of diastereomers, derived from a racemic synthesis. With
respect to PKB PH domain inhibition, the protein would “select” the active enantiomer
from a racemic mixture, presumably the D-enantiomer, given that the L-isomer of
PtdIns(3,4,5)P3 does not bind to the PKB PH domain.151 Crystal structure analysis of
active compounds bound to PKB PH would help confirm which enantiomer of each
analogue is active. The synthetic approach outlined was devised to allow compatibility
with the camphor acetal resolution, permitting the subsequent synthesis of enantiopure
analogues as required. The intention was, therefore, to maximise the output of
analogues for biological testing at as early a stage as possible. Information gained from
the testing of the racemic compounds would direct the synthesis of the enantiomeric
analogues.
3.2. Synthesis of 2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-3,5-
bis(dibenzylphosphate)-myo-inositol 67
The primary objective for this route was to synthesise key intermediate 67 (Scheme 3.2).
This compound represents a versatile intermediate, at which point the phosphodiester is
introduced at the 1-position. The length of the diester group can be varied at this stage,
with the diacetyl glyceryl moiety being employed in the first instance, as indicated. For
this racemic synthesis, the 3,4-vicinal diol was protected as the acetonide, instead of the
camphor acetal, in good yield to afford compound 71 (Scheme 3.2). The 1-position
hydroxyl group was then protected as the triisopropylsilyl (TIPS) ether, followed by acidic
methanolysis of the acetonide, both proceeding in excellent yield, to provide the 3,4-diol
70.
Tin-mediated allyl protection of the 3-position hydroxyl of diol 70, using the optimal
conditions described in the previous chapter, was attempted once. However, the
outcome was again poor, providing the desired product in only 21% yield. Thus attention
was turned to formation of the benzoate ester 73. This was attempted by adding benzoyl
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chloride to a cooled mixture of the pre-formed stannylene acetal derived from diol 70 in
toluene. After reaching room temperature, the reaction was complete within 3 h. This
reaction proved to be highly selective for the 3-position, as only the desired 3-O-benzoyl
protected compound 73 was isolated upon purification of the crude mixture, in an
optimum yield of 73%. Protection at the 4-position was not observed. Regioselectivity
was confirmed by single X-ray crystal structure analysis of the product (Figure 3.1).
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Scheme 3.2. Racemic synthesis of key intermediate 67. Reagents and conditions: i. 2,2-Dimethoxypropane, 4-
TsOH·H2O, DMF, 89% yield; ii. TIPS triflate, 2,6-lutidine, CH2Cl2, 94% yield; iii. 4-TsOH·H2O, MeOH, 95% yield; iv.
a. nBu2SnO, toluene, reflux, b. Benzoyl chloride, 0 °C→RT, 73% yield; v. PMB-trichloroacetimidate 78, Y(OTf)3 (1.2
mol%), PhCH3, -78 → -10 °C, 80% yield (impure); vi. NaOH, MeOH/Et2O, 85% yield, vii. a. Wilkinson’s Catalyst,
Hünig’s base, EtOH, reflux; b. 4-TsOH·H2O, MeOH, 72% yield; viii. a. bis(benzyloxy)-N,N-diisopropylamino
phosphine, 1H-tetrazole, CH2Cl2, b. mCPBA -78 °C → RT; ix. TBAF, THF, 76% yield over 2 steps.
High selectivity for this type of benzoylation process is well documented.142 The
observation that the 4-benzoate ester is not formed in this instance may be due to an
equilibrium in which intramolecular transesterification occurs (Scheme 3.3). In non-polar
solvents, the stannylene exists as a dimer which reacts with the benzoyl chloride. The
resulting esterified compound can undergo transesterification via formation of a cyclic
tetrahedral intermediate.152 The equilibrium promotes accumulation of the less hindered
4-substituted intermediate in the reaction mixture, prior to work-up.
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Scheme 3.3. Proposed transesterification process in the tin-mediated benzoylation of diol 70.
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Figure.3.1. PyMOL representations of the X-ray crystal structure of compound 73. Colour of atoms: green
= carbon; red = oxygen; orange = silicon.
With only the 4-position hydroxyl group exposed, 4-methoxybenzyl (PMB) protection of
alcohol 73 was then attempted. The use of sodium hydride and PMB chloride for this
process failed, as benzoyl migration and partial deprotection could not be prevented
under these conditions. Therefore, the employment of the PMB-trichloroacetimidate
(PMB-TCA) chemistry was required.153 The PMB-TCA 78 was initially synthesised from
PMB alcohol and trichloroacetonitrile using phase transfer catalysis in aqueous KOH
and dichloromethane (Scheme 3.4).154 However, following purification by alumina gel
column chromatography, the trichloroacetimidate 78 was isolated in only 22% yield.
Alternative reaction conditions involved stirring the PMB alcohol with a catalytic amount
(0.15 equiv.) of sodium hydride in diethyl ether for 45 min.155 Subsequent addition of
trichloroacetonitrile resulted in full consumption of the PMB alcohol. Work up involved
solvent exchange for petroleum ether. Addition of a few drops of methanol resulted in
the precipitate of unwanted by-products which could be removed by filtration through
Celite. Facile purification of the crude filtrate by alumina gel column chromatography
provided acetimidate 78 in 90% yield.
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Scheme 3.4. Synthesis of 4-methoxybenzyl trichloroacetimidate (PMB-TCA) 78. Reagents and conditions: i.
nBu4NHSO4, 50% aqueous KOH, Cl3CCN, CH2Cl2, 22% yield; ii. NaH, 0 °C → RT, Cl3CCN, 0 °C → RT, Et2O, 90%
yield.
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Experiment Acid catalyst
mol.% of
catalyst
solvent
Reaction
temperature
Yield of 74
1 CSA 10 CH2Cl2 RT trace
2 TfOH 0.3 - 20 Et2O RT no reaction
3 BF3·Et2O 40 CH2Cl2 RT no reaction
4 Sc(OTf)3 5 PhCH3 -78 to -40 °C
43%
(impure)
5 Y(OTf)3 5 PhCH3 -78 to -10 °C
45%
(impure)
6 Y(OTf)3 2 PhCH3 -78 to -10 °C
68%
(impure)
7 Y(OTf)3 1.2 PhCH3
-78 to -10 °C
to RT
80%
(impure)
Table 3.1. Results of the PMB protection of 73 using PMB-TCA under various conditions. CSA = camphor
sulfonic acid; RT = room temperature. Yields quoted are approximate due to the presence of a trace
impurity.
The protection of alcohol 73 using PMB-TCA required significant optimisation, the
results of which are summarised in Table 3.1. Many acid catalysts have been employed
for such transformations in the literature, although the commonly used camphor sulfonic
acid,156 triflic acid157 and boron trifluoride diethyl etherate155 (Experiments 1-3) all failed
to promote the reaction. However, some transition metal triflates have been identified in
the literature as highly activating catalysts for this type of process, with complete PMB
protection observed in only 5 minutes in certain instances.158 Indeed, complete
consumption of starting material 73 was observed after 2 h of stirring the alcohol with
PMB-TCA and 5 mol% Sc(OTf)3 at -40 °C (Experiment 4). However, inositol 74 was
obtained in a modest 43% yield. The use of 5 mol% Y(OTf)3 with the reaction
proceeding at -10 °C gave a similar yield (Experiment 5). For such reactions, formation
of an isomeric by-product was identified from a complex product mixture. It is believed
that this material was derived from the migration of the benzoyl group to the 4-position,
prior to reaction with the PMB-TCA. Performing the reaction on a large scale facilitated
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the lowering of the catalyst loading to 2 or even 1.2 mol%, which afforded the desired
compound in an optimal yield of 80%. One remaining problem with the reaction was that
it did not prove possible to completely remove a PMB-related impurity from the material
by silica gel column chromatography, although the impurity was a very minor component
of the product as adjudged by 1H NMR analysis. Thus, the yields quoted in Table 3.1 are
approximate. In any case, the impurity could be easily separated from the product of the
subsequent reaction.
Following PMB-protection of the 4-position alcohol, the benzoyl group was removed,
using 2 M NaOH in methanol/ether (3:1), in 85% yield providing alcohol 75. Subsequent
allyl deprotection was performed in reasonable yield. This deprotection was achieved by
refluxing the inositol 75, Wilkinson’s catalyst [(Ph3P)3RhCl] and Hünig’s base in ethanol
for 2.5 h to perform isomerisation of the allyl group, followed by cleavage of the resulting
vinyl ether with 4-toluenesulfonic acid in methanol.
The 3,5-diol 68 thus formed was subjected to the standard conditions for
phosphitylation. Treatment with excess bis(benzyloxy)-N,N-diisopropylamino phosphine
and 1-H tetrazole, followed by oxidation of the resulting phosphite groups by mCPBA,
afforded the benzyl-protected 3,5-bisphosphate 76 in high yield. This material was again
difficult to purify. For this type of reaction on an inositol substrate, the desired
compound, bearing the polar phosphate groups, is typically easy to separate from the
less polar phosphoramidite by-products by silica gel chromatography. However, the
triisopropylsilyl ether group at the 1-positon of compound 76 renders this compound
relatively non-polar. This made chromatographic separation of 76 from such by-products
difficult by column chromatography, although a number of solvent elution systems were
attempted. Once the TIPS group was removed in the following step, using TBAF in THF,
the alcohol 67 could then be separated from any remaining phosphoramidite impurities
by silica gel chromatography. Thus, overall, pure intermediate 67 was obtained from
compound 68 in 76% yield over two steps. Several grams of this versatile intermediate
could be obtained using the route described.
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3.3. Synthesis of the key 4-hydroxy intermediate 66
The next key step in the synthesis involved the introduction of the phosphodiester group
at the 1-position of alcohol 67. This reaction required the synthesis of a phosphoramidite
bearing the diacyl glyceryl moiety, achieved in five steps from commercially available
(S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (+)-79 (Scheme 3.5). Thus, benzyl
protection of compound (+)-79159 followed by acidic methanolysis afforded diol (-)-81 in
high yield.159 Acylation of the 1- and 2-positions gave (+)-3-O-benzyl-1,2-diacetylglycerol
(+)-82.160 The observed specific rotation for intermediate (+)-82 ( 20D[α] = +16.4) compared
favourably with the literature value ( 20D[α] = +16.2).
160 However, hydrogenolysis of the
benzyl group of this glycerol did not prove straightforward. Following the conditions
previously reported in the literature,161 which involved stirring compound (+)-82 with
palladium on carbon in methanol under hydrogen for 12 hours, afforded a mixture of two
products as adjudged by 1H NMR analysis. These compounds had identical TLC Rf
values and were inseparable by silica gel column chromatography. Analysis of the 1H
NMR indicated that partial migration of an acetyl group had occurred following
debenzylation, to give a mixture of meso 1,3-diacetyl glycerol as well as the desired
product (-)-83. Attempts to separate these compounds by silica gel chromatography
appeared to result in an increase in the ratio of migrated compound. Repeating the
reaction, ensuring minimum reaction time for full consumption of starting material, gave
the same result.
It was evident that the reaction conditions had to be altered to ensure that clean product
was obtained. Using THF as the solvent instead of methanol, the migration process was
avoided, giving the alcohol (-)-83 in 96% yield without the need for chromatographic
purification. However, reaction times under these conditions were significantly extended,
with 5-7 days typically required for full consumption of starting material. Replacing
palladium on carbon with palladium hydroxide (Pearlman’s catalyst), resulted in a more
efficient hydrogenolysis process. Under such conditions, the reaction was complete in
22 h (91% yield). It should be noted that the observed specific rotation for product (-)-83
for the two debenzylation conditions were in good agreement ( 20D[α] = -3.40, c 0.6 and
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D[α] = -4.10, c 1.0 in CHCl3 where Pd/C and Pd(OH)2 are used respectively). These
values differ from the only value reported in the literature ( 20D[α] = +8.3, c 0.4 in
CHCl3),161 derived from the report describing the method where the debenzylation was
performed in methanol. As noted, however, the use of this procedure did not appear
conducive to providing pure material, due to acetyl migration.
Finally, intermediate (-)-83 was successfully reacted with benzyloxy bis(N,N-
diisopropylamino)phosphine with 1-H tetrazole in dichloromethane to give the desired
phosphoramidite 84. It should be noted that compound 84 was unstable and, therefore,
this compound had to be synthesised shortly before the time of use.
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Scheme 3.5. Synthesis of phosphoramidite 84. Reagents and conditions: i. NaH, BnBr, DMF, 0 °C → RT 87% yield; 
ii. Conc. HCl, MeOH, reflux, 91% yield; iii. Acetic anhydride, DMAP, triethylamine, THF, 91% yield; iv. Pd/C, H2, THF,
5-7 days, 96% yield; v. Pd(OH)2, H2, THF, 22 h, 91% yield; vi. Benzyloxy bis(N,N-diisopropylamino)phosphine, 1H-
tetrazole, CH2Cl2, 76% yield.
The reaction of phosphoramidite 84 and 1-H tetrazole with the 1-hydroxyl 67 in
dichloromethane proceeded smoothly, giving compound 85 in 84% yield following
mCPBA oxidation and subsequent purification (Scheme 3.6). One problem with the
product of this reaction is that as the inositol starting material was racemic, a mixture of
four diastereomers resulted, due to the chiral nature of the 1-position phosphate being
introduced. The consequence of this, coupled with the complexity of the molecule
bearing seven benzyl groups, is that the 1H, 13C and 31P NMR spectra are convoluted
(see Figure 3.2). This remains the case for any subsequent intermediates, until the
benzyl group of the 1-position phosphodiester is removed in the final deprotection step
to give a racemic final product.
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Scheme 3.6. Synthesis of key 4-OH intermediate 66. Reagents and conditions: i. a. Phosphoramidite 84, 1H-
tetrazole, CH2Cl2, b. mCPBA -78 °C → RT, 84% yield; ii. CAN, MeCN/H2O (4:1), 84% yield.
The synthesis of key intermediate 66 was completed by the oxidative cleavage of the
PMB protecting group using ceric ammonium nitrate (CAN) in acetonitrile/water (84%
yield). From alcohol 66, the 4-dimethylphosphinate 33 and several other 4-position
analogues could be synthesised in two steps.
Figure 3.2. The partial 1H NMR spectrum (300 MHz, CDCl3) of compound 85. The complexity of the spectrum is partly
due to the introduction of the chiral phosphate at the 1-position, producing 4 diastereomers, with the stereocentre of
the glyceryl moiety fixed. The appearance of the two acetyl CH3 groups as a complex multiplet demonstrates this.
3.4. The synthesis of 4-position-modified PtdIns(3,4,5)P3 analogue precursors
3.4.1 Synthesis of the 4-dimethylphosphinate precursor
In order to complete the synthesis of the 4-phosphinate target compound,
phosphinylation of alcohol 66 was now required, followed by global deprotection.
Several conditions for this reaction were tested before an efficient approach was found
(Table 3.2). Compound 66 proved unreactive under the conditions previously employed
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for the phosphinylation of inositol intermediate (-)-39 described in chapter 2. Thus, the
reaction of alcohol 66 with dimethylphosphinic chloride and 2,6-lutidine in DMF provided
the desired product in only 5% yield after 3 days at room temperature (Table 3.2,
Experiment 1), with recovered starting material as the major by-product. Changing the
solvent to acetonitrile resulted in gradual decomposition of the starting material
(Experiment 2), with several products forming as adjudged by TLC analysis. Returning
to DMF as solvent (Experiment 3), but trying a different base while heating the reaction
mixture, did not promote the reaction to any noticeable extent.
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Conditions
Experiment Reagents Solvent Time,Temperature Yield of 86
1 Excess Me2P(O)Cl and2,6-lutidine DMF 3 days, RT 5%
2 Excess Me2P(O)Cl and2,6-lutidine CH3CN 18 h, RT
Decomposition
of starting
material
3 Excess Me2P(O)Cl andHünig’s base DMF 48 h, 50 °C
No significant
reaction
4
i. Excess Me2PCl and
triethylamine
ii. mCPBA
CH2Cl2 48 h, RT 9%
5 Excess Me2PCl
Pyridine/CH2Cl2
(5:1) 2.5 h, RT 60%
Table 3.2. Experimental conditions for the phosphinylation of compound 66. RT = room temperature.
It was evident that an alternative phosphinylating reagent was required. The 4-position
hydroxyl of alcohol 66 was clearly somewhat hindered by the 3- and 5-position
bisbenzyl-protected phosphates. It was believed that the use of a smaller, more reactive
electrophile might improve the outcome of the reaction. Dimethylchlorophosphine was
therefore employed, using triethylamine as base in dichloromethane (Experiment 4).
However, the reaction again proved sluggish. A thick precipitate quickly formed during
the reaction and additional equivalents of reagents were required throughout in order to
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force full consumption of the starting material after 48 h. mCPBA was then added to
ensure formation of the phosphinate. Following chromatographic purification, compound
86 was isolated in a disappointing 9% yield. Although the starting material was
consumed, prolonged reaction times under the conditions employed appeared to result
in decomposition, probably of both starting material and product. A far more favourable
outcome was achieved by reacting the alcohol with dimethylchlorophosphine in
pyridine/CH2Cl2 (5:1) (Experiment 5). The reaction completed in 2.5 h, and oxidation of
the resulting phosphine to the phosphinate occurred spontaneously during work-up of
the reaction, providing compound 86 in 60% yield.
3.4.2 Synthesis of 4-sulfonate precursors
While optimisation of the phosphinylation was being performed, the synthesis of other
analogue precursors was attempted. The introduction of sulfonates to the 4-position via
an appropriate sulfonyl chloride offered an attractive means by which to probe the PKB
PH binding site with the derived analogues.
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Scheme 3.7. Synthesis of sulfonates 87 and 88. Reagents and conditions: i. CH3SO2Cl, triethylamine, DMAP, CH2Cl2,
55% yield of 87; ii. PhSO2Cl, triethylamine, DMAP, THF, 40% yield of 88.
Reaction of alcohol 66 with methanesulfonyl chloride, triethylamine and
dimethylaminopyridine (DMAP) in dichloromethane gave the 4-mesylate 87 in 55% yield
(Scheme 3.7). The introduction of aromatic functionality at the 4-position was sought
through the synthesis of the 4-phenylsulfonate 88. This was achieved by using the
electrophile benzenesulfonyl chloride effectively as a co-solvent, as otherwise the
reaction would not proceed at an appreciable rate. Again, this is most likely due to steric
hindrance from the the 3- and 5-position phosphates. Reaction under these conditions
with the addition of triethylamine and DMAP afforded the 4-sulfonate 88 in 40% yield.
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However, this compound was again difficult to fully purify, and was found to be relatively
unstable, decomposing over time. Therefore, an alternative approach for the introduction
of aromatic groups at the 4-position was required.
3.4.3 Synthesis of the 4-phenylcarbonate and 4-O-phenoxyacetyl precursors
In order to probe the aromatic hydrophobic pocket proximal to the PKB PH ligand
binding site, the synthesis of 4-position-modified PtdIns(3,4,5)P3 analogues with an
aromatic group of variable distance from the inositol ring was attempted (Scheme 3.8).
Thus, the 4-O-phenoxyacetyl intermediate 89 was synthesised by reaction of compound
66 with excess phenoxyacetyl chloride, triethylamine and DMAP in THF in 67% yield.
Rapid silica gel chromatographic purification was required following completion of the
reaction to prevent degradation of the product and to afford the optimum yield. The
analogous reaction using phenylchloroformate as the electrophile, to form the carbonate
90, was inefficient, resulting in isolation of impure product 90 in only 11% yield.
Alternative conditions, where alcohol 66 is stirred with phenylchloroformate and DMAP
in pyridine/CH2Cl2 (5:1), provided the desired 4-phenylcarbonate in 60% yield.
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Scheme 3.8. Synthesis of 4-position ester and carbonate compounds 89-91. Reagents and conditions: i.
PhOCH2C(O)Cl, triethylamine, DMAP, THF, 67% yield of 89; ii. PhOC(O)Cl, DMAP, pyridine/CH2Cl2 (5:1), 60% yield
of 90; iii. BnOC6H4C(O)Cl, triethylamine, DMAP, THF, 20% yield of 91 (impure).
The introduction of a phenolic group at the 4-position of a PtdIns(3,4,5)P3 analogue was
attractive as it offered the potential to interact with Phe-55 of the PH domain, as well as
possessing hydrogen bonding capacity for binding to the basic amino acid residues in
the binding site around where the 4-position of the ligand is located. Therefore, as a
precursor to such an analogue, the synthesis of the benzyl-protected phenolic ester 91
was attempted. Alcohol 66 was thus stirred with (4-benzyloxy)benzoyl chloride,
triethylamine and DMAP in THF. However, conversion of the starting material to product
was slow, and after two days degradation of the inositol material was seen to occur by
63
TLC analysis. Consequently, compound 91 was only formed in approximately 20% yield,
and could not be isolated sufficiently pure by chromatography. Performing the reaction
in pyridine resulted in negligible conversion of starting material.
3.4.4 Attempted synthesis of acidic 4-position derivatives
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Experiment Targetcompound Electrophile Conditions
Reaction
outcome
1 92 BrCH2CO2Bn NaH, THF, -5 °C to RT
Inseparable
mixture of
products
2 92 TfOCH2CO2Bn NaH, THF, -5 °C to RT
Inseparable
mixture of
products
3 93 ClC(O)CH2CO2Bn DMF
29% yield of
93 (impure)
4 94 1H-tetrazole-5-acetic acid DCC, DMAP, DMF, RT
Formation of
94 not
observed
5 94 1H-tetrazole-5-acetic acid
Hünig’s base, HOBt,
EDCI, DMF, RT to 50 °C
Formation of
94 not
observed
Table 3.3. Conditions used for the attempted synthesis of 4-O-acetylbenzoate 92, 4-malonylbenzoate 93 and 4-O-
acetyl(1'H-tetrazole) 94.
Given the highly basic nature of the PKB PH ligand binding site, it was considered that
replacing the 4-phosphate with an alternative acidic group may be necessary to maintain
reasonable affinity. Thus, synthesis of the 4-O-acetylbenzoate 92 was attempted under
various conditions (Table 3.3). Addition of sodium hydride to a mixture of alcohol 66 and
excess benzyl 2-bromoacetate in THF resulted in slow consumption of starting material,
yielding a complex mixture of products, inseparable by silica gel column
chromatography. It is believed that the reaction conditions may have resulted in the
migration of the 3- and/or 5-position phosphates to the 4-position, prior to the reaction of
alkoxide with benzyl 2-bromoacetate. Attempts to limit phosphate migration by
maintaining the reaction temperature below 0 °C merely prolonged reaction times
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further, resulting in gradual decomposition of starting material and product. It was
reasoned that if the electrophile was more reactive, reaction with the 4-position alkoxide
may occur prior to phosphate migration. However, using the triflate of benzyl glycolate
as the reagent, instead of the bromide, again resulted in formation of a complex mixture
of products (Experiment 2)
The introduction of a malonate ester at the 4-position appeared more promising. Alcohol
66 could be reacted with mono-benzyl malonyl chloride to give analogue precursor 93
(Experiment 3). However, again the reaction was sluggish, and addition of excess
reagents was once more required to drive consumption of the starting material.
Purification of the desired compound 93 was difficult, and the desired product was only
obtained in 29% yield as an impure gum.
A bid was also made to synthesise analogue precursor 94 bearing a tetrazole group, an
isostere of a carboxylic acid, at the 4-position (Experiments 4 and 5). Coupling of alcohol
66 with 1H-tetrazole-5-acetic acid was attempted using 1,3-dicyclocarbodiimide (DCC)
and DMAP in DMF. A second attempt involved heating to 50 °C a mixture of the inositol
66, Hunig’s base, 1-hydroxy-benzotriazole, EDCI and 1H-tetrazole-5-acetic acid in DMF.
Both reactions were monitored by TLC and LC-MS, but formation of the desired product
was not observed in either case, with recovered starting material the major product.
3.5. Global deprotection of PtdIns(3,4,5)P3 analogue precursors
The final step in the synthesis of the PtdIns(3,4,5)P3 analogues required global
debenzylation under hydrogenolysis conditions. This reaction was performed on those
precursor compounds that had been successfully synthesised, purified and that were
sufficiently stable. The global debenzylation of inositol polyphosphates, including
PtdIns(3,4,5)P3, has strong literature precedent.134,162 Several varying conditions have
been employed successfully. Previously within the group, a range of bisphosphate InsP3
analogues were synthesised by hydrogenolysis using palladium black (20 equivalents)
in t-butanol/water (6:1) in the presence of sodium bicarbonate to generate bisphosphate
sodium salts 95-98 (Scheme 3.9).136,163 Migration of one of the phosphate groups is
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always a possibility during such reactions, where a free alcohol can potentially attack a
phosphate in an intra- or intermolecular migration process. However, migration was only
observed in attempts to synthesise compound 99. All other reactions gave clean
products after 5-8 h.
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Scheme 3.9. The reported synthesis of InsP3 analogues following global debenzylation.15,16 Reagents and conditions:
i. Pd black (20 equiv.), NaHCO3 (4 equiv.), tBuOH/H2O (6:1), H2. 5-8 h. Yields shown in parenthesis.
These conditions were therefore the starting point for the synthesis of the
PtdIns(3,4,5)P3 analogues. In an initial attempt, the 4-dimethlyphosphinate 86 was
subjected to the same conditions (Scheme 3.10). After 4 h reaction time, debenzylation
was incomplete as adjudged by 1H NMR analysis, with no migration observed, and the
material was returned to reaction conditions for a further 3 h. Although debenzylation
was complete by this time, some migration is believed to have occurred, as indicated by
analysis of the 31P NMR. The reaction was repeated, but with the addition of further Pd
black after 3 h in an effort to reduce reaction time and aid completion of the
debenzylation. The reaction was allowed to proceed for an additional 3 h, after which
time full deprotection was complete. However, 1H and 31P NMR analysis revealed small
amounts of an impurity, ~ 3% (Figure 3.4); probably a compound which is produced as a
result of migration of one of the phosphate groups. This result raised serious concerns
over the tendency of analogue 33 to undergo migration in aqueous conditions. Such a
process could disrupt any biological testing that would be carried out in an aqueous
environment.
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Scheme 3.10. Attempted global debenzylation of compounds 86, 87, 89, and 90. Reagents and conditions: i. Pd
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Figure 3.4. Partial 31P NMR spectrum (300 MHz, D2O) for compound 33, following debenzylation of inositol 86. The
NMR indicates migration of the 1-position phosphate.
In an effort to reduce reaction times, Pearlman’s catalyst was used as an alternative to
Pd black for several substrates. However, although debenzylation was quicker, the
conditions appeared to promote phosphate migration further, providing complicated 31P
31P NMR signal for compound
in which it is assumed the 1-position phosphate
has migrated
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NMR spectra. Returning to the use of Pd black, global deprotection of the 4-mesylate
intermediate to give compound 100 completed in a much reduced reaction time
compared with the deprotection of the phosphinate 66 (3 h, 80% yield). This compound
was, therefore, initially isolated without any evidence of migration. However, following
several weeks of cold storage, analysis by 1H and 31P NMR did reveal that migration
occurred over time to a degree, even with isolated material.
Judging from the 31P NMR of analogue 33, it appeared that it was the 1-position
phosphate which underwent migration in the debenzylation of compound 86. This
contrast with the lack of migration observed with similar compounds in Scheme 3.9 can
be rationalised. It is believed that the formation of the disodium salt following phosphate
debenzylation may stabilise a phosphate group against migration. Furthermore, it is
understood that phosphate esters are more susceptible to migration than both the acid
and the sodium salt. This would explain why migration is observed only in the formation
of compound 99 in the InsP3 analogue syntheses (Scheme 3.9), where the
dimethylphosphate group at the 4-position is thought to have migrated. Since the 1-
position phosphate of the PtdIns(3,4,5)P3 analogues bears an ester unit, it seems logical
that this phosphate group is most susceptible to migration. Although
phosphatidylinositols have been synthesised under the same conditions previously in
the literature,141,164 such compounds possess considerably longer diester chains on the
1-position phosphate. Such long chains presumably prevent the phosphate from
migrating, due to steric interactions. Although analogues bearing relatively short-chain
esters on the glyceryl unit, such as dibutyryl or dioctanoyl groups, have been reported
on several occasions,164,165 there are few reports of acetyl groups being employed for
the phosphodiester chain. Possibly, PtdIns(3,4,5)P3 analogues will require relatively
lengthy diester chains to stabilise the compounds against migration.
Problems were also encountered with the final deprotection step in the synthesis of the
4-phenylcarbonate 90. Following initial reaction of 3 hours, 1H and 31P NMR analysis
indicated the presence of two compounds; one major and one minor. To ensure
completion of the debenzylation process, the material was returned to reaction
conditions for a further 1 hour. However, two compounds remained, and it emerged
following 1H and 31P NMR analysis that what was the minor component was now the
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major one. Comparison of the data revealed that the amount of material bearing the
carbonate at the 4-position was diminishing over time under the reaction conditions (see
Figure 3.5). It was therefore apparent that the carbonate group was being cleaved under
such conditions.
Figure 3.5. 1H NMR spectra in D2O demonstrating the cleavage of the carbonate group during the debenzylation of
86. Comparison of the integrals for the CHOAc glyceryl proton (multiplet) and the 4-H proton of the inositol ring (triplet)
indicates a reduction in material bearing the carbonate group over time. A. 1H NMR spectrum after 3 hours reaction;
B. 1H NMR spectrum after 4 hours reaction.
A similar outcome was observed for the deprotection of 1-O-phenoxyacetyl 89. Partial
cleavage of the ester group was observed, even when reaction time was minimised.
Presumably the sodium bicarbonate used to generate the sodium salts of the
phosphates must play a role in this unwanted side-reaction. Potentially, this problem
A
B
69
may be overcome simply by omitting the sodium bicarbonate for the duration of the
debenzylation, then adding it to rapidly form the desired salt before work-up. This way,
the length of time that the compound is exposed to the bicarbonate is minimised.
However, given the apparent tendency of the 1-phosphate of this class of compounds to
migrate over time, further efforts to optimise conditions for this step could not be
justified.
3.6 Summary
Following the problems encountered in the first synthetic approach towards novel
PtdIns(3,4,5)P3 analogues, a second approach was devised. This involved the
introduction of appropriate functionality to the 4-position as the penultimate step in the
synthesis. A racemic synthesis of the key 4-hydroxy intermediate 66, bearing protected
phosphates at the 3- and 5-positions and a phosphodiester at the 1-position, was
achieved in high overall yield. Despite steric hindrance from the neighbouring phosphate
groups, the 4-position of alcohol 66 was successfully functionalised to synthesise
analogue precursors with either phosphinate, sulfonate, carbonate or ester groups at
this position. Several attempts had been made to synthesise further analogue
precursors, but the lack of reactivity of alcohol 66 and purification difficulties curtailed the
success of such efforts.
Unfortunately, final debenzylation of the penultimate compounds was problematic.
Prolonged exposure to aqueous conditions facilitated the migration of the 1-position
phosphodiester to a neighbouring alcohol of the inositol ring. This was observed to occur
during reaction in basic conditions, as with the synthesis of the 4-dimethlphosphinate 33,
or with the isolated material over time as with the 4-mesylate 100. Furthermore, the
carbonate and ester groups of compounds 89 and 90 were partially cleaved under the
deprotection conditions employed.
In order to reduce the chances of migration of the 1-position phosphate, both during the
final step, in storage and in conditions for biological testing, it seemed that modification
of the target compound was required. Also, alteration of debenzylation conditions
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appears necessary in order to isolate carbonate and ester-bearing analogues such as
89 and 90. The introduction of less base-labile groups at the 4-position may well be
required if analogues bearing an aromatic group are to be synthesised.
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Chapter 4. Results and Discussion Part 3
4.1 The rationale for InsP4 analogue synthesis
The second route towards the rationally designed PtdIns(3,4,5)P3 analogues (chapter 3)
enabled the synthesis of several precursor compounds. However, the fact that the 1-
phosphodiester was prone to migration either during the final deprotection, or over time
with the stored product, suggested that the design of the target compounds should be
modified. One option was to increase the size or length of the diester group to provide
the more commonly reported dibutanoyl or dihexanoyl phosphodiester, to give
analogues of the type 103 (Figure 4.1). The added steric bulk of the diester should
prevent migration. However, one potential problem with this approach is that additional
lipophilicity, and the resulting disordered nature, of the phosphodiester is likely to reduce
the chances of achieving co-crystallisation of the analogues with PKB PH. This is
evidenced by the fact that biologists have failed to obtain crystal structures of short
chain PtdIns(3,4,5)P3 compounds bound to PKB PH, and have only achieved co-
crystallisation with the inositol head group InsP4.54 Another option would be to replace
the phosphodiester altogether with a simple phosphate, to give trisphosphates of the
type 104 (Figure 4.1). If anything, this modification should increase the chances of
obtaining ligand-PKB PH crystal structure complexes, as compared to the original
design. Given the potential utility of such crystal structures for active compounds, it was
decided that this latter approach would be adopted. Such a modification should also
significantly reduce the likelihood of phosphate migration, as there would be no
phosphate ester in the molecule.
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Figure 4.1. Modified target compounds as potential PKB PH inhibitors.
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Compounds such as trisphosphate 104 can be seen as 4-position-modified InsP4
analogues. InsP4 itself is synthesised from Ins(1,4,5)P3 by Ins(1,4,5)P3-3-kinase.166 Its
characteristic short life-time has led to the proposition that this inositol may also act as a
second messenger.167 As noted earlier, InsP4 binds PKBαPH with similar affinity to
PtdIns(3,4,5)P3 in vitro.34 This is not the case for all the PH domain-containing proteins
that bind to PtdIns(3,4,5)P3, where InsP4 affinity is sometimes significantly less than for
the phospholipid. Proteins that are selective for InsP4 are rare. Also, the ability of
proteins such as PKB to distinguish between InsP4 and PtdIns(3,4,5)P3 in vivo remains
unclear. Clearly, the crucial difference between these inositols involves the presence of
the fatty glyceryl unit at the PtdIns(3,4,5)P3 1-position phosphate. As it is the phosphate
interactions which are seen as most significant for binding, it is possible that the glyceryl
unit acts more as a recognition module, the extent to which may vary between the
protein substrate. The lipid chains themselves serve only to anchor the molecule in the
membrane. Such debate further underlines the complexity of inositol signalling.
It is, therefore, conceivable that omitting the glyceryl unit in the proposed analogues may
improve selectivity against some PtdIns(3,4,5)P3-binding proteins that display reduced
affinity for InsP4. A long-term aim for the project would involve the initial discovery of an
active InsP4 analogue, followed by the synthesis of a related PtdIns(3,4,5)P3 analogue
which bears a long-chain phosphodiester at the 1-position. Comparison of activity could
reveal useful information concerning the nature of PtdIns(3,4,5)P3/InsP4 selectivity for
PH domain binding.
4.2. The racemic synthesis of 4-position InsP4 analogues
4.2.1 Synthesis of the 4-dimethylphosphinate InsP4 analogue 108
The synthesis of the racemic bisphosphate 67 was outlined in chapter 3. This material
was used to synthesise the key 1-hydroxy intermediate 106 in two steps. Thus,
phosphitylation of the 1-position of 67 was achieved by reaction with bis(benzyloxy)-N,N-
diisopropylamino phosphine and 1H-tetrazole followed by oxidation by mCPBA, giving
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intermediate 105 in 87% yield (Scheme 4.1). Efficient PMB-deprotection of compound
105 using ceric ammonium nitrate afforded the 4-hydroxy-trisphosphate 106.
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Scheme 4.1. Synthesis of key intermediate 106. Reagent and conditions: i. a. bis(Benzyloxy)-N,N-diisopropylamino
phosphine, 1H-tetrazole, CH2Cl2, b. mCPBA -78 °C → RT, 87% yield; ii. CAN, CH3CN/H2O (4:1), 85% yield.
The synthesis of the first 4-position modified InsP4 analogue was achieved as outlined in
Scheme 4.2. The previously optimised conditions for phosphinylation were employed, in
which alcohol 106 was reacted with dimethylchlorophosphine in
pyridine/dichloromethane to give compound 107 in 62% yield. Global debenzylation was
then performed under the same conditions employed previously, using 20 equivalents of
Pd black in the presence of sodium bicarbonate (6 equivalents), with t-butanol/water
(6:1) as the solvent under an atmosphere of hydrogen. Clean product 108 was obtained
in quantitative yield after 5 hours. As anticipated, no phosphate migration was observed
by 1H and 31P NMR analysis. However, obtaining useful mass spectrometric data proved
difficult. It was found that the addition of diethylamine to a dilute solution of the sample in
methanol/water was required to obtain interpretable spectra. This promoted the
association of the phosphate groups with H+ as opposed to Na+ to form the phosphate
acid. Thus, in ES- mode, the (M-6Na+5H)- ion for the resulting acid of compound 108
was identified, as well as the ions corresponding to the mono- and di-sodiated material
(see Figure 4.2). The fully sodiated material, however, was not observed by this method.
Also, due to the hygroscopic nature of polyphosphorylated compounds such as
analogue 108, as well as the likely preference of mixed sodium salts of the compound,
accurate elemental analysis could not be obtained.
Scheme 4.2. Synthesis of the 4-dimethylphosphinate InsP4 analogue 108. Reagents and conditions: i. Me2PCl,
pyridine/CH2Cl2 (5:1), 62% yield; ii. Pd black (20 equiv.), NaHCO3 (6 equiv.), t-BuOH/H2O (6:1), H2, 100% yield.
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Figure 4.2. The low resolution electrospray mass spectrum for compound 108. The spectrum demonstrates that the
mass ions for (M-6Na+5H)-, (M-5Na+4H)- and (M-4Na+3H)- are all observed, but the mass ions for the tri-, tetra-,
penta- or hexasodiated salts are absent.
4.2.2. Synthesis of a 4-sulfate InsP4 analogue
The introduction of an alternative acidic group to the 4-position, in order to enhance
analogue binding affinity, remained an important aim. A sulfate group is frequently
incorporated into bioactive molecules, and was deemed an appropriate group to employ
for a 4-position-modified InsP4 analogue. A common method for the formation of a
sulfate from an alcohol involves treating the alcohol with an excess of powdered sulfur
trioxide–pyridine complex in DMF.168 For the sulfation of intermediate 106 to complete
using this reagent, heating to 50 °C was required (Scheme 4.3). It was generally found
that full consumption of the starting material would not occur, for an unknown reason,
limiting the eventual yield. Purification of the intermediate sulfate by silica gel
chromatography was performed, although obtaining pure product proved challenging,
with repeated attempts at purification required. The sodium salt was then formed, by
stirring a solution of the inositol in methanol with strongly acidic Dowex Na+ form resin.
After freeze-drying a solution of the product, compound 109 was obtained in 44% yield
as a colourless solid. The compound proved to be very hygroscopic, turning into a gum
(M-6Na+5H)- (M-5Na+4H)-
(M-4Na+3H)-
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after brief exposure to the air. In fact, this intermediate was not found to be very stable
as, after several days, degradation of the material was observed by TLC analysis.
Therefore, the material had to be prepared immediately prior to use. It should also be
noted that it was not possible to prove that the product was indeed the sodium salt of the
sulfate, as the hygroscopic nature and instability of the compound precluded the
possibility of reliable elemental analysis. The mass spectrometric analysis obtained in
ES- mode provided the expected (M-Na)- ion, as opposed to the ion for the sodium salt.
Such difficulties in obtaining proof of sodium salt formation are not unexpected for this
type of compound.
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Scheme 4.3. Synthesis of 4-sulfate InsP4 analogue 110. Reagents and conditions: i. a. SO3·Pyridine complex, DMF,
50 °C; b. Dowex Marathon C resin Na+ form, MeOH, 44% yield; ii. Pd black (20 equiv.), NaHCO3 (6 equiv.), t-
BuOH/H2O (6:1), H2, 99% yield.
The debenzylation of intermediate 109 appeared to proceed smoothly under the
conditions previously employed, using 6 equivalents of sodium bicarbonate, to give the
analogue 110 in high yield (Scheme 4.3). This compound was thus submitted for
biological testing along with the 4-dimethylphosphinate 108, although it was
subsequently discovered that the compound 110 may have contained traces of sodium
bicarbonate impurity. Thus, the tetrasodium salt of the 4-sulfate analogue was also
synthesised to ensure pure product was obtained. In this instance, 3 equivalents of
sodium bicarbonate were used in the debenzylation of compound 109 (Scheme 4.4).
Therefore, compound 111 was obtained as a pure analogue in high yield.
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Scheme 4.4. Synthesis of the 4-sulfate InsP4 analogue 111. i. Pd black (20 equiv.), NaHCO3 (3 equiv.), t-BuOH/H2O
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Figure 4.3. Graphs displaying the FRET ratio analyses which assess the binding affinity of the InsP4 analogues 108
and 110, PtdIns(3,4,5)P3, Ins(1,4,5)P3 and PtdIns(4,5)P2 with GPR1 PH and PLCδPH.
The 4-dimethylphosphinate 108 and the 4-sulfate 110 have yet to be tested for their
affinity for the PKB PH domain. However, their affinity for GRP1 PH and PLCδ PH has
been assessed (Figure 4.3). FRET ratio analysis revealed that the InsP4 analogues 108
and 109 do not appear to bind to the GRP1 PH domain at concentrations of up to
100 μM. The 4-dimethylphosphinate also failed to bind PLCδPH at this concentration,
although the data do indicate that the 4-sulfate does bind very weakly at 100 μM. As
noted, this analogue may contain traces of bicarbonate impurity, although it is not
believed that this would interfere significantly with the results. However, it is perhaps not
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surprising that this compound displays some affinity for PLCδPH at high concentration,
given that this PH domain can bind several of the natural inositol polyphosphates in vitro
with reasonable affinity, including Ins(1,4,5)P3 as Figure 4.3 shows. The activity of an
enantiomeric form of the 4-sulfate may enhance the activity of the analogue. Further
testing of such compounds for activity towards other PH domain containing proteins,
particularly PKB PH, is ongoing.
4.2.3 Attempted synthesis of a 4-O-phenoxyacetyl InsP4 analogue
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Scheme 4.5. Attempted synthesis of the 4-phenoxyacetyl InsP4 analogue 113. Reagents and conditions: i.
Phenoxyacetyl chloride, triethylamine, DMAP, THF, 53% yield; ii. a. Pd black (20 equiv.), t-BuOH/H2O (6:1), H2; b.
Dowex Marathon C resin Na+ form; c. NaHCO3, H2O, impure product.
In a continuing effort to synthesise a suitable analogue with which to probe the aromatic
pocket of PKB PH, the 4-O-phenoxyacetyl InsP4 analogue precursor 112 was prepared
from alcohol 106 (Scheme 4.5). As noted in chapter 3, the phenoxyacetyl ester is not
stable to the usual debenzylation conditions employed for the final step. In order to avoid
cleavage of the ester group, the sodium bicarbonate was omitted from the
hydrogenolysis conditions. The acid was thus isolated following complete debenzylation
as indicated by 1H NMR, with the ester group intact. However, it was anticipated that the
sodium salt of the phosphates would help stabilise the compound against potential
transesterification during storage. The acid was therefore passed through an ion
exchange resin (Dowex Marathon C Na+ form, strongly acidic) in an attempt to form the
sodium salt. However, the 31P NMR spectra was unaffected by this process, indicating
that the resin used was not able to sodiate the phosphates. In another attempt to form
the sodium salt, sodium bicarbonate (6 equivalents) was added to an aqueous solution
of the acid, rapidly followed by freeze-drying of the solution. However, a small degree of
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ester cleavage was again observed. Attention was thus turned to an alternative method
by which an aromatic 4-position InsP4 analogue could be synthesised.
4.2.4 Synthesis of 4-position carbamate InsP4 analogues 115 and 118
It was envisioned that the synthesis of a carbamate, via the reaction of alcohol 106 with
an appropriate isocyanate, could provide an alternative method by which to introduce
aromatic functionality at the 4-position of the ring. Carbamates are more stable to basic
cleavage than the carbonate or ester groups previously employed for this purpose, and
should therefore remain stable to the final deprotection conditions. Therefore, a cooled
solution of alcohol 106 and DMAP in pyridine/dichloromethane (5:1) was treated with
excess phenylisocyanate (Scheme 4.6). After warming to room temperature, the
reaction was complete within 2 hours. The reaction mixture was immediately subjected
to silica gel chromatography. This procedure was necessary, otherwise yields were
found to be impaired. Compound 114 was thus obtained in 80% yield. Final
deprotection, using the same conditions as for the 4-dimethylphosphinate, gave the
InsP4 analogue 115 in high yield, with no evidence of migration or carbamate cleavage
by 1H or 31P NMR.
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Scheme 4.6. Synthesis of the 4-phenylcarbamate InsP4 analogue 115. Reagent and conditions: i. phenylisocyanate
(20 equiv.), DMAP (cat.), pyridine/CH2Cl2 (5:1), 80% yield; ii. Pd black (20 equiv.), NaHCO3 (6 equiv.), t-BuOH/H2O
(6:1), H2, 84% yield.
Encouraged by the success of the phenylcarbamate synthesis, this method was then
considered as a route towards an analogue bearing a phenol group. As described in
chapter 3, a previous attempt to achieve this using an aromatic acid chloride had failed.
However, the reaction of alcohol 106 with excess 4-(benzyloxy)phenyl isocyanate in
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pyridine/dichloromethane was considerably more efficient (Scheme 4.7). Again, rapid
purification was required to provide the carbamate 116 as a gum in good yield.
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Scheme 4.7. Synthesis of the 4-phenoxycarbamate InsP4 analogue 118. Reagent and conditions: i. 4-
(benzyloxy)phenyl isocyanate (17 equiv.), DMAP (cat.), pyridine/CH2Cl2 (5:1), 76 % yield; ii. Pd black (20 equiv.),
NaHCO3 (7 equiv.), t-BuOH/H2O (6:1), H2, 92 % yield.
Debenzylation of analogue precursor 116 did not prove as straightforward as with the
phenylcarbamate 114. Exposing the precursor to the same hydrogenolysis conditions,
using 6 equivalents of sodium bicarbonate, did not provide clean product. The 1H and
31P NMR analysis suggested that some unexpected phosphate migration may have
occurred. Given that this migration was not observed for the phenylcarbamate
deprotection, it was presumed that the presence of the acidic phenol group must have
affected the outcome of the reaction in some way, promoting migration. The reaction
was repeated using an extra equivalent of sodium bicarbonate (7 equivalents in total), in
order to see if this would result in the formation of a fully sodiated product, where the
sodium phenolate 118 is formed. Under these conditions, the reaction did indeed
proceed more smoothly, providing pure carbamate 118 in 92% yield. Comparison of the
31P NMR spectra of the two experiments demonstrates the occurrence of migration in
the first attempt, and how the second experiment using 7 equivalents of sodium
bicarbonate provided clean inositol material (Figure 4.4). No carbonate peak was
observed in the 13C NMR of product 118, indicating that all the sodium bicarbonate was
consumed, resulting in the formation of a heptakis-sodium salt.
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Figure 4.4. 31P NMR spectra of the products of the hydrogenolysis of carbamate 116 (162 MHz, D2O). A. Product of
the hydrogenolysis conditions using 6 equivalents of sodium bicarbonate. Note the apparent by-product formation,
presumably due to phosphate migration. B. Product of the hydrogenolysis conditions using 7 equivalents of sodium
bicarbonate. No migration is observed in this instance.
4.2.5 Towards an enantiopure 4-position analogue synthesis
As outlined in the previous chapter, the synthesis of enantiopure analogues was highly
desirable. This could be achieved using the synthetic route already optimised for the
synthesis of the racemic analogues as described. The synthesis of the enantiopure
camphor derivative (-)-41 was outlined in chapter 2, and could be prepared in multi-gram
quantities. The diol (-)-17 was then formed by TIPS protection of the 1-position alcohol
followed by efficient acidic methanolysis of the camphor acetal (Scheme 4.8). The
following steps proceeded in the same manner, and in similar yields, as described in
chapter 3 for the analogous racemic synthesis, up until the synthesis of alcohol (+)-75
had been achieved.
The allyl deprotection of intermediate (+)-75 gave an unexpected result, as the
additional, unwanted cleavage of the PMB group at the 4-position occurred during the
reaction/work-up conditions. Isomerisation of the allyl group proceeded as normal. For
the racemic synthesis, 4-toluenesulfonic acid was used to affect the cleavage of the
vinyl ether. For de-allylation of compound (+)-75, acetyl chloride was used for this
purpose, and the acid was quenched by the addition of triethylamine as normal. TLC
BA
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analysis did not indicate significant cleavage of the PMB group prior to work-up. It is
proposed that this cleavage occurred during work-up, possibly due to incomplete
quenching of the acid by triethylamine. Thus, two products were formed; the desired diol
(+)-68 as the minor product and the triol (+)-120 as the major. This outcome was
unfortunate, as only 74 mg (5% yield) of the desired enantiopure 3,5-diol was isolated
from 1.63 g of the precursor inositol (+)-75. With significant PMB-deprotection observed,
658 mg of the 3,4,5-triol (+)-120 was obtained. However, potentially this enantiomerically
pure material could be used for the synthesis of 1-position-modified InsP4 analogues (as
described below), or for the production of biologically relevant phosphatidylinositol
derivatives. In order to ensure that the unwanted PMB deprotection does not occur in
the future, alternative reaction conditions will be employed. Such conditions involve
stirring a solution of the allyl-protected compound and palladium
tetrakis(triphenylphosphine) in acetic acid either at room temperature or with gentle
heating.169
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82
The 3,5-diol (+)-68 that was obtained from the de-allylation step was subjected to TIPS
deprotection followed by formation of the trisphosphate, under previously described
conditions, to provide intermediate (-)-105. Deprotection of the PMB group afforded the
desired 1-hydroxy trisphosphate (-)-106. However, due to the low-yielding allyl
deprotection step, only 55 mg of this enantiopure material was acquired. As this is only
enough material to synthesise one 4-position analogue, it will only be used once testing
of the racemic compounds is complete, to assess which analogue is the most active,
and thus most necessary to synthesise in enantiopure form.
4.3 The synthesis of racemic and enantiopure 1-position InsP4 analogues
As discussed in chapter 2, the rationale behind the synthesis of PtdIns(3,4,5)P3
analogues modified at the 4-position was to inhibit the activating conformational change
in PKB PH that occurs upon binding of the natural ligand. Modification of the 4-position
was seen as a good starting point, due to the possibility of altering the conformational
change observed for variable loop VL3 in particular. However, alteration of the 1- or 3-
position phosphates could potentially affect conformational change in VL1 or VL2, and
thus may also result in the desired PH domain inhibition. For instance, as noted in
chapter 2, Arg-23 is seen to move a full 6.2 Å towards these two phosphates upon
binding of InsP4 to PKBαPH.54 The synthesis of novel InsP4 analogues modified at the 1-
position (Figure 4.5) was therefore proposed as another route towards potential PKB PH
inhibitors.
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The activity of some myo-inositol compounds possessing phosphates at the 3-, 4- and 5-
positions, with an alternative group at the 1-position, has been reported in the literature.
In 1995, Sawada et al. reported the synthesis of 3,4,5 trisphosphates bearing simple 1-
O-alkyl and 1-O-acyl groups of varying length as analogues of PtdIns(3,4,5)P3.170 Such
compounds were tested only against PtdIns(3,4,5)P3 5-phosphatase. A few of the
analogues synthesised did display high activity against the phosphatase, suggesting
that in some instances, a substitute for the 1-phosphate group may be tolerated.
In another study, Shirai et al. reported the use of analogue 122 attached to a solid phase
in affinity chromatography experiments, to detect PtdIns(3,4,5)P3 binding proteins.171 It
was found that this compound showed less affinity and specificity for PH-domain-
containing proteins than the analogue 123, although PKB itself was not discussed in the
study. The implication is, though, that the potential for electrostatic interactions that the
1-position phosphate provides may be crucial for high affinity binding to PKB PH. It
would be intriguing to see if replacing the phosphate with an alternative acidic group
could be tolerated with respect to PKB PH binding, and if so, whether an activating
conformational change results. Thus, the objective was to synthesise 1-position sulfate
and phosphonate analogues, test their binding affinity for the PH domain, and obtain
crystal structures of such ligands bound to PKB PH where possible.
4.3.1 Attempted synthesis of the racemic 1-sulfate InsP4 analogue 127
The racemic synthesis of the required 1-hydroxy trisphosphate intermediate 125 was
straightforward, as it could be derived from the previously synthesised diol 70 in three
steps (Scheme 4.9). De-allylation of 70 was achieved in moderate yield, using the
Wilkinson’s catalyst-mediated isomerisation and 4-toluenesulfonic acid cleavage
conditions described earlier. The 3-, 4- and 5-positions were then subjected to the
standard phosphitylation and oxidation conditions to provide the benzyl-protected
trisphosphate 124. The facile cleavage of the TIPS ether was then performed using
TBAF to afford alcohol 125 in good yield.
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Scheme 4.9. Synthesis of the 1-hydroxy trisphosphate intermediate 125. Reagents and conditions: i. a. Wilkinson’s
Catalyst, Hünig’s base, EtOH, reflux; b. 4-TsOH·H2O, MeOH, 53% yield; ii. a. bis(benzyloxy)-N,N-diisopropylamino
phosphine, 1H-tetrazole, CH2Cl2, b. mCPBA -78 °C → RT, 74% yield; iii. TBAF, THF, 80%, yield.
Sulfation of the 1-position was performed under the conditions optimised for the
synthesis of the 4-sulfate 109. Compound 126 was thus obtained in 44% yield and, like
the 4-sulfate, was again very hygroscopic and seemingly unstable (Scheme 4.10).
Hydrogenolysis was performed using six equivalents of sodium bicarbonate to give the
1-sulfate analogue 127. However, on this occasion a very clear, unexpected peak was
present in the 13C spectrum at 160.8 ppm. This peak presumably corresponded to the
presence of a carbonate group. The intensity of the peak relative to those corresponding
to the carbons of the inositol ring suggested that a significant amount of carbonate
impurity was present, and was unlikely to be due to accidental addition of excess
sodium bicarbonate. In order to confirm this, the reaction was repeated under the same
conditions. However, the outcome was the same. Furthermore, mass spectrometric
analysis provided the expected (M-nNa+nH)- ions, suggesting that an ionic complex may
have formed between the inositol salt and a carbonate species.
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Scheme 4.10. Attempted synthesis of 1-sulfate InsP4 analogue 127. Reagents and conditions: i. a. SO3·Pyridine
complex, DMF, 50 °C; b. Dowex Marathon C resin Na+ form, MeOH, 44% yield; ii. Pd black (20 equiv.), NaHCO3 (6
equiv.), t-BuOH/H2O (6:1), H2, impure product.
Purification of the sulfate 127 was attempted by reverse phase silica gel column
chromatography. However, the carbonate impurity remained. Another attempt at
purification involved the application of ion exchange chromatography, using Sepharose
fast flow resin, eluting with TEAB using a procedure reported by Potter and co-
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workers.172 However, no inositol-based material was isolated from the ion exchange
column.
4.3.2 Synthesis of the racemic 1-methylenephosphonate InsP4 analogue 134
The preparation of a suitable reagent was required for the synthesis of a 1-
methylenephosphonate analogue. Initially, the synthesis of bromide 130 was attempted.
Thus, using conditions described in the literature, dibenzyl(hydroxymethyl)phosphonate
129 was obtained from the reaction of dibenzyl phosphite with paraformaldehyde using
catalytic triethylamine (Scheme 4.11).173 The reaction required heating the mixture at
130 °C until the paraformaldehyde was fully consumed/dissolved after which, according
to the literature, the reaction was complete. However, the reaction appeared incomplete
after this time by TLC analysis, and further heating resulting in the formation of by-
products. Compound 129 was therefore obtained in only 31% yield following silica gel
column chromatography, although this was sufficient for the purpose of the InsP4
analogue synthesis.
Synthesis of the bromide 130 was then attempted (Scheme 4.11). Literature bromination
conditions using carbontetrabromide and triphenylphosphine in dry acetonitrile were
employed,173 but failed to yield the desired product. It was noted that maintaining the
reaction temperature below 0° C did not allow the reaction to proceed, but allowing the
mixture to slowly warm to room temperature resulted in benzyl alcohol formation, without
isolation of the desired bromide. Treatment of the hydroxyphosphonate with
phosphorous tribromide in diethyl ether174 appeared to give similar results. Attention was
therefore turned to the synthesis of the triflate 131. Although the synthesis of this triflate
has been reported in the literature,175 the formation of this compound was also
problematic. A solution of the alcohol 129 in dichloromethane at -78 °C was treated with
triflic anhydride. In order for the reaction to proceed, the reaction temperature had to be
slowly raised to -40 °C, then to -15 °C at which it was maintained until full consumption
of starting material. If the temperature was raised to 0 °C or higher, a complex mixture
formed. Even so, despite efforts to minimise the formation of unwanted by-products, side
reactions were observed. The major products isolated by silica gel column
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chromatography were the desired triflate 131 and the dimer 132. Consequently, the
reagent 131 was isolated in only 26% yield. The formation of compound 132 as an
unwanted by-product of this reaction has been reported in the literature.12 However, this
method provided sufficient material for subsequent reaction with the requisite inositol.
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Scheme 4.11. The synthesis of methylenephosphonate reagents. Reagents and conditions: i. Paraformaldehyde,
triethylamine, 130 °C, 15 min, 31% yield; ii. CBr4, Ph3P, MeCN, product not isolated; iii. Trifluoromethanesulfonic
anhydride, 2,6-lutidine, CH2Cl2, 26% yield.
The introduction of the phosphonate to alcohol 125 is outlined in Scheme 4.12. Sodium
hydride was added to a cooled mixture of the alcohol and the triflate 131 in THF (Figure
4.12). Given the possibility that intermolecular attack of the alkoxide on a phosphate
group could lead to phosphate migration, the reaction temperature was initially kept
below 0 °C. However, the mixture had to warm to room temperature for reaction to
occur, after which the starting material was fully consumed within 2 h. Initial purification
by silica gel chromatography provided moderately pure material in a yield of about 46%.
However, further chromatographic purification was required. After exhaustive column
chromatography, the desired phosphonate of satisfactory purity was isolated in 24%
yield.
Debenzylation of intermediate 133 proceeded smoothly. For this reaction, 8 equivalents
of sodium bicarbonate were used to synthesise the fully sodiated 1-position
methylenephosphonate InsP4 analogue 134 (Scheme 4.12). No evidence for migration
or the presence of carbonate was found on the 1H, 13C or 31P NMR spectra.
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4.3.3 Synthesis of enantiopure 1-position InsP4 analogues
The enantiopure syntheses of the 1-sulfate and 1-methylenephosphonate analogues
were attempted. The enantiomeric 1-hydroxy (-)-125 was synthesised in the same
manner as the racemic compound, and was derived from the previously prepared diol
(-)-70 (Scheme 4.13). The 1-phosphonate (-)-133 was synthesised using the same
conditions as outlined above. As with the synthesis of the racemic phosphonate,
purification of the intermediate again proved difficult. Pure inositol was therefore isolated
in only 28% yield. Global deprotection provided the desired analogue 134. However, a
significant peak in the 13C NMR spectrum at 160.7 ppm relating to carbonate impurity
was present. This was unexpected, as it was not observed with the analogous racemic
phosphonate synthesis, although the chemical shift of the anomalous peak had the
same chemical shift as the impurity present in the 13C spectrum of 1-sulfate 127
described above. The mass spectrometric data provided the expected (M-8Na+7H)- ion
for the acid derivative, thus it is presumed that the carbonate species is ionically
associated with the inositol phosphate. Attempts to purify compound 134 or re-
synthesise the compound without the use of sodium bicarbonate have yet to be
attempted.
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Scheme 4.13. Attempted synthesis of the enantiopure 1-methylenephosphonate 134. Reagents and conditions: i. a.
Wilkinson’s Catalyst, Hünig’s base, EtOH, reflux; b. 4-TsOH·H2O, MeOH, 54% yield; ii. a. bis(Benzyloxy)-N,N-
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Figure 4.6. Comparison of the 13C and 31P NMR spectra (300 MHz, D2O) of the racemic 1-sulfate heptasodium salt
127 and the enantiopure 1-sulfate tetrasodium salt (-)-135. A.1 and A.2 display the respective 13C and 31P NMR
spectra for compound 127; B.1 and B.2 display the respective 13C and 31P NMR spectra of compound (-)-135. As the
spectra indicate, using only 3 equivalents of sodium bicarbonate for the synthesis of the tretrasodium salt (-)-135
prevented the appearance of bicarbonate impurity in the product.
In order to synthesise an enantiopure 1-position sulfate analogue, the alcohol (-)-125
was sulfated in the manner described above to give compound (+)-126 in 68% yield
(Scheme 4.14). In an attempt to avoid the problem of bicarbonate impurity appearing in
the 13C NMR of the final product, hydrogenolysis was performed with a reduced 3
A.1 A.2
B.1 B.2
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equivalents of sodium bicarbonate, instead of 6 equivalents. This reaction proceeded in
80% yield to provide pure 1-sulfate InsP4 analogue (-)-135. Thus, the tetrasodium salt of
(-)-135 was formed, instead of the fully sodiated heptasodium salt. There was no
evidence of phosphate or sulfate migration from 1H NMR analysis, and there was no
indication of the presence of bicarbonate in the 13C NMR spectrum (see Figure 4.6).
It is apparent from the 13C and 31P NMR data for the racemic sulfate 127 (Figure 4.6, A.1
and A.2) and the enantiopure sulfate (-)-135 (Figure 4.6, B.1 and B.2) that only one
inositol trisphosphate was formed in the synthesis of each compound. The differences in
the chemical shifts between the NMR spectra for the two compounds can be attributed
to differences in counterion formation and the degree of ionisation of each compound
(compound (-)-135 can only form the tetrasodium salt). Given that the mass
spectrometric data for both compounds provided the expected M- ions, the implication is,
therefore, that the expected product was obtained in both instances, and that the
carbonate impurity possibly arose due to carbonate interaction with compound 127.
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4.4. Future Work
With respect to the synthesis of C-4 position-modified InsP4 analogues, future work will
depend partly on the outcome of the biological testing on those compounds already
obtained. A 4-position methylphosphonate analogue such as compound 136 (Figure 4.7)
may also be synthesised as another potential inhibitor which bears an alternative acidic
group at the C-4 position. All compounds need to be assessed for activity against PKB
PH, as well as other PH domain-containing proteins in order to assess their selectivity.
Analogues displaying significant activity will be synthesised as a single enantiomer using
the methods outlined above.
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Figure 4.7. Structure of a 4-methylphosphonate InsP4 analogue 136 and C-3 position-modified analogues 137 and
138 to be synthesised.
Additionally, the PKB PH domain ligand binding pocket will be probed further by the
production of compounds which are modified at the 3-position of the inositol ring.
Examples of target compounds include the 3-methylphosphonate 137 and the 3-sulfate
138 (Figure 4.7). It is predicted that such compounds may also act as inhibitors of the
PKB PH domain. Any active compounds that are altered at the C-3 or C-4 positions can
also be modified to include a long-chain phosphodiester group at the C-1 position, in
order to assess the influence of this group on binding and selectivity.
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4.5. Summary and Conclusions
The discovery of selective inhibitors of protein kinase B remains a primary target for
chemotherapeutic research. Furthermore, such inhibitors would act as useful biological
tools in the ongoing processes of delineating the PI3-K/PKB signalling cascade. This
project has investigated the synthesis of PtdIns(3,4,5)P3 and InsP4 analogues modified
at the C-4 position. Such compounds have been designed to bind to the PH domain of
PKB, but not induce the activating conformational change that the protein undergoes
upon binding of the natural ligand. It has been discovered that in order to produce
PtdIns(3,4,5)P3 analogues that possess the phosphoglyceryl diester at the 1-position,
relatively lengthy ester chains on the glyceryl moiety are required in order to produce
stable compounds. Thus, in the search for novel PKB PH inhibitors C-4 and C-1
position-modified InsP4 analogues have been synthesised (Figure 4.8).
OH
O
HO
O
O
O
P
OH
PO O-Na+
S
O-Na+O
O
(-)-135
O
O-Na+P
O
O-Na+HO
OH
OH
O
HO
O
O
O
P P
O-Na+
+Na-O
O O
P
O
O-Na+
O-Na+
O-Na+
O-Na+P O
108
OH
O
HO
O
O
O
P P
O-Na+
+Na-O
O
+Na-O O
-Na+
O
P
O
O-Na+
O-Na+
NH
O
115
OH
O
HO
O
O
O
P P
O-Na+
+Na-O
O
+Na-O O
-Na+
O
P
O
O-Na+
O-Na+
NH
O
NaO
134
OH
O
HO
O
O
O
P
O-Na+
PO O-Na+
O
O-Na+P
O
+Na-O O-Na+
O-Na+
P
O
O-Na+
O-Na+
OH
O
HO
O
O
O
P P
O-Na+
HO
O O
P
O
O-Na+
OH
O-Na+
OHSO O
+Na-O 111
118
Figure 4.8. Structure of the C-4 and C-1 position InsP3 analogues that have been synthesised.
These compounds were produced via an efficient divergent synthesis, using orthogonal
protecting group strategies. The routes that have been devised have been shown to be
compatible with the synthesis of single enantiomers of the InsP4 analogues. The
information gained from the biological testing of such compounds will be used to
synthesise a second generation of such inositol-based analogues, with the view to
increasing potency and selectivity for PKB inhibition.
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Experimental Section
General
1H NMR spectra were recorded on a Bruker Advance 300 (300 MHz) or Bruker Advance
400 (400 MHz) instrument using deuterated solvent as a reference. The chemical shift
data for each signal are given as δ in units of parts per million (ppm) relative to
tetramethylsilane (TMS) where δ (TMS) = 0.00 ppm. The multiplicity of each signal is
indicated by: s (singlet); br s (broad singlet); d (doublet); t (triplet); dd (doublet of
doublets); ddd (doublet of doublet of doublets); dt (doublet of triplets); dddd (doublet of
doublet of triplets) or m (multiplet). The number of protons (n) for a given resonance is
indicated by “n H”. Coupling constants (J) are quoted in Hz and are recorded to the
nearest 0.1 Hz.
13C NMR spectra were recorded on a Bruker Advance 300 (75.5 MHz) or Bruker
Advance 400 (101 MHz) instrument using the PENDANT sequence and internal
deuterium lock. The chemical shift data for each signal are given as δ in units of ppm
relative to tetramethylsilane (TMS) where δ (TMS) = 0.00 ppm. Signals are assigned as
C, CH, CH2 or CH3 according to the number of protons bonded to the carbon atom.
Where appropriate, coupling constants (J) are quoted in Hz and are recorded to the
nearest 0.1 Hz.
31P NMR data were recorded on a Bruker Advance 300 (121.5 MHz) instrument using
proton decoupling and internal deuterium lock. The chemical shift data for each signal
are given as δ in units of ppm relative to an external standard of 85% H3PO4.
Melting points were determined using a Gallenkamp MF-370 or an Electrothermal 9100
melting point instrument and are uncorrected.
Optical specific rotations were measured using either an Optical Activity AA-1000
automatic polarimeter, a Bellingham and Stanley Ltd ADP220 instrument or a Perkin
Elmer Model 341 Polarimeter, in cells with a path length of 2 or 1 dm. The concentration
(c) is expressed in g/100 mL. Specific rotations are given in implied units of 10-1 deg cm2
g-1 (T = ambient temperature in °C).
Infra red (IR) spectra were recorded on a Perkin Elmer Spectrum GX FT-IR system.
93
Analytical thin layer chromatography (TLC) was carried out on pre-coated 0.25 mm ICN
Biomedicals GmbH 60 F254 silica gel plates. Visualisation was achieved by absorption
of UV light, or by an ethanolic phosphomolybdic acid or potassium permanganate dip
staining system followed by thermal development.
Silica gel column chromatography was carried out on silica gel (Apollo Scientific Ltd 40-
63 micron) under a positive pressure of compressed air.
Kugelrohl bulb-to-bulb distillations were carried out using a Büchi GKR-51 machine.
Boiling points are the actual oven temperatures.
Dry dichloromethane was distilled from calcium hydride in a recycling still. Diethyl ether
was distilled from sodium in a recycling still using benzophenone ketyl as an indicator.
Dry dichloromethane, THF, diethyl ether and toluene were also obtained by being
passed through two columns of alumina using an MBRAUN (SPS-800) solvent
purification system. Anhydrous DMF was purchased from Aldrich UK and dried by
distillation from 4 Å molecular sieves onto 4 Å molecular sieves under nitrogen
atmosphere. Chemicals were purchased from Acros UK, Aldrich UK, Avocado UK,
Fisher UK or Fluka UK. All solvents and reagents were purified and dried, where
necessary, by standard techniques.176 Where appropriate and if not stated otherwise, all
non-aqueous reactions were performed under an inert atmosphere of nitrogen, using a
vacuum manifold with nitrogen passed through 4 Å molecular sieves and self-indicating
silica gel. In vacuo refers to the use of a rotary evaporator attached to a diaphragm
pump. Brine refers to a saturated aqueous solution of sodium chloride. Hexane refers to
n-hexane and petroleum ether to the fraction boiling between 40-60 °C. Room
temperature (RT) refers to an ambient temperature of approximately 25 °C.
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2,4,10-Trioxatricyclo[3.3.1.13,7]decane-6,8,9-triol 43138
HO
OH
O
HO
O O
43
myo-Inositol (40.0 g, 222 mmol, 1 equiv.) and 4-toluenesulfonic acid monohydrate (12.7
g, 67 mmol, 0.3 equiv.) were dissolved in dry N,N-dimethylformamide (250 mL). Triethyl
orthoformate (98.9 g, 111 mL, 666 mmol, 3 equiv.) was added and the reaction mixture
was stirred at 100 °C for 30 h. The reaction was adjudged to be complete by TLC
analysis. The mixture was allowed to cool to room temperature and the 4-toluenesulfonic
acid was quenched with a saturated aqueous solution of sodium bicarbonate (50 mL).
The resulting sodium tosylate was removed by filtration, washing with methanol (20 mL),
and the filtrate was concentrated under reduced pressure. Crystallisation from methanol
gave the desired orthoformate (13.20 g) as a colourless solid. The mother liquor was
concentrated and adsorbed onto silica gel. Purification by silica gel column
chromatography, eluting with methanol/dichloromethane (5:95) gave the desired product
(16.90 g) as a colourless crystalline solid. This solid was combined with the product
obtained from crystallisation to give 2,4,10-trioxatricyclo[3.3.1.13,7]decane-6,8,9-triol 43
(30.10 g, 71% yield); Rf 0.53 (methanol/chloroform, 20/80); mp 220 °C dec. (Lit.,138 300-
302 °C sealed tube); δH (300 MHz, DMSO-D6) 5.47 (1 H, d, J 6.1, equatorial OH), 5.44
(2 H, d, J 1.3, 2 × axial OH), 5.31 (1 H, d, J 6.4, 3-H), 4.30-4.22 (2 H, m, 2 × inositol
ring), 4.08–4.04 (1 H, m, inositol ring), 4.03-4.00 (1 H, m, inositol ring), 3.96-3.92 (2 H,
m, 2 × inositol ring). The data are in good agreement with literature values.138
(±)-6-[(4'-Methoxy)benzyloxy]-2,4,10-trioxatricyclo[3.3.1.13,7]decane-8,9-diol 44134
HO
OPMB
O
HO
O O
44
Sodium hydride (60 % dispersion in mineral oil, 3.28 g, 82.0 mmol, 1.3 equiv.) was
added portionwise to a stirred solution of 2,4,10-trioxatricyclo[3.3.1.13,7]decane-6,8,9-
triol 43 (12.00 g, 63.1 mmol, 1 equiv.) in dry N,N-dimethylformamide (220 mL) under
nitrogen at 0 °C. The mixture was stirred at 0 °C for 30 min then left to stir at RT for a
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further 2 h. The suspension was re-cooled to 0 °C and 4-(methoxy)benzyl chloride (10.9
g, 9.41 mL, 69.4 mmol, 1.1 equiv.) was added dropwise. The mixture was left to stir for
30 min at 0 °C and then overnight at RT. The reaction mixture was quenched with ice-
water (20 mL) and concentrated under reduced pressure. The resulting residue was
dissolved in ethyl acetate (100 mL) and water (100 mL). The organic layer was collected
and the aqueous phase was further extracted with ethyl acetate (3 × 80 mL). The
combined organic extracts were dried (MgSO4), filtered and the solvent was removed in
vacuo. The resulting solid was purified by silica gel column chromatography, eluting with
ethyl acetate/petroleum ether (20:80, 30:70, 40:60 then 50:50) to give (±)-6-[(4'-
methoxy)benzyloxy]-2,4,10-trioxatricyclo[3.3.1.13,7]decane -8,9-diol 44 (16.70 g, 85%
yield) as a colourless solid; Rf 0.34 (1:1 ethyl acetate/petroleum ether); mp 98-100 °C
(diethyl ether/petroleum ether) (Lit.,177 99-101 °C); δH (300 MHz, CDCl3) 7.28-7.24 (2 H,
m, OCH2C6H4OCH3), 6.94-6.88 (2 H, m, OCH2C6H4OCH3), 5.44 (1 H, d, J 1.2, 3-H),
4.64 (1 H, d, JAB 11.5, OCHAHB), 4.58 (1 H, d, JAB 11.5, OCHAHB), 4.41-4.40 (2 H, m, 2 ×
inositol ring), 4.25-4.20 (3 H, m, 3 × inositol ring), 3.84 (3 H, s, OCH3), 3.79 (1 H, d, J
10.5, OH), 3.14 (1 H, d, J 11.7, OH). The data are in good agreement with literature
values.134,177
(±)-8,9-Bis-O-benzyl-6-[(4'-methoxy)benzyloxy]-2,4,10-trioxa-
tricyclo[3.3.1.13,7]decane 45134
BnO
OPMB
O
BnO
O O
45
Sodium hydride (60 % dispersion in mineral oil, 4.49 g, 112.3 mmol, 2.5 equiv.) was
suspended in N,N-dimethylformamide (175 mL) and the suspension was cooled to -5 oC
under argon. A solution of (±)-6-[(4'-methoxy)benzyloxy]-2,4,10-trioxa-
tricyclo[3.3.1.13,7]decane-8,9-diol 44 (13.20 g, 42.6 mmol, 1 equiv.) in N,N-
dimethylformamide (90 mL) was transferred via cannula to the cooled sodium hydride
suspension. The mixture was stirred for 30 min at -5 °C and for 1 h at RT, then re-cooled
to -5 °C and benzyl bromide (19.3 g, 13.4 mL, 112.3 mmol, 2.5 equiv.) was added
dropwise, keeping the temperature between 0 °C and -5 °C. The reaction mixture was
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stirred for 30 min at 0 °C and for 20 h at RT, after which time the reaction was judged to
be complete by TLC analysis. The reaction was quenched by the addition of water (20
mL), and all volatile components were removed in vacuo. The resulting residue was
reconstituted in ethyl acetate (150 mL) and water (100 mL). The organic layer was
collected and the aqueous portion was extracted further with ethyl acetate (3 × 100 mL).
The combined organic extracts were washed with water (100 mL) and brine (100 mL),
dried (MgSO4), filtered and the solvent was removed in vacuo. The resulting oil was
purified by silica gel column chromatography, eluting with ethyl acetate/petroleum ether
(20:80 then 30:70) to give (±)-8,9-bis-O-benzyl-6-[(4'-methoxy)benzyloxy]-2,4,10-trioxa-
tricyclo[3.3.1.13,7]decane 45 (20.50 g, 98% yield) as a colourless oil; Rf 0.32 (ethyl
acetate/petroleum ether 25:75); δH (300 MHz, CDCl3) 7.40-7.19 (10 H, m, 2 × Ph), 7.10
(2 H, d, J 8.7, OCH2C6H4OCH3), 6.81 (2 H, d, J 8.7, OCH2C6H4OCH3), 5.55 (1 H, d, J
1.3, 3-H), 4.66 (2 H, s, OCH2Ph), 4.64 (1 H, d, JAB 11.5, OCHAHBPh), 4.56 (1 H, d, JA'B'
11.2, OCHA'HB'-C6H4OCH3), 4.50 (1 H, d, JAB 11.5, OCHAHBPh), 4.46 (1 H, d, J 11.2
OCHA'HB'-C6H4OCH3), 4.40-3.37 (1 H, m, inositol ring), 4.30-4.20 (4 H, m, inositol ring),
4.07-4.04 (1 H, m, inositol ring), 3.82 (3 H, s, OCH3). The data are in good agreement
with literature values.134
(±)-6,8-Bis-O-benzyl-9-[(4'-methoxy)benzyloxy]-2,4-dioxabicyclo[3.3.1]nonan-7-ol
46134
BnO
OPMB
O
BnO
O OH
46
The protected orthoformate (±)-8,9-bis-O-benzyl-6-[(4΄-methoxy)benzyloxy]-2,4,10-
trioxatricyclo[3.3.1.13,7]decane 45 (15.02 g, 30.6 mmol, 1 equiv.) was dissolved in dry
dichloromethane (150 mL) under nitrogen and cooled to 0 °C. Diisobutylaluminium
hydride (1.0 M solution hexanes, 79 mL, 79.2 mmol, 2.5 equiv.) was added dropwise,
maintaining a temperature of 0 °C. The mixture was stirred at RT for 5 h, after which
time the reaction was adjudged to be complete by TLC analysis. To quench the reaction,
the mixture was cannulated onto a vigorously stirred solution of 1.0 M aqueous sodium
potassium tartrate (100 mL) and saturated aqueous ammonium chloride solution (100
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mL), and the resulting mixture was stirred overnight. The aqueous and organic layers
were separated and the organic phase was collected. The aqueous layer was extracted
with dichloromethane (3 × 100 mL). The combined organic extracts were washed with
brine (100 mL), dried (MgSO4), filtered and the solvent removed under reduced pressure
to give (±)-6,8-O-benzyl-9-[(4'-methoxy)benzyloxy]-2,4-dioxabicyclo[3.3.1]nonan-7-ol 46
(14.52 g, 96% yield) as a colourless oil; Rf 0.28 (ethyl acetate/petroleum ether 40:60); δH
(300 MHz, CDCl3) 7.36-7.28 (10 H, m, 2 × Ph), 7.20 (2 H, d, J 8.7, OCH2C6H4OCH3),
6.84 (2 H, d, J 8.7, OCH2C6H4OCH3), 5.57 (1 H, d, J 4.9, 3-H), 4.68 (1 H, d, JAB 12.0,
OCHAHB-Ph), 4.66 (1 H, d, J 4.9, 3-H), 4.62 (2 H, s, OCH2-Ph), 4.60 (1 H, d, JA'B' 11.5,
OCHA'HB'-C6H4OCH3), 4.59 (1 H, d, JAB 12.0, OCHAHB-Ph), 4.53 (1 H, d, JA'B' 11.5,
OCHA'HB'-C6H4OCH3), 4.45-4.41 (2 H, m, inositol ring), 4.32-4.29 (1 H, m, inositol ring),
4.03-4.00 (2 H, m, inositol ring), 3.96 (1 H, br s, inositol ring), 3.81 (3 H, s, OCH3), 2.98
(1 H, br s, OH). The data are in good agreement with literature values.134
(±)-7-Allyoxy-8,9-bis-O-benzyl-8-(4-methoxybenzyloxy)-2,4-
dioxabicyclo[3.3.1]nonane 47134
BnO
OPMB
O
BnO
O OAll
47
Sodium hydride (60 % dispersion in mineral oil, 1.83 g, 45.8 mmol, 1.5 equiv.) was
suspended in N,N-dimethylformamide (100 mL) under nitrogen and cooled to -5 °C. The
alcohol (±)-8,9-bis-O-benzyl-6-[(4΄-methoxy)benzyloxy]-2,4-dioxabicyclo[3.3.1]nonan-7-
ol 46 (14.53 g, 30.5 mmol, 1 equiv) was dissolved in N,N-dimethylformamide (75 mL)
and transferred via cannula to the cooled sodium hydride suspension. The resulting
mixture was stirred at -5 °C for 20 min and for 1 h at RT. The mixture was again cooled
to -5 oC and imidazole (catalytic amount) was added followed by dropwise addition of
allyl bromide (5.6 g, 4.0 mL, 45.8 mmol, 1.5 equiv.). The reaction mixture was stirred for
30 min at -5 °C and then left to stir overnight at RT. Analysis by TLC showed that the
reaction was complete and the mixture quenched with water (10 mL). The solvent was
removed in vacuo and the resulting oil was partitioned between ethyl acetate (100 mL)
and water (100 mL). The organic layer was collected and the aqueous portion was
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extracted with ethyl acetate (3 × 100 mL). The combined organic extracts were washed
with water (50 mL) and brine (50 mL), dried (MgSO4), filtered and the solvent removed
under reduced pressure. The resulting crude oil was purified by flash silica gel column
chromatography eluting with ethyl acetate/petroleum ether (20:80 then 30:70) to give
(±)-7-allyoxy-8,9-bis-O-benzyl-8-(4-methoxybenzyloxy)-2,4-dioxabicyclo[3.3.1]nonane 47
(13.16 g, 84% yield) as a colourless oil; Rf 0.47 (ethyl acetate/petroleum ether 40/60); δH
(300 MHz, CDCl3) 7.40-7.30 (10 H, m, 2 × Ph), 7.26 (2 H, d, J 8.7, OCH2C6H4OCH3),
6.88 (2 H, d, J 8.7, OCH2C6H4OCH3), 5.90 (1 H, dddd, J 17.2, 10.3, 5.7, 5.7, CH=CH2),
5.24 (1 H, dddd, J 17.2, 1.8, 1.6, 1.6, CH=CHH), 5.20 (1 H, d, J 5.5, 3-H), 5.20-5.17 (1
H, m, CH=CHH), 4.84 (1 H, d, J 5.4, 3-H), 4.66 (1 H, d, JAB 11.8, OCHAHB-Ph), 4.65 (2
H, s, OCH2-Ph), 4.61 (1 H, d, JAB 11.8, OCHAHB-Ph), 4.60 (1 H, d, JA'B' 11.5, OCHA'HB'-
C6H4OCH3), 4.54 (1 H, d, JA'B' 11.5, OCHA'HB'-C6H4OCH3), 4.28-4.25 (2 H, m, inositol
ring), 4.15-4.10 (2 H, m, OCH2CH=CH), 3.91-3.88 (1 H, m, inositol ring), 3.80 (3 H, s,
OCH3), 3.53 (1 H, t, J 5.6, inositol ring). The data are in good agreement with literature
values.134
(±)-5-O-Allyl-2,6-bis-O-benzyl-myo-inositol 42134
OBn
OAll
BnO
HO
OH
OH
42
Concentrated hydrochloric acid (80 mL) was slowly poured onto a stirred solution of (±)-
7-allyoxy-8,9-bis-O-benzyl-8-(4-methoxybenzyloxy)-2,4-dioxabicyclo[3.3.1]nonane 47
(60.50 g, 113.7 mmol, 1 equiv.) in methanol (500 mL). The mixture was heated under
reflux for 4 h, then allowed to cool to room temperature. The reaction was quenched by
the addition of sodium hydrogen carbonate (100 g). The solid components were
removed by filtration and rinsed with methanol (30 mL) and the crude filtrate was
adsorbed onto silica gel. Silica gel column chromatography, eluting with ethyl
acetate/petroleum ether (30:70, 40:60 then 80:20) gave (±)-5-O-allyl-2,6-O-dibenzyl-
myo-inositol 42 (37.8 g, 83% yield) as a colourless solid; Rf 0.43 (ethyl acetate); mp 118-
120 °C (ethyl acetate/petroleum ether), (Lit.,134 111-112 °C); δH (300 MHz, CDCl3) 7.39-
7.22 (10 H, m, 2 × Ph) 5.98 (1 H, dddd, J 17.2, 10.3, 5.6, 5.6, CH=CH2), 5.30 (1 H, dddd,
J 17.2, 1.6, 1.6, 1.6, CH=CHH), 5.20 (1 H, dddd, J 10.3, 1.6, 1.2, 1.2, CH=CHH), 4.91 (1
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H, d, JAB 11.5, OCHAHB-Ph), 4.88 (1 H, d, JA'B' 11.3, OCHA'HB'-Ph), 4.78 (1 H, d, JA'B'
11.3, OCHA'HB'-Ph), 4.74 (1 H, d, JAB 11.5, OCHAHB-Ph), 4.38-4.35 (2 H, m,
OCH2CH=CH2), 4.03 (1 H, dd, J 2.7, 2.7, 2-H), 3.82 (1 H, dd, J 9.5, 9.5, inositol ring),
3.74 (1 H, dd, J 9.4, 9.4, inositol ring), 3.58 (1 H, dd, J 9.5, 2.6, inositol ring), 3.48 (1 H,
dd, J 9.7, 2.6, inositol ring), 3.23 (1 H, dd, J 9.3, 9.3 inositol ring), 2.54 (1 H, br s, OH),
2.33 (2 H, br s, 2 × OH). The data are in agreement with the literature values.134
(1S)-(-)-Camphor dimethyl acetal (-)-52178
MeO
OMe
(-)-52
Trimethylorthoformate (33.5 g, 34.5 mL, 315.6 mmol, 4 equiv.) was added to a mixture
of (1S)-(-)-camphor (12.0 g, 78.9 mmol) and Montmorillonite K-10 clay (22 g) in hexane
(100 mL) under an atmosphere of nitrogen and the mixture stirred for 32 h. The clay was
removed by filtration and washed with hexane (100 mL) and the solvent was then
removed under reduced pressure to give (1S)-(-)-camphor dimethyl acetal (-)-52 (11.85
g, ~ 75% conversion to the dimethyl acetal as estimated from 1H NMR) as a colourless
oil; Rf 0.62 (diethyl ether/petroleum ether 30:70); δH (300 MHz, CDCl3) 3.21 (3 H, s,
OCH3), 3.15 (3 H, s, OCH3), 2.22-2.13 (1 H, m, camphor ring), 1.80-1.60 (3 H, m,
camphor ring), 0.95 (3 H, s, 1-CH3), 0.89 (3 H, s, 7-CH3), 0.81 (3 H, s, 7-CH3). The data
are in agreement with literature values.178
(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-3-O-endo-4-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-41134
OBn
OAll
BnO
O
O
OH
(-)-41
The crude (1S)-(-)-camphor dimethyl acetal (-)-52 (8.66 g, 43.8 mmol, 2.5 equiv.), the
triol (±)-5-O-ally-2,6-bis-O-benzyl-myo-inositol 42 (7.00 g, 17.5 mmol, 1 equiv.) and 4-
100
toluenesulfonic acid monohydrate (0.99 g, 5.25 mmol, 0.3 equiv.) were dissolved in dry
dichloromethane (80 mL) under nitrogen and heated under reflux for 48 h. The acidic
reaction mixture was quenched with triethylamine (3 mL), and all volatile components
were removed under reduced pressure. The crude product was purified by silica gel
column chromatography eluting with the following solvent systems to allow maximum
isolation of the desired pure diastereomer: ethyl acetate/petroleum ether (5:95, 6:94,
7:93, 8:92, 9:91, 10:90 – the undesired diastereomers were collected in this solvent
system) then 20:80 elution gave the required diastereomer (-)-1D-5-O-allyl-2,6-bis-O-
benzyl-3-O-endo-4-O-exo-(L-1',7',7'-trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol
(-)-41 as a colourless gum. Additional purification by flash silica gel column
chromatography of impure fractions from the first column, eluting with the solvent system
as above, was required to obtain fully the title compound (combined weight and yield:
2.32 g, 24% yield) as a colourless gum. Rf 0.32 (ethyl acetate/petroleum ether 20:80);
20
D[α] -10.8, (c 0.5 in CHCl3) [(Lit.,
134 20
D[α] -11.7 (c 1.3 in CHCl3)]; δH (300 MHz, CDCl3)
7.40-7.30 (10 H, m, 2 × Ph), 5.95 (1 H, dddd, J 17.3, 10.6, 5.5, 5.5, CH=CH2), 5.32 (1 H,
dddd, J 17.2, 1.7, 1.7, 1.7 CHC=CHH), 5.16 (1 H, dddd, J 10.3, 1.7, 1.3, 1.3,
CHC=CHH), 5.02 (1 H, d, JAB 11.5, OCHAHB-Ph), 4.95 (1 H, d, JA'B' 11.1, OCHA'HB'-Ph),
4.81 (1 H, d, JA'B' 11.1, OCHA'HB'-Ph), 4.70 (1 H, d, JAB 11.5, OCHAHB-Ph), 4.41 (1 H,
dddd, J 12.7, 5.5, 1.7, 1.3, CHH=CH2), 4.21-4.17 (2 H, m, 1 × CHH=CH2, 1 × inositol
ring), 3.96 (1 H, dd, J 9.7, 9.7, inositol ring), 3.70-3.50 (3 H, m, inositol ring), 3.31 (1 H,
dd, J 9.7, 1.8, inositol ring), 2.46 (1 H, d, J 7.6, OH), 2.17 (1 H, dt, J 13.6, 3.9, camphor
ring), 1.94-1.90 (1 H, m, camphor ring), 1.78-1.75 (2 H, m, 2 × camphor ring), 1.47 (1 H,
d, J 13.5, camphor ring), 1.30-1.23 (2 H, m, 2 × camphor ring), 1.03 (3 H, s, CH3), 1.28-
1.10 (3 H, m, 3 × camphor ring), 0.86 (3 H, s, CH3 camphor bridge), 0.85 (3 H, s, CH3
camphor bridge). The data are in good agreement with literature values.134
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(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-3-O-endo-4-O-exo-(L-
1',7',7'-trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-56134
OBn
OAll
BnO
O
O
OPMB
(-)-56
A solution of the alcohol (-)-1D-5-O-allyl-2,6-bis-O-benzyl-3-O-endo-4-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-41 (583 mg, 1.09 mmol, 1 equiv.) in
THF (10 mL) was transferred via cannula into a suspension of sodium hydride (60 %
dispersion in mineral oil, 66 mg, 1.65 mmol, 1.5 equiv.) in THF (20 mL) at 0 °C. The
mixture was stirred at RT for 1 h, then cooled to 0 °C after which N,N-
dimethylformamide (10 mL), 4-(methoxy)benzyl chloride (254 mg, 220 μL, 1.64 mmol,
1.5 equiv.) and tetrabutylammonium iodide (catalytic amount) were added. The resulting
mixture was allowed to warm to RT and stirred for 24 h. The reaction was seen to be
incomplete by TLC analysis, therefore more sodium hydride (44 mg, 1.09 mmol, 1
equiv.) was added at 0 °C, and following 30 min stirring at 0 °C, 4-(methoxy)benzyl
chloride (173 mg, 150 μL, 1.09 mmol, 1 equiv.) was added. The mixture was then stirred
for a further 24 h at RT. The reaction was quenched with a 10 % aqueous solution of
sodium hydrogen carbonate (5 mL). The solvent was removed in vacuo and the
resulting residue was reconstituted with ethyl acetate (50 mL) and water (50 mL). The
layers were separated and the aqueous layer was extracted with ethyl acetate (3 × 50
mL). The combined organic extracts were washed with brine (50 mL), dried (MgSO4),
filtered and concentrated under reduced pressure to give a yellow oil. Purification by
silica gel column chromatography, eluting with ethyl acetate/petroleum ether (10:90)
gave (-)-1D-5-O-allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-3-O-endo-4-O-exo-(L-
1',7',7'-trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-56 (577 mg, 83% yield) as a
colourless oil. Rf 0.46 (ethyl acetate/petroleum ether 20/80); 20D[α] -18.3, (c 0.5 in CHCl3)
[Lit.,134 20D[α] -20.1 (c 2.6 in CHCl3)]; δH (300 MHz; CDCl3) 7.45-7.29 (10 H, m, 2 × Ph),
7.20 (2 H, d, J 8.7, OCH2C6H4OCH3), 6.82 (2 H, d, J 8.7, OCH2C6H4OCH3), 5.95 (1 H,
dddd, J 17.2, 10.3, 5.6, 5.6, CH=CH2), 5.32 (1 H, dddd, J 17.2, 1.7, 1.7, 1.7, CH=CHH),
5.18 (1 H, dddd, J 10.3, 1.7, 1.3, 1.3, CH=CHH), 4.91 (1 H, d, JAB, 12.2, OCHAHBPh),
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4.90 (1 H, d, JA΄B΄ 10.7, OCHA΄HB΄Ph), 4.84 (1 H, d, JA΄B΄ 10.7, OCHA΄HB΄Ph), 4.81 (1 H, d,
JAB 12.2, OCHAHBPh), 4.51 (2 H, s, OCH2C6H4OCH3), 4.38 (1 H, dddd, J 13.2, 5.6, 1.7,
1.3, CHHCH=CH2), 4.20 (1 H, dddd, J 13.2, 5.6, 1.7, 1.3, CHHCH=CH2), 4.11 (1 H, dd, J
2.8, 1.9, inositol ring), 4.03 (1 H, dd, J 9.6, 9.6, inositol ring), 3.85 (1 H, dd, J 9.1, 9.1,
inositol ring), 3.80 (3 H, s, OCH3), 3.52-3.42 (2 H, m, inositol ring), 3.17 (1 H, dd, J 9.9,
1.6, inositol ring), 2.12 (1 H, dt, J 13.6, 3.8, camphor ring), 1.96-1.87 (1 H, m, camphor
ring), 1.74-1.70 (2 H, m, camphor ring), 1.43 (1 H, d, J 13.6, camphor ring), 1.44-1.34 (1
H, m, camphor ring), 1.25-1.13 (1 H, m, camphor ring), 1.02 (3 H, s, camphor bridge),
0.86 (3 H, s, camphor bridge), 0.85 (3 H, s, camphor bridge). These data are in good
agreement with the literature values.134
(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-myo-inositol (-)-40141
OBn
OAll
BnO
HO
OH
OPMB
(-)-40
Acetyl chloride (46 mg, 42 μL, 0.52 mmol, 0.6 equiv.) was added to a solution of (-)-1D-
5-O-allyl-2,6-di-O-benzyl-1-O-(4'-methoxybenzyl)-3-O-endo-4-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-56 (550 mg, 0.86 mmol, 1 equiv.) in
dichloromethane (12 mL) and methanol (8 mL) and the solution was stirred for 5 h. The
reaction mixture was quenched by the addition of triethylamine (1 mL), and all volatile
components were removed in vacuo to give a colourless solid. Purification by silica gel
column chromatography, eluting with ethyl acetate/petroleum ether (20:80, 30:50, 50:50)
then 100 % ethyl acetate gave (-)-1D-5-O-allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-
myo-inositol (-)-40 (366 mg, 82% yield) as a colourless solid. Rf 0.28 (ethyl acetate/
petroleum ether 1:1); mp 124-126 °C, (ethyl acetate/hexane, Lit.141 mp 125-126 °C);
20
D[α] -24.3, (c 0.14 in CHCl3) [Lit.,
141 20
D[α] -26.4, (c 1.2 in CHCl3)]; δH (300 MHz; CDCl3)
7.30-7.18 (12 H, m, 10 × Ph and 2 × OCH2C6H4OCH3), 6.80 (2 H, d, J 8.7,
OCH2C6H4OCH3), 5.90 (1 H, dddd, J 17.2, 10.2, 5.5, 5.5, CH=CH2), 5.24 (1 H, dddd, J
17.2, 1.7, 1.6, 1.6, CH=CHH), 5.12 (1 H, dddd, J 10.2, 1.7, 1.2, 1.2, CH=CHH), 5.01 (1
H, d, JAB, 11.5, OCHAHBPh), 4.83 (1 H, d, JA΄B΄ 10.6, OCHA΄HB΄Ph), 4.75 (1 H, d, JA΄B΄ 
10.6, OCHA΄HB΄Ph), 4.63-4.53 (3 H, m, 2 × OCH2C6H4OCH3 and 1 × OCHAHBPh), 4.33
(1 H, dddd, J 12.5, 5.5, 1.6, 1.2, CHHCH=CH2), 4.20 (1 H, dddd, J 12.5, 5.5, 1.6, 1.2,
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CHHCH=CH2), 3.92 (1 H, dd, J 2.5, 2.5, inositol ring), 3.88 (1 H, dd, J 9.5, 9.5, inositol
ring), 3.75 (3 H, s, OCH3), 3.75-3.71 (1 H, m, inositol ring), 3.37 (1 H, dd, J 9.7, 2.5,
inositol ring), 3.31-3.28 (1 H, m, inositol ring), 3.13 (1 H, dd, J 9.2, 9.2, inositol ring), 2.43
(1 H, br s, OH), 2.18 (1 H, d, J 1.8, OH). These data are in good agreement with the
literature values.141
(-)-1D-3,5-bis-O-Allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-myo-inositol (-)-39
OBn
OAll
BnO
AllO
OH
OPMB
(-)-39
A mixture of (-)-1D-5-O-allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-myo-inositol (-)-40
(288 mg, 0.56 mmol, 1 equiv.) and dibutyltin oxide (279 mg, 1.12 mmol, 2 equiv.) in
toluene (12 mL) was heated under reflux, using Dean-Stark apparatus for azeotropic
removal of water, for 24 h. The solvent was removed in vacuo and the residue dissolved
in N,N-dimethylformamide (10 mL). Allyl bromide (531 mg, 380 μL, 4.45 mmol, 8.0
equiv.) and caesium fluoride (170 mg, 1.12 mmol, 2.0 equiv.) were both added and the
reaction mixture was stirred for 24 h. Solvents and any remaining volatile compounds
were removed under reduced pressure and the resultant solid material was partitioned
between ethyl acetate (30 mL) and water (30 mL). The aqueous layer was extracted with
ethyl acetate (3 × 30 mL). The combined organic extracts were washed with saturated
aqueous sodium bicarbonate solution (30 mL) then brine (30 mL), dried (MgSO4),
filtered and concentrated under reduced pressure. Exhaustive purification by silica gel
column chromatography, eluting with ethyl acetate/petroleum ether (10:90, 15:85 then
20:80) gave (-)-1D-3,5-bis-O-allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-myo-inositol
(-)-39 (116 mg, 37% yield) as a colourless solid. Rf 0.54 (ethyl acetate/petroleum ether
60/40); mp 55-57 °C (diethyl ether/hexane); 20D[α] -3.02 (c 0.5 in CHCl3); νmax (thin
film)/cm-1 2924 (m), 2874 (m), 1515 (w), 1254 (w), 1077 (m); δH (300 MHz; CDCl3) 7.34-
7.18 (10 H, m, 2 × Ph), 7.19 (2 H, d, J 8.6, OCH2C6H4OCH3), 6.79 (2 H, d, J 8.6,
OCH2C6H4OCH3), 5.89 (1 H, dddd, J 17.2, 10.4, 5.6, 5.6, CH=CH2), 5.66 (1 H, dddd, J
17.2, 10.4, 5.6, 5.6, CH=CH2), 5.23 (1 H, dddd, J 17.2, 1.7, 1.7, 1.7, CH=CHxHy), 5.18 (1
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H, dddd, J 17.2, 1.7, 1.7, 1.7, CH=CHx'Hy'), 5.11 (1 H, dddd, J 10.4, 1.7, 1.3, 1.3,
CH=CHxHy), 5.08 (1 H, dddd, J 10.4, 1.7, 1.3, 1.3, CH=CHx'Hy'), 4.83 (1 H, d, JAB, 10.5,
OCHAHBPh), 4.80 (1 H, d, JA΄B΄ 12.1, OCHA΄HB΄Ph), 4.74 (1 H, d, JAB 10.5, OCHAHBPh),
4.75 (1 H, d, JA'B', 12.1, OCHA'HB'Ph), 4.56 (1 H, d, J 11.4, OCH2C6H4OCH3), 4.50 (1 H,
d, J 11.4, OCH2C6H4OCH3), 4.30-4.26 (2 H, m, CH2ACH=CH2), 4.01-3.96 (5 H, m, 2 ×
CH2BCH=CH2 and 3 × inositol ring), 3.74 (3 H, s, OCH3), 3.27 (1 H, dd, J 9.7, 2.3,
inositol ring), 3.16 (1 H, dd, J 9.2, 9.2, inositol ring), 3.01 (1 H, dd, J 9.9, 2.3, inositol
ring), 2.43 (1 H, d, J 1.5 OH); δC (75 MHz, CDCl3); 159.6 (C), 139.3 (C), 135.7 (CH),
134.9 (CH), 130.9 (C), 129.6 (2C, C6H4), 128.7 (CH), 128.6 (CH), 128.5 (CH), 128.2
(CH), 128.0 (CH), 127.8 (CH), 117.8 (CH2), 117.2 (CH2), 114.2 (2C, C6H4), 83.3 (CH),
81.8 (CH), 81.2 (CH), 80.1 (CH), 76.2 (CH2), 74.6 (CH2), 74.4 (CH2), 73.7 (CH), 73.0
(CH2), 72.9 (CH), 71.5 (CH2), 55.7 (CH3); HRMS m/z (ES+) [Found: (M+Na)+ 583.2655.
C34H40O7Na requires M+ 583.2672], m/z (ES+) 583 ([M+Na]+, 100%).
Tetramethyl biphosphine disulfide 61146
P P
S S
61
Thiophosphoryl chloride (8.3 g, 5.0 mL, 49.2 mmol, 1 equiv.) was added dropwise over a
period of 40 min to a cooled solution of methylmagnesium bromide (3 M solution in
diethyl ether, 66 mL, 4.0 equiv.). The reaction was very exothermic and cautious
addition of the thiophosphoryl chloride ensured the reaction mixture temperature
remained between 0 °C and 8 °C. Following addition, the mixture was stirred at room
temperature for 20 min, then heated under reflux for 1 h. The mixture was poured into a
flask containing ice and conc. HCl (10 mL), and diluted with diethyl ether (100 mL). The
colourless precipitate thus formed was filtered from the organic/aqueous mixture and
recrystallised from ethanol to give the first batch of tetramethyl biphosphine disulfide
product. The organic and aqueous mixture was then separated and the aqueous layer
extracted with diethyl ether (3 × 100 mL). The combined organic extracts were washed
with water (50 mL), concentrated under reduced pressure and the crude product
recrystallised from ethanol and combined with the first crystallised batch to give
tetramethyl biphosphine disulfide 61 (2.13 g, 23% yield) as a colourless crystalline solid.
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mp 220-222 °C (ethanol), (Lit.146 mp 221-223 °C); δH (300 MHz; CDCl3) 2.05-1.90 (12 H,
m, 4 × CH3); δP (122 MHz, CDCl3) 36.5 (2 P, s); m/z (ES+) 209 ([M+Na]+, 100%). The
data are in good agreement with the literature values.146
Dimethylphosphinic chloride 62147
P
Cl
O
62
Thionyl chloride (2.04 g, 1.25 mL, 17.1 mmol, 4.8 equiv.) was added dropwise to a
cooled suspension of tetramethyl biphosphine disulfide 61 (665 mg, 3.57 mmol, 1
equiv.) in dry toluene (4 mL) at -5 °C. The mixture turned a peach colour during initial
reaction. Following complete mixing of reactants, the mixture was stirred for 30 min at
room temperature, then heated under reflux for 1 h with the mixture turning a yellow
colour on heating. Analysis by 31P NMR showed complete consumption of the
tetramethyl biphosphine disulfide. Most of the toluene and excess thionyl chloride were
removed in vacuo. Kugelrohl distillation of the crude yellow residue first yielded a yellow
liquid impurity (70 °C, 32 Torr) then dimethylphosphinic chloride 62 (140 °C, 28 Torr) as
a colourless solid (458 mg, 57% yield) which was stored in a desiccator under nitrogen.
mp – material unstable to air; δH (300 MHz; CDCl3) 2.05 (6 H, d, JP-H 13.6, 2 × CH3); δP
(122 MHz, CDCl3) 61.0. The data are in agreement with the literature values.147
(-)-1D-3,5-bis-O-Allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-4-O-
(dimethylphosphinyl)-myo-inositol (-)-38
OBn
OAll
BnO
AllO
O
OPMB
P
O
(-)-38
A solution of dimethylphosphinic chloride (46 mg, 0.41 mmol, 4 equiv.) in N,N-
dimethylformamide (1 mL) was added via cannula to a stirred solution of alcohol (-)-1D-
3,5-bis-O-allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-myo-inositol (-)-39 (57 mg, 0.10
mmol, 1 equiv.) and 2,6-lutidine (31 mg, 23 μL, 0.20 mmol, 2 equiv.) in N,N-
dimethylformamide (2 mL) at -5 °C. The mixture was allowed to slowly warm to room
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temperature and stirred for 20 h, after which time TLC analysis showed the consumption
of starting materials. The solvent was removed in vacuo to give a light brown solid.
Purification by silica gel column chromatography, eluting with methanol/dichloromethane
(2:98) gave 1D-3,5-bis-O-allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-4-O-
(dimethylphosphinyl)-myo-inositol (-)-38 (58 mg, 89% yield) as a colourless crystalline
solid. Rf 0.49 (methanol/dichloromethane 5:95); mp 79-82 °C (diethyl ether/hexane);
20
D[α] -0.24 (c 0.42 in CHCl3); νmax (nujol)/cm
-1 2726 (w), 1211 (m), 1080 (m), 817 (w); δH
(300 MHz; CDCl3) 7.36-7.20 (10 H, m, 2 × Ph), 7.19 (2 H, d, J 8.7, OCH2C6H4OCH3),
6.81 (2 H, d, J 8.6, OCH2C6H4OCH3) 5.97-5.74 (2 H, 2 × CH=CH2), 5.25-5.23 (1 H, m,
CH=CH2), 5.20-5.18 (1 H, m, CH=CH2), 5.12-5.09 (2 H, m, CH=CH2), 4.84 (1 H, d, JAB
10.6, OCHAHBPh), 4.77 (2 H, s, OCH2Ar), 4.74 (1 H, d, JAB 10.6, OCHAHBPh), 4.56-4.46
(1 H, m, CH2CH=CH2) 4.51 (1 H, s, CH2Ar), 4.49 (1 H, s, CH2Ar), 4.36-4.29 (1 H, m,
CH2CH=CH2), 4.25-4.17 (1 H, m, CH2CH=CH2), 3.98-3.90 (4 H, m, 1 × CH2CH=CH2, 3 ×
inositol ring), 3.76 (3 H, s, OCH3), 3.24 (1 H, dd, J 9.3, 9.3, inositol ring), 3.28-3.21 (1 H,
m, inositol ring), 3.10 (1 H, dd, J 9.9, 2.2, inositol ring), 1.50 (3 H, d, 1JP-H 14.0,
P(O)CH3), 1.46 (3 H, d, 1JP-H 14.0, P(O)CH3); δC (75 MHz, CDCl3) 159.6 (C), 139.1 (C),
139.06 (C), 135.4 (CH), 134.7 (CH), 130.7 (C), 129.7 (CH), 128.8 (CH), 128.6 (CH),
128.5 (CH), 128.3 (CH), 128.0 (CH), 127.9 (CH), 118.0 (CH2), 117.1 (CH2), 114.2 (CH),
82.0 (1 C, d, 3JP-C 2.3, CH), 81.8 (CH), 80.6 (CH), 79.1 (CH), 76.6 (1 C, d, 2JP-C 8.3, CH),
76.2 (CH2), 74.7 (CH2), 74.5 (CH2), 73.7 (CH), 72.9 (CH2), 71.7 (CH2), 55.7 (CH3), 17.7
(1 C, d, 1JP-C 93.0, PCH3), 17.6 (1 C, d, 1JP-C 93.0, PCH3); δP (122 MHz, CDCl3) 54.8;
HRMS m/z (ES+) [Found: (M+Na)+ 659.2736. C36H45O8PNa requires M+ 659.2750]; m/z
(ES+) 659 ([M+Na]+, 100%).
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Attempted synthesis of 1D-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-4-O-
(dimethylphosphinyl)-3,5-bis(dibenzylphosphate)-myo-inositol 37
OBn
OH
BnO
HO
O
OPMB
P
O
OBn
OAll
BnO
AllO
O
OPMB
P
OBn
O
BnO
O
O
OPMB
P
P P
OBn
BnO
O
BnO OBn
O
37
O O
(-)-38 63
A mixture of 1D-3,5-bis-O-allyl-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-4-O-
(dimethylphosphinyl)-myo-inositol (41 mg, 0.065 mmol, 1.0 equiv.), palladium on carbon
(10 % w/w, 10 mg) and 4-toluenesulfonic acid (7 mg, 0.039 mmol, 0.6 equiv.) in
methanol (2 mL) and water (0.5 mL) was heated under reflux for 18 h. The mixture was
then filtered through a pad of Celite and the filtrate concentrated under reduced
pressure. Purification by silica gel column chromatography, eluting with dichloromethane
then methanol/dichloromethane (1:99 then 2:98) gave 1D-2,6-bis-O-benzyl-1-O-(4'-
methoxybenzyl)-4-O-(dimethylphosphinyl)-myo-inositol 63 (11.5 mg, 32 % yield) as a
yellow oil. Analysis by 1H and 31P NMR confirmed de-allylation was complete and only
the desired product was formed as a colourless gum. Rf 0.22
(methanol/dichloromethane 5:95); δH (300 MHz; CDCl3) 7.40-7.22 (12 H, m, 2 × Ph, 2 ×
OCH2C6H4OCH3), 6.86 (2 H, d, J 8.7, CH2C6H4OCH3), 4.98 (2 H, d, J 11.2, CH2Ph), 4.81
(1 H, d, J 11.7, CH2Ph), 4.79 (1 H, d, J 11.2, CH2Ph), 4.58 (2 H, s, CH2Ar), 4.36 (1 H,
ddd, J 9.1, 9.1, 9.1, inositol ring 4-H), 4.04 (1 H, dd, J 2.4, 2.4, inositol ring 2-H), 3.94-
3.84 (2 H, m, 2 × inositol ring), 3.81 (3 H, s, OCH3), 3.56-3.49 (2 H, m, 1 × inositol ring, 1
× OH), 3.45 (1 H, dd, J 9.8, 2.4, inositol ring), 1.60 (3 H, d, J 14.1, P(O)CH3), 1.55 (3 H,
d, J 14.1, P(O)CH3); δP (122 MHz, CDCl3) 60.8. The product was then used immediately
for the next step. 1H-Tetrazole in acetonitrile (3 % w/v, 209 μL, 0.09 mmol, 5.0 equiv.)
was added to a solution of bis(benzyloxy)-N,N-diisopropylamino phosphine 65 (31 mg,
0.09 mmol, 5.0 equiv.) in dichloromethane (0.8 mL) and the mixture stirred for 20 min. A
solution of 1D-2,6-bis-O-benzyl-1-O-(4'-methoxybenzyl)-4-O-(dimethylphosphinyl)-myo-
inositol 63 (10 mg, 0.018 mmol, 1.0 equiv.) in dichloromethane (0.6 mL) was added via
cannula and the resulting mixture stirred for 20 h. The mixture was cooled to -78 °C and
3-chloroperbenzoic acid (assume 60 %, 26 mg, 0.09 mmol, 5 equiv.) was added. The
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reaction mixture was allowed to reach RT and stirred for 3 h. The 3-chloroperbenzoic
acid was quenched with a 10 % aqueous solution of sodium bisulfite (30 mL). The
mixture was stirred for 10 min and the layers separated. The aqueous layer was
extracted with dichloromethane (3 × 50 mL). The combined organic extracts were
washed with saturated aqueous sodium bicarbonate solution (100 mL), brine (100 mL),
dried (MgSO4), filtered and concentrated under reduced pressure. Purification by silica
gel chromatography, eluting with dichloromethane then methanol/dichloromethane
(1:99) gave an inseparable mixture of products (8 mg) as a yellow gum.
Benzyloxy bis(N,N-diisopropylamino)phosphine 64179
PBnO
NiPr2
NiPr2
64
Dry pyridine (16.7 mL, 206 mmol, 1.0 equiv.) was added to a stirred solution of
phosphorus trichloride (18.0 mL, 206 mmol, 1.0 equiv.) in dry diethyl ether (200 mL).
The mixture was cooled to -78 °C and a solution of benzyl alcohol (21 mL, 206 mmol,
1.0 equiv.) in diethyl ether (150 mL) was added slowly over 1 h. The mixture was
allowed to reach RT and stirred for 1.5 h. The resulting colourless precipitate was
removed by filtration under a blanket of nitrogen and washed with dry diethyl ether (2 ×
50 mL). The filtrate was placed under nitrogen and cooled to -10 °C. Dry N,N-
diisopropylamine (111 mL, 855 mmol, 4.1 equiv.) was added dropwise over 15 min. The
mixture was allowed to reach RT and stirred for 20 h. The resulting precipitate was
removed by filtration under an a blanket of nitrogen and the filtrate was concentrated
under reduced pressure to give benzyloxy bis(N,N-diisopropylamino)phosphine 64 (43.0
g, 62% yield) as a yellow oil. The crude product was stored in the fridge under an
atmosphere of nitrogen. δH (300 MHz; CDCl3) 7.40-7.20 (5 H, m, Ph), 4.67 (2 H, d, J 7.3,
OCH2Ph), 3.65-3.50 (4 H, m, NCH(CH3)2), 1.20 (24 H, dd, J 6.7, 3.5, NCH(CH3)2); δP
(122 MHz, CDCl3) 124.8. The data are in good agreement with literature values.179
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Bis(benzyloxy)-N,N-diisopropylamino phosphine 65150
P
BnO
NiPr2
BnO
65
1H-Tetrazole in acetonitrile (3 % w/v, 73 mL, 31.3 mmol, 0.4 equiv.) was added to a
stirred solution of benzyloxy bis(N,N-diisopropylamino)phosphine (26.50 g, 78.3 mmol,
1.0 equiv.) in dichloromethane (200 mL). Dry benzyl alcohol (7.62 g, 7.30 mL, 70.5
mmol, 0.9 equiv.) was added dropwise over a period of 40 min. The resulting mixture
was stirred for 2 h. The solvent was removed in vacuo to give a colourless paste which
was purified by silica gel column chromatography, eluting with triethylamine, ethyl
acetate and petroleum ether (5:15:80) to give bis(benzyloxy)-N,N-diisopropylamino
phosphine 65 (19.30 g, 71% yield) as a colourless oil. δH (300 MHz; CDCl3) 7.40-7.24
(10 H, m, Ph), 4.81 (2 H, dd, J 12.7, 8.2, OCHAHBPh), 4.72 (2 H, dd, J 12.7, 8.6,
OCHAHBPh), 3.78-3.65 (2 H, m, NCH(CH3)2), 1.23 (12 H, d, J 6.8, NCH(CH3)2); δP (122
MHz, CDCl3) 148.8. The data are in good agreement with literature values.150
(±)-5-O-Allyl-2,6-bis-O-benzyl-3,4-isopropylidine-myo-inositol 71
OBn
OAll
BnO
O
O
OH
71
The triol (±)-5-O-allyl-2,6-O-dibenzyl-myo-inositol 42 (11.07 g, 27.68 mmol) and 4-
toluenesulfonic acid monohydrate (1.58, 8.3 mmol, 0.3 equiv.) were dissolved in N,N-
dimethylformamide (150 mL). 2,2-Dimethoxypropane (86.3 g, 102 mL, 830 mmol, 30
equiv.) was added to the solution and the mixture was allowed to stir at RT for 5 h. The
reaction was quenched with triethylamine (5 mL) and all volatile components were
removed in vacuo. The resulting oil was partitioned between ethyl acetate (50 mL) and
water (50 mL). The aqueous phase was extracted with ethyl acetate (3 × 50 mL) and the
combined organic extracts were washed with aqueous saturated sodium bicarbonate
(100 mL), brine (100 mL), dried (MgSO4), filtered and concentrated. The resulting crude
product was adsorbed onto silica gel and purified by silica gel column chromatography,
eluting with ethyl acetate and petroleum ether (20:80 then 30:70) to give (±)-5-O-allyl-
2,6-bis-O-benzyl-3,4-isopropylidine-myo-inositol 71 (10.8 g, 89% yield) as a colourless
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solid. Rf 0.28 (ethyl acetate/petroleum ether 25:75); mp 88-90 °C (ethyl
acetate/petroleum ether); νmax (thin film)/cm-1 3438 (m), 2923 (m), 2874 (m), 1719 (w),
1369 (m), 1047 (m); δH (300 MHz, CDCl3) 7.40-7.29 (10 H, m, 2 × Ph), 5.96 (1 H, dddd,
J 17.3, 10.5, 5.5, 5.5, CH=CH2), 5.30 (1 H, dddd, J 17.3, 1.7, 1.6, 1.6, CH=CHH), 5.15 (1
H, dddd, J 10.5, 1.7, 1.3, 1.3, CH=CHH), 5.03 (1 H, d, JAB 11.3, OCHAHB-Ph), 4.92 (1 H,
d, JA'B' 10.9, OCHA'HB'-Ph), 4.83 (1 H, d, JA'B' 10.9, OCHA'HB'-Ph), 4.68 (1 H, d, JAB 11.3,
OCHAHB-Ph), 4.40 (1 H, dddd, J 12.7, 5.5, 1.6, 1.3, CHHCH=CH2), 4.24-4.20 (1 H, m,
CHHCH=CH2), 4.19-4.12 (2 H, m, inositol ring 2-H, 4-H), 3.71-3.67 (1 H, m, inositol ring
1-H), 3.66-3.53 (2 H, m, inositol ring 5-H, 6-H), 3.49 (1 H, dd, J 9.9, 1.8, inositol ring 3-
H), 2.43 (1 H, d, J 7.8, OH), 1.48 (3 H, s, CH3), 1.45 (3 H, s, CH3); δC (75 MHz, CDCl3)
139.1 (C), 138.5 (C), 135.4 (CH), 128.8 (CH), 128.8 (CH), 128.5 (CH), 128.2 (CH), 128.2
(CH), 128.1 (CH), 117.1 (CH2), 112.2 (C), 84.6 (CH), 80.6 (CH), 78.3 (CH), 77.0 (CH),
76.4 (CH2), 74.8 (CH), 74.7 (CH2), 74.0 (CH), 72.6 (CH2), 27.5 (CH3), 27.1 (CH3); HRMS
m/z (ES+) [Found: (M+Na)+ 463.2079. C26H32O6Na requires M+ 463.2097], m/z (ES+)
463 ([M+Na]+, 100%); Anal. Calcd for C26H32O6: C, 70.89; H 7.32. Found: C, 70.86; H,
7.40.
(±)-5-O-Allyl-2,6-bis-O-benzyl-3,4-O-isopropylidine-1-O-triisopropylsilyl-myo-
inositol 72
OBn
OAll
BnO
O
O
OTIPS
72
Triisopropylsilyl triflate (15.60 g, 13.7 mL, 50.8 mmol, 2.2 equiv.) was added to a stirred
solution of the (±)-5-O-allyl-2,6-bis-O-benzyl-3,4-O-isopropylidine-myo-inositol 71 (10.17
g, 23.1 mmol, 1.0 equiv.) and 2,6-lutidine (12.40 g, 13.4 mL, 115.5 mmol, 5.0 equiv.) in
dichloromethane (200 mL) at 0 °C. The mixture was allowed to warm to RT and stirred
for 36 h. Water (100 mL) was added to the mixture and the organic and aqueous phases
separated. The organic phase was collected and the aqueous portion extracted with
dichloromethane (3 × 100 mL). The combined organic extracts were washed with brine
(200 mL), then dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by silica gel column chromatography, eluting with ethyl acetate/petroleum
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ether (5:95), gave (±)-5-O-allyl-2,6-bis-O-benzyl-3,4-isopropylidine-1-O-triisopropylsilyl-
myo-inositol 72 (12.9 g, 94% yield) as a colourless gum. Rf 0.64 (ethyl
acetate/petroleum ether 30:70); νmax (thin film)/cm-1 3031 (w), 2867 (s), 1454 (m), 1370
(m), 1086 (s); δH (300 MHz, CDCl3) 7.41-7.24 (10 H, m, 2 × Ph), 5.89 (1 H, dddd, J 17.2,
10.5, 5.4, 5.4, CH=CH2), 5.26 (1 H, dddd, J 17.2, 1.7, 1.7, 1.7, CH=CHH), 5.11 (1 H,
dddd, J 10.5, 1.7, 1.3, 1.3, CH=CHH), 4.98 (1 H, d, JAB 11.3, OCHAHB-Ph), 4.94 (1 H, d,
JA' 11.3, OCHAHB-Ph), 4.81 (1 H, d, JA'B' 11.2, OCHA'HB'-Ph), 4.73 (1 H, d, JA'B' 11.2,
OCHA'HB'-Ph), 4.34 (1 H, dddd, J 12.6, 5.4, 1.7, 1.3, CHHCH=CH2), 4.21 (1 H, dd, J 9.7,
9.7, inositol ring), 4.13 (1 H, dddd, J 12.6, 5.4, 1.7, 1.3, CHHCH=CH2), 4.14-4.12 (1 H,
m, inositol ring), 3.92 (1 H, dd, J 9.2, 2.9, inositol ring), 3.77 (1 H, dd, J 8.7, inositol ring),
3.55 (1 H, dd, J 9.6, 8.3, inositol ring), 3.46 (1 H, dd, J 9.8, 1.5, inositol ring), 1.45 (6 H,
s, 2 × CCH3), 1.08-1.06 (21 H, m, 3 × SiCH, 18 × SiCHCH3); δC (75 MHz, CDCl3) 139.7
(C), 139.3 (C), 135.5 (CH), 128.5 (CH), 128.4 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH),
127.5 (CH), 116.9 (CH2), 112.1 (C), 83.4 (CH), 81.4 (CH), 78.3 (CH), 77.3 (CH), 76.5
(CH), 76.3 (CH2), 75.2 (CH), 74.2 (CH2), 72.6 (CH2), 27.6 (CH3), 27.1 (CH3), 18.6 (CH3),
13.3 (CH); HRMS m/z (ES+) [Found: (M+Na)+ 619.3455. C35H52O6NaSi requires M+
619.3431], m/z (ES+) 619 ([M+Na]+, 100%).
(±)-5-O-Allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol 70
OBn
OAll
BnO
HO
OH
OTIPS
70
A mixture of (±)-5-O-allyl-2,6-bis-O-benzyl-3,4-isopropylidine-1-O-triisopropylsilyl-myo-
inositol 72 (26.2 g, 43.96 mmol, 1.0 equiv.) and 4-toluenesulfonic acid monohydrate
(4.18 g, 21.98 mmol, 0.5 equiv.) in methanol (300 mL) was stirred at RT for 2.5 h. The
reaction was quenched with triethylamine (15 mL) and all volatile components were
removed in vacuo. Purification of the crude product by silica gel column
chromatography, eluting with ethyl acetate/petroleum ether (25:75 then 30:70) gave (±)-
5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol 70 (23.3 g, 95% yield) as a
colourless oil. Rf 0.18 (ethyl acetate/petroleum ether 30:70); νmax (thin film)/cm-1 3421
(m), 2943 (s), 1457 (m), 1060 (s); δH (300 MHz, CDCl3) 7.39-7.23 (10 H, m, 2 × Ph),
5.88 (1 H, dddd, J 17.1, 10.4, 5.7, 5.7, CH=CH2) 5.20 (1 H, dddd, J 17.1, 1.7, 1.6, 1.6,
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CH=CH2), 5.10 (1 H, d, JAB 11.4, OCHAHB-Ph), 5.12-5.07 (1 H, m, CH=CH2), 4.91 (1 H,
d, J A'B' 11.7, OCHA'HB'-Ph), 4.86 (1 H, d, JA'B' 11.7, OCHA'HB'-Ph), 4.75 (1 H, d, JAB 11.3,
OCHAHB-Ph), 4.30 (1 H, dddd, J 12.3, 5.7, 1.6, 1.3, CHHCH=CH2), 4.24 (1 H, dddd, J
12.3, 5.7, 1.6, 1.3, CHHCH=CH2), 4.01-3.99 (1 H, m, inositol ring 2-H), 3.87-3.84 (2 H,
m, 2 × inositol ring 1-H, 6-H), 3.81 (1 H, dd, J 9.3, 1.2, inositol ring 4-H), 3.46 (1 H, ddd,
J 10.0, 7.8, 2.7, inositol ring 3-H), 3.24-3.14 (1 H, m, inositol ring 5-H), 2.63 (1 H, d, J
1.9, OH), 2.42 (1 H, d, J 7.8, OH), 1.10-1.07 (21 H, m, 3 × SiCH, 18 × SiCHCH3); δC (75
MHz, CDCl3) 139.1 (C), 139.0 (C), 135.1 (CH), 128.4 (CH), 128.1 (CH), 127.6 (CH),
127.4 (CH), 127.1 (CH), 116.9 (CH2), 83.1 (CH), 81.7 (CH), 81.5 (CH), 75.3 (CH2), 75.2
(CH2), 74.5 (CH), 74.3 (CH), 74.3 (CH2), 72.4 (CH), 18.3 (CH3), 12.9 (CH); HRMS m/z
(ES+) [Found: (M+Na)+ 579.3100. C32H48O6NaSi requires M+ 579.3118], m/z (ES+) 579
([M+Na]+, 100%).
(±)-3-O-Benzoyl-5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol 73
OBn
OAll
BnO
BzO
OH
OTIPS
73
A mixture of (±)-5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol 70 (2.45 g,
4.41 mmol, 1.0 equiv.) and dibutyltin oxide (3.29 g, 13.22 mmol, 3.0 equiv.) in dry
toluene (40 mL) was heated under reflux for 16 h with Dean-Stark apparatus for the
azeotropic removal of water. The resulting solution was allowed to cool to RT and 4 Å
molecular sieves were added. The mixture was cooled to -5 °C and benzoyl chloride
(1.2 g, 1.0 mL, 8.8 mmol, 2.0 equiv.) was added slowly. After 10 min, the mixture was
warmed to RT and stirred for 2.5 h. The molecular sieves were removed by filtration and
the toluene removed in vacuo. The residue was partitioned between ethyl acetate (30
mL) and water (20 mL). The organic layer was collected and the aqueous phase
extracted with ethyl acetate (3 × 30 mL). The combined organic extracts were washed
with aqueous saturated sodium bicarbonate solution (80 mL), saturated aqueous
ammonium chloride solution (80 mL), brine (80 mL), dried (MgSO4), filtered and
concentrated under reduced pressure. Purification by silica gel column chromatography,
eluting with ethyl acetate/petroleum ether (10:90) gave (±)-3-O-benzoyl-5-O-allyl-2,6-bis-
O-benzyl-1-O-triisopropylsilyl-myo-inositol 73 (2.1 g, 73% yield) as a colourless solid. Rf
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0.56 (ethyl acetate/petroleum ether 30:70); mp 94-96 °C (dichloromethane/petroleum
ether); νmax (thin film)/cm-1 3518 (m), 2948 (m), 1696 (s), 1101 (m); δH (300 MHz, CDCl3)
8.10-8.05 (2 H, m, C6H5C(O)CH), 7.61-7.56 (1 H, m, C6H5C(O)CH) 7.47-7.42 (2 H, m,
C6H5C(O)CH), 7.39-7.23 (10 H, m, 2 × Ph), 5.87 (1 H, dddd, J 17.1, 10.4, 5.6, 5.6,
CH=CH2), 5.22 (1 H, dddd, J 17.1, 1.7, 1.6, 1.6, CH=CHH), 5.10 (1 H, dddd, J 10.4, 1.7,
1.1, 1.1, CH=CHH), 5.00 (1 H, dd, J 10.3, 2.4, inositol ring 3-H), 4.90 (2 H, s, OCH2-Ph),
4.86 (1 H, d, J A'B' 11.2, OCHA'HB'-Ph), 4.76 (1 H, d, JA'B' 11.4, OCHA'HB'-Ph), 4.36 (1 H,
dddd, J 12.5, 5.6, 1.6, 1.1, CHHCH=CH2), 4.27-4.28 (1 H, m, inositol ring 4-H), 4.25 (1
H, dddd, J 12.5, 5.6, 1.6, 1.1, CHHCH=CH2), 4.15 (1 H, dd, J 2.4, 2.4, inositol ring 2-H),
4.00-3.92 (2 H, m, inositol ring 1-H, 6-H), 3.31 (1 H, dd, J 8.7, 8.7, inositol ring 5-H), 2.36
(1 H, br s, OH), 1.10-1.07 (21 H, m, 3 × SiCH, 18 × SiCHCH3); δC (75 MHz, CDCl3)
166.7 (C=O), 139.5 (C), 139.3 (C), 135.4 (CH), 133.7 (CH), 130.3 (CH), 130.2 (CH),
128.9 (CH), 128.6 (CH), 128.5 (CH), 127.8 (CH), 127.6 (CH), 127.5 (CH), 117.4 (CH2),
84.3 (CH), 81.9 (CH), 80.8 (CH), 75.74 (CH2), 75.7 (CH2), 74.9 (CH2), 74.8 (CH), 74.3
(CH), 72.1 (CH), 18.7 (CH3), 18.6 (CH3), 13.2 (CH); HRMS m/z (ES+) [Found: (M+Na)+
683.3392. C39H52O7NaSi requires M+ 683.3380], m/z (ES+) 683 ([M+Na]+, 100%); Anal.
Calcd for C39H52O7Si: 70.87; H 7.93. Found: C, 70.45; H, 7.82.
(±)-3-O-Benzoyl-5-O-allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-
triisopropylsilyl-myo-inositol 74
OBn
OAll
BnO
BzO
OPMB
OTIPS
74
To a solution of 4-methoxybenzyltrichloroacetimidate (10.94 g, 38.73 mmol, 1.5 equiv.)
and (±)-3-O-benzoyl-5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol 73
(17.04 g, 25.82 mmol, 1.0 equiv.) and 4 Å molecular sieves in toluene (500 mL) was
added yttrium (III) triflate (110 mg, 0.206 mmol, 0.008 equiv.) at -78 °C. The mixture was
stirred at -78 °C for 30 min, then at -40 °C. After 5 h at this temperature the mixture was
re-cooled to -78 °C. 4-Methoxybenzyltrichloroacetimidate (7.29 g, 5.36 mL, 25.82 mmol,
1.0 equiv.) and yttrium(III) triflate (55 mg, 0.103 mmol, 0.004 equiv.) were added, and
the mixture was allowed to warm slowly to RT overnight. After 16 h the mixture was
again cooled to -78 °C and 4-methoxybenzyl-trichloroacetimidate (3.65 g, 2.70 mL,
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12.91 mmol, 0.5 equiv.) was added. The reaction mixture was quenched by the addition
of saturated aqueous sodium bicarbonate solution (1 mL) and filtered through a pad of
Celite. The filtrate was concentrated under reduced pressure, and the residue
partitioned between ethyl acetate (100 mL) and water (100 mL). The aqueous phase
was extracted with ethyl acetate (3 × 100 mL) and the combined organic fractions were
washed with saturated aqueous sodium bicarbonate solution (150 mL) and brine (150
mL), dried (MgSO4), filtered and concentrated under reduced pressure. Exhaustive
purification by silica gel column chromatography eluting with ethyl acetate/petroleum
ether (2.5:97.5 then 5:95) gave (±)-3-O-benzoyl-5-O-allyl-2,6-bis-O-benzyl-4-O-(4'-
methoxybenzyl)-1-O-triisopropylsilyl-myo-inositol 74 (16.2 g, 80% yield) as an impure,
colourless gum which was used without further purification. Rf 0.47 (ethyl
acetate/petroleum ether 25:75); δH (300 MHz, CDCl3) 8.01-7.97 (2 H, m, C6H5C(O)CH),
7.61-7.55 (1 H, m, C6H5C(O)CH) 7.46-7.41 (2 H, m, C6H5C(O)CH), 7.37-7.23 (10 H, m,
2 × Ph), 7.07 (2 H, d, J 8.7, C6H4OCH3), 6.67 (2 H, d, J 8.7, C6H4OCH3) 5.87 (1 H, dddd,
J 17.2, 10.5, 5.7, 5.7, CH=CH2), 5.21 (1 H, dddd, J 17.2, 1.8, 1.6, 1.6, CH=CH2), 5.10 (1
H, dddd, J 10.5, 1.8, 1.1, 1.1, CH=CH2), 5.03 (1 H, dd, J 10.0, 2.3, inositol ring), 4.91 (1
H, d, J AB 11.3, OCHAHB-Ph), 4.88 (1 H, d, JA'B' 11.4, OCHA'HB'-Ph), 4.87 (1 H, d, J AB
11.3, OCHAHB-Ph), 4.72 (1 H, d, JAB 10.5, OCHAHBC6H4OCH3), 4.71 (1 H, d, JA'B' 11.4,
OCHA'HB'-Ph), 4.65 (1 H, d, JAB 10.5, OCHAHBC6H4OCH3), 4.38-4.24 (2 H, m,
CH2CH=CH2), 4.16 (1 H, dd, J 10.0, 9.3, inositol ring) 4.10-4.08 (1 H, m, inositol ring),
3.98-3.89 (2 H, m, inositol ring), 3.72 (3 H, s, OCH3), 3.43-3.39 (1 H, m, inositol ring),
1.08-1.05 (21 H, m, 3 × SiCH, 18 × SiCHCH3); HRMS m/z (ES+) [Found: (M+Na)+
803.3955. C47H60O8NaSi requires M+ 803.3954], m/z (ES+) 803 ([M+Na]+, 100%).
(±)-5-O-Allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-myo-
inositol 75
OBn
OAll
BnO
HO
OPMB
OTIPS
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To a solution of (±)-3-O-benzoyl-5-O-allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-
triisopropylsilyl-myo-inositol 74 (16.08 g, 20.6 mmol, 1.0 equiv.) in diethyl ether (120 mL)
and methanol (60 mL) was added 2 M aqueous sodium hydroxide solution (15.5 mL,
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30.9 mmol, 1.5 equiv.). The solution was stirred at RT for 18 h. The mixture was then
neutralised with saturated aqueous ammonium chloride solution (60 mL). All volatile
components were removed in vacuo and the residue partitioned between diethyl ether
(100 mL) and water (100 mL). The aqueous phase was extracted with diethyl ether (3 ×
100 mL) and the combined organic extracts were washed with saturated aqueous
ammonium chloride solution (20 mL), brine (50 mL), dried (MgSO4), filtered and
concentrated under reduced pressure. Purification by silica gel column chromatography
eluting with ethyl acetate/petroleum ether (5:95 then 10:90) gave (±)-5-O-allyl-2,6-bis-O-
benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-myo-inositol 75 (11.80 g, 85% yield)
as a colourless oil. Rf 0.53 (ethyl acetate/petroleum ether 30:70); νmax (thin film)/cm-1
3550 (m), 2942 (s), 1612 (m), 1514 (s), 1249 (s), 1068 (s); δH (300 MHz, CDCl3) 7.38-
7.24 (12 H, m, 10 × C6H5, 2 × C6H4OCH3), 6.89 (2 H, d, J 8.7, C6H4OCH3) 5.89 (1 H,
dddd, J 17.1, 10.5, 5.6, 5.6, CH=CH2), 5.22 (1 H, dddd, J 17.1, 1.7, 1.6, 1.6, CH=CHH),
5.11 (1 H, dddd, J 10.5, 1.7, 1.3, 1.3, CH=CHH), 5.00 (1 H, d, J AB 11.3, OCHAHB-Ph),
4.88 (1 H, d, JA'B' 11.5, OCHA'HB'-Ph), 4.86 (1 H, d, JA'B' 11.5, OCHA'HB'-Ph), 4.83 (1 H, d,
JAB 10.7, OCHAHBC6H4OCH3), 4.77 (1 H, d, J AB 11.3, OCHAHB-Ph), 4.67 (1 H, d, JAB
10.7, OCHAHBC6H4OCH3), 4.32-4.27 (2 H, m, CH2CH=CH2), 3.96 (1 H, dd, J 2.2, 2.2,
inositol ring 2-H), 3.88 (1 H, dd, J 9.2, 9.2, inositol ring 6-H), 3.81-3.77 (1 H, m, inositol
ring 1-H), 3.80 (3 H, s, OCH3), 3.75 (1 H, dd, J 9.2, 9.2, inositol ring 4-H), 3.51-3.48 (1 H,
m, inositol ring 3-H), 3.30 (1 H, dd, J 9.2, 9.2, inositol ring 5-H), 2.20 (1 H, d, J 5.4, OH),
1.08-1.05 (21 H, m, 3 × SiCH, 18 × SiCHCH3); δC (75 MHz, CDCl3) 159.7 (C), 139.6 (C),
139.5 (CH), 135.5 (C), 131.2 (CH), 130.2 (CH), 128.7 (CH), 128.4 (CH), 127.9 (CH),
127.8 (CH), 127.5 (CH), 127.4 (CH), 117.1 (CH2), 114.3 (CH), 84.4 (CH), 82.4 (CH),
82.3 (CH), 82.0 (CH), 75.8 (CH2), 75.4 (2 × CH2), 74.8 (CH2), 74.6 (CH), 72.9 (CH), 55.7
(CH3), 18.7 (CH3), 18.6 (CH3), 13.2 (CH); HRMS m/z (ES+) [Found: (M+Na)+ 699.3696.
C40H56O7NaSi requires M+ 699.3693], m/z (ES+) 699 ([M+Na]+, 100%).
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(±)-2,6-bis-O-Benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-myo-inositol 68
OBn
OH
BnO
HO
OPMB
OTIPS
68
A stirred solution of (±)-5-O-allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-
triisopropylsilyl-myo-inositol 75 (3.08 g, 4.56 mmol, 1 equiv.), Wilkinson’s catalyst (422
mg, 0.46 mmol, 0.2 equiv.) and diisopropylethyl amine (588 mg, 793 μL, 4.56 mmol, 1
equiv.) in absolute ethanol (50 mL) was heated under reflux for 2.5 h. Analysis by 1H
NMR showed that full isomerisation of the allyl double bonds had occurred. The reaction
mixture was then filtered through a pad of Celite and concentrated under reduced
pressure. The residue was dissolved in methanol (40 mL) and 4-toluenesulfonic acid
monohydrate (260 mg, 1.37 mmol, 0.3 equiv.) was added. The mixture was stirred for 4
h after which the reaction was quenched with triethylamine (3 mL). All volatile
components were removed in vacuo and the residue partitioned between ethyl acetate
(30 mL) and water (30 mL). The aqueous phase was extracted with ethyl acetate (3 × 30
mL) and the combined organic extracts were washed with aqueous saturated sodium
bicarbonate solution (80 mL) and brine (80 mL), dried (MgSO4), filtered and
concentrated in vacuo. Purification of the crude product by silica gel column
chromatography, eluting with ethyl acetate and petroleum ether (5:95, 10:90, then
15:85) gave (±)-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-myo-
inositol 68 (2.10 g, 72% yield) as a colourless oil. Rf 0.42 (ethyl acetate/petroleum ether
30:70); νmax (thin film)/cm-1 3561 (m), 3470 (m), 2944 (s), 1612 (m), 1514 (s), 1250 (s),
1065 (s); δH (300 MHz, CDCl3) 7.38-7.26 (10 H, m, 2 × Ph), 7.29 (2 H, d, J 8.6,
C6H4OCH3), 6.89 (2 H, d, J 8.6, C6H4OCH3), 5.01 (1 H, d, J AB 11.3, OCHAHB-Ph), 4.98
(1 H, d, JA'B' 11.7, OCHA'HB'-Ph), 4.82 (1 H, d, JAB 10.8, OCHAHBC6H4OCH3), 4.80 (1 H,
d, J AB 11.3, OCHAHB-Ph), 4.74 (1 H, d, JA'B' 11.7, OCHA'HB'-Ph) 4.67 (1 H, d, JAB 10.8,
OCHAHBC6H4OCH3), 3.98 (1 H, dd, J 2.2, 2.2, inositol ring 2-H), 3.87-3.77 (2 H, m,
inositol ring 3-H, 4-H), 3.80 (3 H, s, OCH3), 3.67 (1 H, dd, J 9.1, 9.1, inositol ring 6-H),
3.49 (1 H, dd, J 2.2, 9.1, inositol ring 1-H), 3.43 (1 H, m, inositol ring 5-H), 2.38 (1 H, br
s, OH), 2.33 (1 H, d, J 5.9, OH), 1.11-1.09 (21 H, m, 3 × SiCH, 18 × SiCHCH3); δC (75
MHz, CDCl3) 159.3 (C), 139.0 (C), 138.9 (C), 130.8 (CH), 129.7 (CH), 128.4 (CH), 128.3
(CH), 127.7 (CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 113.9 (CH), 81.9 (CH), 81.6
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(CH), 81.5 (CH), 75.3 (CH2), 75.25 (CH), 74.9 (CH2), 74.4 (CH), 74.3 (CH2), 72.4 (CH),
55.3 (CH3), 18.2 (CH3), 12.8 (CH); HRMS m/z (ES+) [Found: (M+Na)+ 659.3354.
C37H52O7NaSi requires M+ 659.3380], m/z (ES+) 659 ([M+Na]+, 100%).
(±)-2,6-bis-O-Benzyl-4-O-(4'-methoxybenzyl)-3,5-bis(dibenzylphosphate)-myo-
inositol 67
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1H-Tetrazole in acetonitrile (3 % w/v, 37 mL, 15.7 mmol, 5.0 equiv.) was added to a
solution of bis(benzyloxy)-N,N-diisopropylamino phosphine (5.42 g, 15.7 mmol, 5.0
equiv.) in dichloromethane (10 mL) and the mixture stirred for 10 min. A solution of (±)-
2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-myo-inositol 68 (2.00 g,
3.14 mmol, 1.0 equiv.) in dichloromethane (30 mL) was added via cannula and the
resulting mixture stirred for 6 h. After this time, bis(benzyloxy)-N,N-diisopropylamino
phosphine (1.62 g, 4.71 mmol, 1.5 equiv.) in dichloromethane (5 mL) was added via
cannula, followed by 1H-tetrazole in acetonitrile (3 % w/v, 11 mL, 1.5 mmol, 1.5 equiv.),
and the mixture was stirred for 16 h. The mixture was cooled to -78 °C and 3-
chloroperbenzoic acid (assume 60 %, 5.87 g, 20.4 mmol, 6.5 equiv.) was added. The
reaction mixture was allowed to reach RT and stirred for 1.5 h. The 3-chloroperbenzoic
acid was quenched with a 10 % aqueous solution of sodium bisulfite (30 mL). The
mixture was stirred for 10 min and the organic and aqueous phases were separated.
The aqueous layer was extracted with dichloromethane (3 × 50 mL). The combined
organic extracts were washed with saturated aqueous sodium bicarbonate solution (100
mL), brine (100 mL), dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by silica gel chromatography, eluting with ethyl acetate/petroleum ether
(15:85, 20:80 then 30:70) gave (±)-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-
triisopropylsilyl-3,5-bis(dibenzylphosphate)-myo-inositol 76 (3.40 g) as an impure,
colourless gum which was used without further purification. The gum was dissolved in
THF (40 mL) and tetrabutylammonium fluoride (1 M in THF, 3.8 mL, 1.3 equiv.) was
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added. The mixture was stirred for 3 h then diluted with diethyl ether (50 mL). Water (50
mL) was added and the layers separated and the aqueous phase was extracted with
diethyl ether (3 × 50 mL). The combined organic extracts were washed with aqueous
saturated bicarbonate solution (80 mL) and brine (80 mL), dried (MgSO4), filtered and
concentrated. Purification by silica gel column chromatography eluting with ethyl
acetate/petroleum ether (30:70, 50:50 then 70:30) gave 2,6-bis-O-benzyl-4-O-(4'-
methoxybenzyl)-3,5-bis(dibenzylphosphate)-myo-inositol 67 (2.38 g, 76% yield over 2
steps) as a colourless oil. Rf 0.47 (ethyl acetate/petroleum ether 80:20); νmax 3387 (m),
3053 (m), 2954 (m), 1514 (m), 1266 (s), 1014 (s); δH (300 MHz, CDCl3) 7.37-7.16 (28 H,
m, 26 × Ph, 2 × C6H4OCH3), 7.14-7.09 (4 H, m, Ph), 6.73 (2 H, d, J 8.8, C6H4OCH3),
4.97-4.66 (14 H, m, 12 × OCH2Ph, 2 × OCH2C6H4OCH3), 4.41 (1 H, ddd, J 9.5, 9.5, 9.5,
inositol ring 5-H), 4.29-4.19 (2 H, m, inositol ring 3-H, 2-H), 4.03 (1 H, dd, J 9.5, 9.5,
inositol ring 4-H), 3.82 (1 H, dd, J 9.5, 9.5, inositol ring 6-H), 3.72 (3 H, s, OCH3), 3.52-
3.46 (1 H, m, inositol ring 1-H), 2.07 (1 H, d, J 5.3, OH); δC (75 MHz, CDCl3) 159.3 (C),
139.0 (C), 138.7 (C), 136.5 (C), 136.4 (C), 136.1 (C), 136.0 (C), 130.7 (C), 129.7 (CH),
129.0 (CH), 128.97 (CH), 128.8 (CH), 128.7 (CH), 128.5 (CH), 128.32 (CH), 128.3 (CH),
128.2 (CH), 128.1 (CH), 128.0 (CH), 113.9 (CH), 80.7 (1 C, d, 2JP-C 5.7, CH), 80.4 (CH),
79.0 (CH), 78.6 (1 C, d, 2JP-C 5.4, CH), 75.9 (CH2), 75.0 (CH2), 74.9 (CH2), 71.8 (CH),
70.0 (1 C, d, 2JP-C 5.6, CH2), 69.9 (1 C, d, 2JP-C 5.5, CH2), 69.7 (1 C, d, 2JP-C 5.0, CH2),
69.6 (1 C, d, 2JP-C 5.0, CH2), 55.6 (CH3); δP (121 MHz, CDCl3) -0.18, -0.41; HRMS m/z
(ES+) [Found: (M+NH4)+ 1018.3689. C56H62O13NP2 requires M+ 1018.3691]; m/z (ES+)
1023 ([M+Na]+, 100%).
4-Methoxybenzyl-2,2,2-trichloroacetimidate 78180
MeO
O
NH
CCl3
78
A solution of (4-methoxy)benzyl alcohol (2.50 g, 18.09 mmol, 1 equiv.) in diethyl ether
(50 mL) was cannulated onto a suspension of sodium hydride (60 % dispersion in
mineral oil, 109 mg, 2.71 mmol, 0.15 equiv.) in diethyl ether (15 mL) at 0 °C. The
mixture was stirred at RT for 45 min then cooled to 0 °C. Trichloroacetonitrile (2.87 g,
119
2.0 mL, 19.9 mmol, 1.1 equiv.) was added slowly, and the mixture was allowed to warm
to RT and stirred for 2.5 h. Wet diethyl ether (20 mL) was added and the solvent
removed in vacuo. To the resulting orange oil was added hexane (30 mL) and several
drops of methanol. The mixture was filtered through Celite and concentrated. Purification
by basic alumina column chromatography eluting with ethyl acetate/petroleum ether
(2:98) gave 4-methoxybenzyl-2,2,2-trichloroacetimidate 78 (4.59 g, 90% yield), as a
colourless oil. Rf 0.38 (alumina, ethylacetate/hexane 5:95); δH (300 MHz, CDCl3) 8.38 (1 
H, s, C=NH), 7.36 (2 H, d, J 10.2, ArH), 6.90 (2 H, d, J 10.2, ArH), 5.28 (2 H, s, CH2Ar),
3.78 (3 H, s, OCH3). The data are in agreement with literature values.180
(+)-Benzyl-2,2-dimethyl-1,3-dioxolane (+)-80181
BnO O
O
(+)-80
A solution of (S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (2.00 g, 15.13 mmol, 1
equiv.) in N,N-dimethylformamide (20 mL) was cannulated onto a cooled suspension of
sodium hydride (60 % dispersion in mineral oil, 1.51 g, 37.83 mmol, 2.5 equiv.) in N,N-
dimethylformamide (30 mL) at -5 °C. The mixture was stirred for 30 min at -5 °C then 1 h
at RT. The alkoxide that formed was insoluble in the N,N-dimethylformamide. The
mixture was cooled to -5 °C and benzyl bromide (4.50 mL, 37.83 mmol, 2.5 equiv.) was
added slowly. The mixture was allowed to slowly warm to room temperature and stirred
for 20 h. The reaction was quenched by the addition of water (10 mL). All volatile
compoments were removed in vacuo and the residue partitioned between ethyl acetate
(20 mL) and water (20 mL). The organic layer was collected and the aqueous phase
extracted with ethyl acetate (3 × 15 mL). The combined organic extracts were washed
with brine (40 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by
silica gel column chromatography, eluting with ethyl acetate/petroleum ether (10:90)
gave (+)-benzyl-2,2-dimethyl-1,3-dioxolane (+)-80 (2.92 g, 87% yield) as a colourless oil.
Rf 0.51 (ethyl acetate/petroleum ether 20:80); 20D[α] + 21.9, (c 0.51 in CHCl3) [Lit.,
181 20
D[α]
+ 20.3, (c 2.56 in CHCl3)]; δH (300 MHz; CDCl3) 7.36-7.26 (5 H, m, Ph), 4.60 (1 H, d, J
12.1, CHAHBPh), 4.58 (1 H, d, J 12.1, CHAHBPh), 4.32 (1 H, ddd, J 12.0, 6.3, 5.8,
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CH2CHCH2), 4.07 (1 H, dd, J 8.3, 6.4, CHHCHCH2), 3.75 (1 H, dd, J 8.3, 6.4,
CHHCHCH2), 3.57 (1 H, dd, J 9.8, 5.7, CH2CHCHH), 3.47 (1 H, dd, J 9.8, 5.5,
CH2CHCHH), 1.43 (3 H, s, CH3), 1.38 (3 H, s, CH3). The data are in good agreement
with literature values.181
(-)-3-O-Benzyl-sn-glycerol (-)-81182
BnO
OH
OH
(-)-81
(S)-(+)-Benzyl-2,2-dimethyl-1,3-dioxolane (+)-80 was dissolved in methanol (10 mL) and
concentrated hydrochloric acid (870 μL) was added slowly with stirring. The mixture was
heated under reflux for 2 h. The acid was neutralised with NaHCO3(s) (5 g), and the
resulting precipitate removed by filtration. The solvent was removed under reduced
pressure and the residue reconstituted with ethyl acetate (10 mL) and water (10 mL).
The organic phase was collected and the aqueous phase extracted with ethyl acetate (3
× 10 mL). The combined organic extracts were washed with brine (10 mL), dried
(MgSO4), filtered and concentrated under reduced pressure. Purification of the crude
product by silica gel column chromatography, eluting with ethyl acetate/petroleum ether
(20:80) gave (-)-3-O-benzyl-sn-glycerol (-)-81 (470 mg, 91% yield) as a colourless oil. Rf
0.21 (ethyl acetate/petroleum ether 50:50); 20D[α] -0.23, (c 0.61 in CHCl3) [Lit.,
182 20
D[α] -
3.65, (c 5.0 in CHCl3)]; δH (300 MHz; CDCl3) 7.40-7.28 (5 H, m, Ph), 4.57 (2 H, s,
CH2Ph), 3.93-3.89 (1 H, m, CH2CHCH2), 3.75-3.66 (2 H, m, CH2CHCH2), 3.59 (1 H, dd,
J 9.6, 4.0, CH2CHCHH), 3.56 (1 H, dd, J 9.6, 6.1, CH2CHCHH), 2.66 (1 H, d, J 3.7, OH),
2.16 (1 H, s, OH). The data are in good agreement with literature values.182
(+)-3-O-Benzyl-1,2-diacetyl-sn-glycerol (+)-82160
BnO
OAc
OAc
(+)-82
To a stirred solution of (-)-3-O-benzyl-sn-glycerol (-)-81 (448 mg, 2.46 mmol, 1.0 equiv.)
and 4-dimethylamino pyridine (256 mg, 0.49 mmol, 0.2 equiv.) in THF (10 mL) were
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added triethylamine (1.03 mL, 7.38 mmol, 3.0 equiv.) and acetic anhydride (0.93 mL,
9.85 mmol, 4.0 equiv.). The mixture was stirred for 14 h, then diluted with diethyl ether
(20 mL). Water (20 mL) was added and the layers separated. The organic phase was
collected and the aqueous layer was extracted with diethyl ether (3 × 20 mL). The
combined organic extracts were washed with saturated aqueous sodium bicarbonate
solution (20 mL), saturated aqueous ammonium chloride solution (20 mL) and brine,
dried (MgSO4), filtered and concentrated under reduced pressure. Purification by silica
gel column chromatography, eluting with ethyl acetate/petroleum ether (10:90, 15:85
then 25:75) gave (+)-3-O-benzyl-1,2-diacetyl-sn-glycerol (+)-82 (654 mg, 91% yield) as a
colourless oil. Rf 0.59 (ethyl acetate/petroleum ether 50:50); 20D[α] +16.4, (c 0.5 in CHCl3)
[Lit.,160 20D[α] +16.2, (c 1.01 in CHCl3)]; δH (300 MHz; CDCl3) 7.39-7.28 (5 H, m, Ph),
5.24-5.20 (1 H, m, CH2CHCH2) 4.59 (1 H, d, J 12.1, CHAHBPh), 4.54 (1 H, d, J 12.1,
CHAHBPh), 4.36 (1 H, dd, J 11.9, 3.8, CHHCHCH2), 4.20 (1 H, dd, J 11.9, 6.3,
CHHCHCH2), 3.61 (2 H, d, J 5.2, CH2CHCH2), 2.09 (3 H, s, CH3), 2.05 (3 H, s, CH3).
The data are in good agreement with literature values.160
(-)-1,2-O-Diacetyl-sn-glycerol (-)-83161
HO
OAc
OAc
(-)-83
Method A.
A mixture of (+)-3-O-benzyl-1,2-diacetyl-sn-glycerol (+)-82 (250 mg, 0.939 mmol, 1.0
equiv.) and palladium on carbon (10 % on carbon, 115 mg, 10 % w/w of glycerol) in THF
(10 mL) was stirred under an atmosphere of hydrogen for 7 days. The mixture was
filtered through a pad of Celite and the solvent removed in vacuo to give (-)-1,2-O-
diacetyl-sn-glycerol (-)-83 (159 mg, 96% yield) as a colourless oil. Rf 0.18 (ethyl
acetate/petroleum ether 50:50); 20D[α] -3.40 (c 0.6 in CHCl3) [Lit.,
161 20
D[α] +8.3, (c 0.4 in
CHCl3); δH (300 MHz; CDCl3) 5.11-5.08 (1 H, m, CHOAc), 4.34 (1 H, dd, J 12.9, 4.8,
CH2), 4.24 (1 H, dd, J 12.0, 5.6, CH2), 3.75 (2 H, d, J 4.8, CH2), 2.11 (3 H, s, CH3), 2.09
(3 H, s, CH3); m/z (ES+) [Found: (M+Na)+ 199.0578. C7H12O5Na requires M+ 199.0582],
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m/z (ES+) 199 ([M+Na]+, 100%). The 1H NMR data are in good agreement with the
literature values.161
Method B
A mixture of (+)-3-O-benzyl-1,2-diacetyl-sn-glycerol (+)-82 (1.47 g, 5.52 mmol, 1.0
equiv.) and Pd(OH)2 (20 % on carbon, 147 mg, 10 % w/w) in THF (5 mL) was stirred
under an atmosphere of hydrogen for 22 h. The mixture was filtered through a pad of
Celite and the solvent removed in vacuo to give (-)-1,2-O-diacetyl-sn-glycerol (-)-83 (890
mg, 91%) as a colourless oil. Rf 0.18 (ethyl acetate/petroleum ether 50:50); 20D[α] -4.10 (c
1.0 in CHCl3) [Lit.,161 20D[α] +8.3, (c 0.4 in CHCl3); δH (300 MHz; CDCl3) 5.12-5.09 (1 H,
m, CHOAc), 4.32 (1 H, dd, J 12.9, 4.8, CH2), 4.23 (1 H, dd, J 12.0, 5.6, CH2), 3.73 (2 H,
d, J 4.8, CH2), 2.10 (3 H, s, CH3), 2.08 (3 H, s, CH3). The 1H NMR data are in good
agreement with the literature values.161
Benzyloxy-1,2-O-diacyl-sn-glycerol N,N-diisopropylamino phosphine 84
O
OAc
OAc
P
BnO
N
84
1H-Tetrazole (141 mg, 2.0 mmol, 0.4 equiv.) was added to a stirred solution of
benzyloxy bis(N,N-diisopropylamino)phosphine (1.86 g, 5.5 mmol, 1.1 equiv.) in
dichloromethane (10 mL). (-)-1,2-O-Diacetyl-sn-glycerol (-)-83 (0.88 g, 5 mmol, 1.0
equiv.) was added dropwise via cannula over 30 min. The resulting mixture was stirred
for 2 h. The solvent was removed in vacuo to give a colourless paste which was purified
by silica gel column chromatography, eluting with triethylamine/ethyl acetate/petroleum
ether (5:10:85) to give benzyloxy-1,2-O-diacyl-sn-glycerol N,N-diisopropylamino
phosphine 84 (1.57 g, 76% yield) as a colourless oil. The compound was unstable and
used directly for phosphitylation. Rf 0.65 (ethyl acetate/petroleum ether 50:50); δH (300
MHz; CDCl3) 7.39-7.26 (5 H, m, Ph), 5.21-5.15 (1 H, m, CHOAc), 4.78-4.60 (2 H, m,
OCH2Ph), 4.34 (1 H, ddd, J 11.9, 6.9, 3.7, CHHOAc), 4.18 (1 H, ddd, J 11.9, 6.1, 2.4,
CHHOAc), 3.84-3.58 (4 H, m, 2 × NCH(CH3)2, 2 × CH2OP), 2.07-2.06 (6 H, m, 2 ×
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COCH3), 1.21 (3 H, s, NCHCH3), 1.19 (3 H, s, NCHCH3), 1.18 (3 H, s, NCHCH3), 1.17 (3
H, s, NCHCH3); δP (121 MHz, CDCl3) 150.1, 149.9.
2,6-bis-O-Benzyl-4-O-(4'-methoxybenzyl)-1-[(1',2'-di-O-acetyl-sn-glycerol)-
(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-myo-inositol 85
OBn
O
BnO
O
OPMB
O
P P
OBn
BnO
O O
P
O
OBn
O
OAc
OAc
OBn
OBn
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1H-Tetrazole in acetonitrile (3 % w/v, 885 μl, 0.38 mmol, 2.5 equiv.) was added to a
solution of benzyloxy-1,2-O-diacyl-sn-glycerol N,N-diisopropylamino phosphine (157 mg,
0.38 mmol, 2.5 equiv.) in dichloromethane (2 mL) and the mixture stirred for 10 min. A
solution of 2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-3,5-bis(dibenzylphosphate)-myo-
inositol 67 (152 mg, 0.152 mmol, 1.0 equiv.) in dichloromethane (4 mL) was added via
cannula and the resulting mixture stirred for 2.5 h. The mixture was cooled to -78 °C and
3-chloroperbenzoic acid (assume 60 %, 109 mg, 0.38 mmol, 2.5 equiv.) was added. The
reaction mixture was allowed to reach RT and stirred for 2 h. The 3-chloroperbenzoic
acid was quenched with a 10 % aqueous solution of sodium bisulfite (5 mL). The mixture
was stirred for 10 min, then the organic and aqueous phases were separated. The
aqueous layer was extracted with dichloromethane (3 × 5 mL). The combined organic
extracts were washed with saturated aqueous sodium bicarbonate solution (10 mL),
brine (10 mL), dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by silica gel chromatography, eluting with ethyl acetate/petroleum ether
(30:70 then 60:40) gave 2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-[(1',2'-di-O-acetyl-
sn-glycerol)-(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-myo-inositol 85 (169 mg,
84% yield), a colourless gum, as a mixture of 4 diastereomers. Rf 0.58 (ethyl
acetate/petroleum ether 80:20); δH (300 MHz, CDCl3) 7.39-7.16 (33 H, m, 33 × Ar), 7.05-
6.99 (4 H, m, Ar), 6.70 (2 H, d, J 8.7, C6H4OCH3), 5.03-4.66 (17 H, m, 1 × CHOAc, 14 ×
OCH2Ph, 2 × OCH2C6H4OCH3), 4.53 (1 H, m, inositol ring), 4.48-3.77 (9 H, m, 5 ×
inositol ring, 2 × POCH2CHOAc, 2 × CH2OAc), 3.71 (3 H, s, OCH3), 1.98-1.91 (6 H, m, 2
× COCH3); δC (75 MHz, CDCl3) 170.3 (C=O), 170.0 (C=O), 159.0 (C), 138.4 (C), 138.1
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(C), 138.0 (C), 136.0 (1 C, d, 3JP-C 6.9, C), 135.8 (1 C, d, 3JP-C 6.9, C), 135.6 (1 C, d, 3JP-
C 6.9, C), 135.5 (1 C, d, 3JP-C 6.9, C), 130.1 (C), 129.4 (CH), 128.7 (CH), 128.6 (CH),
128.5 (CH), 128.4 (CH), 128.33 (CH), 128.3 (CH), 128.2 (CH), 127.9 (CH), 127.8 (CH),
127.74 (CH), 127.7 (CH), 127.64 (CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 127.35
(CH), 127.3 (CH), 113.5 (CH), 79.8 (1 C, d, 2JP-C 5.7, CH) 78.1-77.4 ( 4 C, m, 4 × CH),
77.4 (1 C, dd, 3JP-C 5.4, 5.4, CH), 75.8 (CH2), 74.7 (CH2), 74.6 (CH2), 74.4 (CH2), 69.8-
69.2 (4 C, m, 4 × CH2), 65.7-65.5 (1 C, m, 1 × CH2), 61.6 (CH2), 55.2 (CH3), 20.8 (CH3),
20.6 (CH3); δP (121 MHz, CDCl3) -0.26 - -0.61 (3 P); m/z (ES+) 1351 ([M+Na]+, 100%).
2,6-bis-O-Benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzylphosphate)-myo-inositol 66
OBn
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A mixture of 2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-[(1',2'-di-O-acetyl-sn-glycerol)-
(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-myo-inositol 85 (165 mg, 0.124 mmol,
1.0 equiv.) and ceric ammonium nitrate (170 mg, 0.310 mmol, 2.5 equiv.) in acetonitrile
(4 mL) and water (1 mL) was stirred for 1.5 h open to the air. The solvent was removed
in vacuo and the resultant residue partitioned between ethyl acetate (5 ml) and water (5
mL). The aqueous layer was extracted with ethyl acetate (3 × 5 mL), and the combined
organic extracts were washed with saturated aqueous sodium bicarbonate solution (10
mL), brine (10 mL), dried (MgSO4), filtered and concentrated under reduced pressure.
The crude residue was purified by silica gel column chromatography, eluting with ethyl
acetate/petroleum ether (80:20) then ethyl acetate to give 2,6-bis-O-benzyl-1-[(1',2'-di-O-
acetyl-sn-glycerol)-(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-myo-inositol 66
(127 mg, 84% yield), a colourless oil, as a mixture of 4 diastereomers. Rf 0.41 (ethyl
acetate/petroleum ether 80:20); νmax (thin film)/cm-1 3370 (m), 3034 (m), 2956 (m), 1746
(s), 1456 (s), 1263 (s), 1012 (s); δH (300 MHz, CDCl3) 7.34-7.14 (35 H, m, Ph), 5.13 (1
H, s, OCH2Ph), 5.11 (1 H, s, OCH2Ph), 5.07-4.86 (9 H, m, 1 × CHOAc, 8 × OCH2Ph),
4.78-4.65 (4 H, m, 4 × OCH2Ph), 4.62-4.59 (1 H, m, inositol ring), 4.37-4.34 (1 H, m,
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inositol ring), 4.32-3.79 (8 H, m, 4 × inositol ring, 2 × POCH2CHOAc, 2 × CH2OAc), 1.97-
1.91 (6 H, m, 2 × COCH3); δC (75 MHz, CDCl3) 170.0 (C=O), 169.9 (C=O), 138.2 (C),
137.8 (C), 137.9 (C), 135.9 (1 C, d, 3JP-C 7.2, C), 135.7 (1 C, d, 3JP-C 7.1, C), 135.6 (1 C,
d, 3JP-C 6.6, C), 135.5 (1 C, d, 3JP-C 7.1, C), 128.7 (CH), 128.62 (CH), 128.6 (CH), 128.5
(CH), 128.7 (CH), 128.3 (CH), 128.0 (CH), 127.9 (CH), 127.7 (CH), 127.6 (CH), 127.43
(CH), 127.4 (CH), 81.9, (CH) 78.1 (CH), 78.0-77.6 (1 C, m), 77.3 (CH), 75.8 (CH2), 75.3
(CH2), 75.2 (CH2), 71.1 (CH), 69.9-69.5 (4 C, m, 4 × CH2), 69.4 (CH), 69.3 (CH), 65.7-
65.4 (1 C, m, CH2), 61.6 (CH2), 20.8 (CH3), 20.6 (CH3); δP (121 MHz, CDCl3) 1.4 - -0.7
(3 P); HRMS m/z (FAB) [Found: (M+Na)+ 1231.3394. C62H67O19NaP3 requires M+
1231.3382]; m/z (ES+) 1231 ([M+Na]+, 100%).
2,6-bis-O-Benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzylphosphate)-4-dimethylphosphinyl-myo-inositol 86
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To a solution of 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzyl phosphate) myo-inositol 66 (198 mg, 0.164 mmol, 1 equiv.) in pyridine
(1.5 mL) and dichloromethane (0.3 mL) was added dimethylchlorophosphine (126.5 mg,
104 µL, 1.311 mmol, 8.0 equiv.). The mixture was stirred for 2 h at RT after which time
the reaction was adjudged to be incomplete by TLC analysis. Dimethylchlorophosphine
(47 mg, 39 µL, 0.492 mmol, 3.0 equiv.) was added and the reaction mixture was stirred
for a further 0.5 h. The mixture was diluted with chloroform (10 mL). Water (10 mL) was
added and the layers separated. The aqueous phase was extracted with chloroform (3 ×
10 mL) and the combined organic extracts were washed with water (2 × 10 mL), brine
(15 mL), dried (MgSO4), filtered and concentrated. The crude product was adsorbed
onto silica gel and purification by silica gel column chromatography eluting with ethyl
acetate/hexane (60:40, 80:20 then 100% ethyl acetate) followed by
methanol/dichloromethane (5:95) to give 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-sn-
glycerol)-(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-4-dimethylphosphinyl-myo-
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inositol 86 (125 mg, 60% yield), light yellow gum, as a mixture of 4 diastereomers. Rf
0.44 (ethyl acetate); νmax (thin film)/cm-1 3468 (w), 3033 (m), 2955 (m), 1746 (s), 1456
(s), 1277 (s), 1019 (s); δH (300 MHz, CDCl3) 7.37-7.17 (33 H, m, Ph), 7.07-7.05 (2 H, m,
Ph), 5.11-4.68 (16 H, m, 1 × CHOAc, 1 × inositol, 14 × OCH2Ph), 4.63-4.60 (1 H, m,
inositol ring), 4.40-3.77 (8 H, m, 4 × inositol ring, 2 × POCH2CHOAc, 2 × CH2OAc), 1.99-
1.93 (6 H, m, 2 × COCH3), 1.47 (3 H, d, J 13.6, POCH3), 1.43 (3 H, d, J 12.5, POCH3);
δC (75 MHz, CDCl3) 170.3 (C=O), 170.0 (C=O), 138.03 (C), 138.0 (C), 135.9-135.3 (5 C,
m, 5 × ArC), 128.8 (CH), 128.7 (CH), 128.67 (CH), 128.4 (CH), 128.33 (CH), 128.3
(CH), 128.27 (CH), 128.2 (CH), 128.1 (CH), 128.06 (CH), 128.0 (CH), 127.9 (CH),
127.88 (CH), 127.8 (CH), 127.7 (CH), 127.6 (CH), 127.44 (CH), 127.4 (CH), 127.38
(CH), 127.3 (CH), 78.5 (CH), 77.7 (CH), 77.4 (CH), 76.0 (CH2), 75.5 (CH), 75.0 (CH2),
74.9 (CH2), 72.0 (CH), 70.1-69.5 (4 C, m, 4 × CH2), 69.4 (CH), 69.3 (CH), 65.7-65.4 (1
C, m, CH2), 61.6 (CH2), 20.8 (CH3), 20.6 (CH3), 17.8 (1 C, d, 1JP-C 91.5, CH3), 17.1 (1 C,
d, 1JP-C 96.2, CH3); δP (121 MHz, CDCl3) 58.7, 0.0 − -0.3 (3 P); HRMS m/z (ES+)
[Found: (M+Na)+ 1307.3457. C64H72O20NaP4 requires M+ 1307.3465], m/z (ES+) 1307
([M+Na]+, 100%).
2,6-bis-O-Benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzylphosphate)-4-methanesulfonyl-myo-inositol 87
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To a stirred mixture of 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-
benzylphosphate]-3,5-bis(dibenzylphosphate)-myo-inositol 66 (15 mg, 12.4 μmol, 1.0
equiv.) and triethylamine (5 mg, 7 μL, 49.6 μmol, 4.0 equiv.) in dichloromethane (1.5 mL)
at 0 °C was added methanesulfonyl chloride (6 mg, 4 μL, 49.6 μmol, 4.0 equiv.). The
mixture was allowed to warm to RT and stirred for 2 h. Dichloromethane (3 mL) and
water (3 mL) was added and the layers separated. The aqueous phase was extracted
with dichloromethane (3 × 5 mL) and the combined organic extracts were washed with
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saturated aqueous sodium bicarbonate solution (10 mL), saturated aqueous ammonium
chloride (10 mL) and brine (10 mL), dried (MgSO4), filtered and concentrated.
Purification by silica gel column chromatography gave 2,6-bis-O-benzyl-1-[(1',2'-di-O-
acetyl-sn-glycerol)-(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-4-
methanesulfonyl-myo-inositol 87 (9 mg, 56% yield), a colourless gum, as a mixture of 4
diastereomers. Rf 0.55 (ethyl acetate/petroleum ether 80:20); νmax (thin film)/cm-1 3479
(w), 3034 (m), 2956 (m), 1746 (s), 1456 (s), 1359 (s), 1266 (s), 1019 (s); δH (300 MHz,
CDCl3) 7.39-7.21 (33 H, m, Ph), 7.07-7.04 (2 H, m, Ph), 5.18-4.64 (17 H, m, 1 × CHOAc,
2 × inositol, 14 × OCH2Ph), 4.45-4.18 (3 H, m), 4.10-3.76 (5 H, m), 2.99 (3 H, SO2CH3),
1.99-1.92 (6 H, m, 2 × COCH3); δC (75 MHz, CDCl3) 170.3 (C=O), 170.0 (C=O), 137.9
(C), 137.8 (C), 135.7 (1 C, d, 3JP-C 7.3, C), 135.6 (1 C, d, 3JP-C 6.6, C), 135.5 (1 C, d, 3JP-
C 6.3, C), 135.5 (1 C, d, 3JP-C 7.3, C), 135.3 (1 C, d, 3JP-C 7.3, C), 128.7 (CH), 128.67
(CH), 128.65 (CH), 128.5 (CH), 128.46 (CH), 128.35 (CH), 128.3 (CH), 128.2 (CH),
128.1 (CH), 128.0 (CH), 127.96 (CH), 127.92 (CH), 127.88 (CH), 127.75 (CH), 127.7
(CH), 127.5 (CH), 127.3 (CH), 78.2-78.0 (1 C, m, CH), 77.8 (CH), 77.3 (CH), 77.2 (CH),
77.1 (CH2), 75.1 (CH2), 75.0 (CH2), 74.3 (CH), 70.2 (1 C, d, 2JP-C 5.5, CH2), 70.0 (2 C, d,
2JP-C 5.5, CH2), 69.7 (1 C, d, 2JP-C 5.5, CH2), 69.4 (1 C, d, JP-C 4.8, CH), 69.3 (1 C, d, JP-C
4.5, CH), 65.5 (1 C, d, 2JP-C 5.3, CH2), 61.6 (CH2), 39.2 (CH3), 20.8 (CH3), 20.6 (CH3); δP
(121 MHz, CDCl3) -1.6 − -2.2 (3 P); HRMS m/z (ES+) [Found: (M+Na)+ 1309.3179.
C63H69O21NaP3S requires M+ 1309.3163], m/z (ES+) 1309 ([M+Na]+, 100%).
2,6-bis-O-Benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzylphosphate)-4-benzenesulfonate-myo-inositol 88
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A mixture of 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-3,5-
bis(dibenzyl phosphate) 66 myo-inositol (51 mg, 0.042 mmol, 1 equiv.), triethylamine (17
mg, 23 µl, 0.168 mmol, 4.0 equiv.) and DMAP (catalytic amount) in benzenesulfonyl
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chloride (0.5 mL) was stirred at RT for 40 h. Dichloromethane (200 µl) and
benzenesulfonyl chloride (200 µl) were added and the mixture stirred for a further 30 h.
The mixture was diluted with dichloromethane (5 mL). Water (5 mL) was added and the
layers separated. The aqueous phase was extracted with dichloromethane (3 × 10 mL)
and the combined organic extracts were washed with saturated aqueous sodium
bicarbonate solution (20 mL), brine (20 mL), dried (MgSO4), filtered and concentrated.
The crude product was adsorbed onto silica gel and purification by silica gel column
chromatography eluting with ethyl acetate:petroleum ether (50:50, 60:40 then 70:30) to
give 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-3,5-
bis(dibenzylphosphate)-4-benzenesulfonate-myo-inositol 88 (26 mg, 45% yield) as an
unstable, colourless gum, and as a mixture of four diastereomers. Rf 0.60 (ethyl
acetate/petroleum ether 80:20); δH (500 MHz, CDCl3) 7.91 (2 H, d, J 8.1, SO2Ph), 7.40-
7.16 (36 H, m, ArH), 7.01 (2 H, d, J 7.1, ArH), 5.31-5.27 (1 H, m, inositol ring 4-H), 5.07-
4.62 (15 H, m, 1 × CHOAc, 14 × OCH2Ph), 4.49-3.77 (9 H, m, 5 × inositol ring, 2 ×
POCH2CHOAc, 2 × CH2OAc), 1.98-1.92 (6 H, m, 2 × C(O)CH3); δP (202 MHz, CDCl3) -
0.2 − -0.9 (3 P); m/z (ES+) 1371 ([M+Na]+, 100%).
2,6-bis-O-Benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzylphosphate)-4-phenoxyacetyl-myo-inositol 89
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To a solution of 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzyl phosphate)-myo-inositol 66 (99 mg, 0.082 mmol, 1 equiv.), triethylamine
(33 mg, 46 µL, 0.328 mmol, 4.0 equiv.) and DMAP (catalytic amount) in THF (2 mL) was
added phenoxyacetyl chloride (56 mg, 45 μL, 0.328 mmol, 4.0 equiv.) at 0 °C. The
mixture was stirred for 18 h during which time a precipitate formed. The mixture was
diluted with ether (5 mL) and quenched by the addition of saturated aqueous sodium
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bicarbonate (5 mL). The aqueous phase was extracted with ether (3 × 5 mL) and the
combined organic extracts were washed with brine (15 mL), dried (MgSO4), filtered and
concentrated. The crude product was immediately adsorbed onto silica gel and
purification by silica gel column chromatography eluting with ethyl acetate/petroleum
ether (60:40 then 70:30) gave a yellow gum. Repeated silica gel column
chromatography using the same elution system gave 2,6-bis-O-benzyl-1-[(1',2'-di-O-
acetyl-sn-glycerol)-(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-4-phenoxyacetyl-
myo-inositol 89 (74 mg, 67% yield), a mixture of 4 diastereomers, as a light yellow gum.
Rf 0.41 (ethyl acetate/petroleum ether 70:30); νmax (thin film)/cm-1 3476 (w), 3034 (m),
2897 (m), 1772 (s), 1745 (s), 1497 (s), 1271 (s), 1009 (s); δH (300 MHz, CDCl3) 7.33-
7.11 (35 H, m, Ph), 7.06-7.03 (2 H, m, Ph), 6.88 (1H, m, Ph), 6.78-6.75 (2 H, m, Ph),
5.77 (1 H, dd, J 9.8, 9.8, inositol ring 4-H), 5.08-4.64 (15 H, m, 1 × CHOAc, 14 ×
OCH2Ph), 4.56-3.80 (11 H, m, 5 × inositol ring, 2 × POCH2CHOAc, 2 × CH2OAc, 2 ×
CH2OPh), 1.97-1.91 (6 H, m, 2 × COCH3); δC (101 MHz, CDCl3) 170.4 (C=O), 170.0
(C=O), 168.5 (C=O), 157.7 (C), 137.9 (C), 137.7 (C), 135.5-135.2 (5 C, m, 5 × C), 129.4
(CH), 128.8 (CH), 128.7 (CH), 128.5 (CH), 128.46 (CH), 128.42 (CH), 128.4 (CH), 128.3
(CH), 128.25 (CH), 128.2 (CH), 128.0 (CH), 127.94 (CH), 127.93 (CH), 127.9 (CH),
127.8 (CH), 127.77 (CH), 127.7 (CH), 127.6 (CH), 127.5 (CH), 127.48 (CH), 127.4 (CH),
114.8 (CH), 77.8 (CH), 77.7 (CH), 76.9 (CH), 76.0 (CH2), 75.3 (CH2), 75.2 (CH2),
75.0 (1 C, dd, 3JP-C 4.3, 4.3, CH), 71.4, (CH), 70.0 (1 C, d, 2JP-C 5.8, CH2), 69.8 (1 C, d,
2JP-C 5.0, CH2), 69.7 (1 C, d, 2JP-C 5.6, CH2), 69.6 (1 C, d, 2JP-C 5.4, CH), 69.4 (1 C, d,
2JP-C 3.0, CH2), 69.3 (1 C, d, 2JP-C 3.3, CH), 65.8-65.5 (1 C, m, CH2), 64.9 (CH2), 61.6
(CH2), 20.8 (CH3), 20.7 (CH3); δP (121 MHz, CDCl3) 0.0 – -0.2 (3 P); HRMS m/z (FAB)
[Found: (M+Na)+ 1365.3771. C62H67O19NaP3 requires M+ 1365.3749]; m/z (ES+) 1365
([M+Na]+, 100%).
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2,6-bis-O-Benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzylphosphate)-4-phenylcarbonate-myo-inositol 90
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To a solution of 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-
3,5-bis(dibenzylphosphate)-myo-inositol 66 (72 mg, 60 μmol, 1 equiv.) in pyridine (0.75
mL) was added phenyl chloroformate (56 mg, 45 µL, 358 μmol, 6.0 equiv.) and a thick
precipitate formed. The mixture was stirred for 2 h at RT after which time the reaction
was adjudged to be incomplete by TLC analysis. Phenyl chloroformate (56 mg, 45 µl,
358 μmol, 6.0 equiv.) was added. The reaction mixture was stirred for a further 2 h after
which phenyl chloroformate (29 mg, 23 µL, 183 μmol, 3.0 equiv.) was again added. After
1 h the mixture was transferred directly onto a silica gel column. Purification by
successive attempts at silica gel column chromatography, eluting with ethyl
acetate/petroleum ether (50:50 then 70:30), gave 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-
sn-glycerol)-(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-4-phenylcarbonate-myo-
inositol 90 (36 mg, 46% yield), a mixture of 4 diastereomers, as a colourless gum. Rf
0.39 (ethyl acetate/petroleum ether 70:30); νmax (thin film)/cm-1 3460 (w), 3034 (m), 2955
(m), 1772 (s), 1745 (s), 1456 (s), 1248 (s), 1011 (s); δH (300 MHz, CDCl3) 7.36-7.16 (31
H, m, Ph), 7.10-7.09 (2 H, m, Ph), 7.00-6.98 (2 H, m, Ph), 5.50 (1 H, dd, J 9.8, 9.8,
inositol ring), 5.02-4.13 (19 H, m, 14 × CH2Ph, 1 × CHOAc, 4 × inositol ring), 4.07-3.73
(5 H, m, 1 × inositol ring, 2 × POCH2CHOAc, 2 × CH2OAc), 1.99-1.93 (6 H, m, 2 ×
COCH3); δP (121 MHz, CDCl3) 0.5−0.0 (3 P, m); HRMS m/z (FAB) [Found: (M+Na)+
1351.3580. C69H71O21NaP3 requires M+ 1351.3593]; m/z (ES+) 1351 ([M+Na]+, 100%).
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(±)-1-[(1',2'-di-O-Acetyl-sn-glycerol)-(3')-benzylphosphate]-4-O-methanesulfonyl-
myo-inositol 3,5-bisphosphate pentakis-sodium salt 100
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Palladium black (58 mg, 0.544 mmol, 20 equiv.) and sodium bicarbonate (11 mg, 0.136
mmol, 5 equiv.) were added to a solution of 2,6-bis-O-benzyl-1-[(1',2'-di-O-acetyl-sn-
glycerol)-(3')-benzylphosphate]-3,5-bis(dibenzylphosphate)-4-methanesulfonyl myo-
inositol 87 (35 mg, 0.027 mmol, 1 equiv.) in t-butanol (3.0 ml) and water (0.5 ml) under
nitrogen. The mixture was then placed under an atmosphere of hydrogen and stirred for
3 h. The organic phase was decanted by pipette and water added to the black residue.
The palladium was removed by filtration and the aqueous filtrate was freeze-dried to
give 1-[(1',2'-di-O-acetyl-sn-glycerol)-(3')-benzylphosphate]-4-O-methanesulfonyl-myo-
inositol 3,5-bisphosphate pentakis-sodium salt 100 (19 mg, 90% yield) as a colourless
solid. This compound proved unstable over time. δH (300 MHz, D2O) 5.08-5.04 (1 H, m,
CHOAc), 4.54 (1 H, dd, J 9.7, 9.7, 4-H inositol ring), 4.38 (1 H, dd, J 2.3, 2.3, 2-H inositol
ring), 4.17 (1 H, dd, J 3.5, 12.2, CH2), 4.06 (1 H, ddd, J 3.5, 6.2, 12.2, CH2), 3.96-3.71 (6
H, m, 2 × CH2, 4 × inositol ring), 3.15 (3 H, s, SO2Me), 1.93 (3 H, s, COCH3), 1.89 (3 H,
s, COCH3); δP (162 MHz, D2O) 3.7, 2.5, -0.9.
(±)-2,6-bis-O-Benzyl-4-O-(4'-methoxybenzyl)-1,3,5-tris(dibenzylphosphate)-myo-
inositol 105
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1H-Tetrazole in acetonitrile (3 % w/v, 4.2 mL, 1.98 mmol, 2.0 equiv.) was added to a
solution of bis(benzyloxy)-N,N-diisopropylamino phosphine (684 mg, 1.98 mmol, 2.0
equiv.) in dichloromethane (5 mL) and the mixture stirred for 10 min. A solution of (±)-
2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-3,5-bis(dibenzylphosphate)-myo-inositol 67
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(992 mg, 0.99 mmol, 1.0 equiv.) in dichloromethane (5 mL) was added via cannula and
the resulting mixture stirred for 26 h. The mixture was cooled to -78 °C and 3-
chloroperbenzoic acid (assume 60 %, 570 mg, 1.98 mmol, 2.0 equiv.) was added. The
reaction mixture was allowed to reach RT and stirred for 1.5 h. The 3-chloroperbenzoic
acid was quenched with a 10 % aqueous solution of sodium bisulfite (10 mL). The
mixture was stirred for 10 min and the organic and aqueous phases were separated.
The aqueous layer was extracted with dichloromethane (3 × 20 mL). The combined
organic extracts were washed with saturated aqueous sodium bicarbonate solution (20
mL), brine (20 mL), dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by silica gel chromatography, eluting with ethyl acetate/petroleum ether
(50:50, 60:40 then 70:30) gave (±)-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1,3,5-
tris(dibenzylphosphate)-myo-inositol 105 (1.08 g, 87% yield) as a colourless oil. Rf 0.56
(ethyl acetate/petroleum ether 80:20); νmax (thin film)/cm-1 3483 (m), 3033 (s), 2895 (s),
1514 (s), 1455 (s), 1272 (s), 1016 (s); δH (400 MHz, CDCl3) 7.42-7.40 (2 H, m, Ph),
7.34-7.14 (36 H, m, 34 × Ph, 2 × C6H4OCH3), 7.08-7.04 (4 H, m, Ph), 6.73 (2 H, d, J 8.7,
C6H4OCH3), 5.00-4.70 (18 H, m, 16 × OCH2Ph, 2 × OCH2C6H4OCH3), 4.59 (1 H, dd, J
2.4, 2.4, inositol ring, 2-H), 4.43 (1 H, ddd, J 9.2, 9.2, 9.2, inositol ring, 5-H), 4.33-4.27 (2
H, m, inositol ring, 1-H and 3-H), 4.09 (2 H, dd, J 9.4, 9.4, inositol ring, 4-H and 6-H),
3.70 (3 H, s, OCH3); δC (75 MHz, CDCl3) 159.4 (C), 138.9 (C), 138.5 (C), 136.3 (1 C, d,
2JP-C 7.1, C), 136.6 (1 C, d, 2JP-C 7.1, C), 136.1-136.0 (4 C, m, 4 × C), 130.6 (C), 129.8
(CH), 129.0 (CH), 128.9 (CH), 128.8 (CH), 128.7 (CH), 128.65 (CH), 128.6 (CH), 128.45
(CH), 128.4 (CH), 128.3 (CH), 128.24 (CH), 128.2 (CH), 128.1 (CH), 127.0 (CH), 127.8
(CH), 113.9 (CH), 80.3, (1 C, d, , 2JP-C 6.9, CH), 78.6-78.4 (1 C, m, CH), 78.3 (CH), 78.2-
78.1 (1 C, m, CH), 77.8 (CH), 77.7 (CH), 76.2 (CH2), 75.1 (CH2), 74.8 (CH2), 70.1 (CH2),
69.8-69.7 (4 C, m, 4 × CH2), 55.6 (CH3); δP (121 MHz, CDCl3) -1.5, -1.7, -1.7; HRMS
m/z (ES+) [Found: (M+NH4)+ 1278.4312. C70H75O16NP3 requires M+ 1278.4293]; m/z
(ES+) 1284 ([M+Na]+, 100%).
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(±)-2,6-bis-O-Benzyl-1,3,5-tris(dibenzylphosphate)-myo-inositol 106
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A mixture of (±)-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1,3,5-tris(dibenzylphosphate)-
myo-inositol 105 (1.02 g, 0.81 mmol, 1.0 equiv.) and ceric ammonium nitrate (1.10 g,
2.02 mmol, 2.5 equiv.) in acetonitrile (20 mL) and water (5 mL) was stirred for 1.5 h open
to the air. Aqueous saturated sodium bicarbonate solution (5 mL) was added and the
solvent was removed in vacuo. The residue was partitioned between dichloromethane
(20 mL) and water (20 mL). The aqueous layer was extracted with dichloromethane (3 ×
20 mL), and the combined organic extracts were washed with saturated aqueous
sodium bicarbonate solution (40 mL), brine (40 mL), dried (MgSO4), filtered and
concentrated under reduced pressure. The crude residue was purified by silica gel
column chromatography, eluting with ethyl acetate/petroleum ether (50:50, 70: 30 then
80:20) to give (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzylphosphate)-myo-inositol 106 (779
mg, 85% yield) as a slow-crystallising colourless solid. Rf 0.41 (ethyl acetate/petroleum
ether 80:20); mp 82-84 °C; νmax (thin film)/cm-1 3367 (m), 3033 (m), 1456 (s), 1266 (s),
1014 (s); δH (300 MHz, CDCl3) 7.38-7.16 (40 H, m, Ph), 5.14 (1 H, s, OCH2Ph), 5.12 (1
H, s, OCH2Ph), 5.06-4.89 (10 H, m, 5 × OCH2Ph), 4.73 (2 H, s, OCH2Ph), 4.69 (2 H, s,
OCH2Ph), 4.55 (1 H, d, J 1.9, OH), 4.36-4.34 (1 H, m, inositol ring), 4.27-4.13 (4 H, m, 4
× inositol ring), 4.00 (1 H, dd, J 9.3, 9.3, inositol ring); δC (101 MHz, CDCl3) 138.3 (C),
137.9 (C), 135.9 (1 C, d, 2JP-C 7.4, C), 135.7 (1 C, d, 2JP-C 7.4, C), 135.63 (1 C, d, 2JP-C
7.4, C), 135.62 (1 C, d, 2JP-C 7.4, C), 135.61 (1 C, d, 2JP-C 7.4, C), 135.5 (1 C, d, 2JP-C
7.4, C), 128.65 (CH), 128.6 (CH), 128.55 (CH), 128.5 (CH), 128.25 (CH), 128.2 (CH),
128.1 (CH), 128.0 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH), 127.65 (CH), 127.6, 127.5
(CH), 127.4 (CH), 82.0 (1 C, d, 2JP-C 6.3, CH), 78.1 (1 C, d, 2JP-C 2.7, CH), 77.9 (1 C, dd,
3JP-C 7.0, 7.0, CH), 77.7 (1 C, d, 2JP-C 5.9, CH), 77.1-77.3 (1 C, m, CH), 75.8 (CH2), 75.3
(CH2), 71.1 (1 C, d, 2JP-C 4.5, CH), 69.9-69.8 (3 C, m, CH2), 69.6 (1 C, d, 2JP-C 5.5, CH2),
69.5 (1 C, d, 2JP-C 5.5, CH2), 69.4 (1 C, d, 2JP-C 5.5, CH2); δP (121 MHz, CDCl3) 0.2, -1.1,
-1.8; HRMS m/z (ES+) [Found: (M+Na)+ 1163.3275. C62H63O15NaP3 requires M+
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1163.3278], m/z (ES+) 1163 ([M+Na]+, 100%). Anal. Calcd for C62H63O15P3: C, 65.26 %;
H 5.56 %. Found: C, 65.30 %; H, 5.56 %.
(±)-2,6-bis-O-Benzyl-4-dimethylphosphinyl-1,3,5-tris(dibenzylphosphate)-myo-
inositol 107
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To a solution of (±)-2,6-bis-O-benzyl-1,3,5-bis(dibenzylphosphate)-myo-inositol 106 (83
mg, 0.07 mmol, 1 equiv.) in pyridine (1 mL) and dichloromethane (0.2 mL) was added
dimethylchlorophosphine (56 mg, 46 µl, 0.58 mmol, 8.0 equiv.). The mixture was stirred
for 3 h at RT then diluted with chloroform (10 mL). Water (10 mL) was added and the
layers separated. The aqueous phase was extracted with chloroform (3 × 10 mL) and
the combined organic extracts were washed with water (2 × 15 mL), brine (15 mL), dried
(MgSO4), filtered and concentrated. The crude product was adsorbed onto silica gel and
purification by silica gel column chromatography eluting with ethyl acetate/hexane
(60:40), ethyl acetate (100%) then methanol/dichloromethane (2:98, then 5:95) gave (±)-
2,6-bis-O-benzyl-4-dimethylphosphinyl-1,3,5-tris(dibenzylphosphate)-myo-inositol 107
(55 mg, 62%) as a colourless gum. Rf 0.39 (ethyl acetate); νmax (thin film)/cm-1 3464 (s),
3064 (m), 3034 (m), 2955 (m), 1497 (m), 1455 (s), 1273 (s), 1216 (s), 1013 (s), 874 (s);
δH (300 MHz, CDCl3) 7.39-7.04 (40 H, m, 8 × Ph), 5.09 (1 H, dd, J 11.7, 6.3, CH2Ph),
5.01-4.66 (16 H, m, 1 × inositol, 15 × OCH2Ph), 4.62 (1 H, dd, J 2.4, 2.4, inositol ring),
4.35-4.24 (2 H, m, 2 × inositol ring), 4.14-4.01 (2 H, m, inositol ring), 1.46 (3 H, d, J 14.2,
POCH3), 1.41 (3 H, d, J 14.2, POCH3); δC (101 MHz, CDCl3) 138.1 (C), 138.0 (C),
135.9-135.4 (6 C, m, C), 128.8 (CH), 128.7 (CH), 128.6 (CH), 128.5 (CH), 128.4 (CH),
128.2 (CH), 128.15 (CH), 128.1 (CH), 128.0 (CH), 127.9 (CH), 127.6 (CH), 127.5 (CH),
127.4 (CH), 127.3 (CH), 78.4 (CH), 77.6 (1 C, d, 2JP-C 7.4, CH), 77.4 (CH), 77.3 (CH),
75.9 (CH2), 75.6 (1 C, d, 2JP-C 5.0, CH), 75.0 (CH2), 72.1-71.9 (1 C, m, CH), 70.0 (1 C, d,
2JP-C 5.6, CH2), 69.8 (1 C, d, 2JP-C 5.5, CH2), 69.7 (1 C, d, 2JP-C 5.3, CH2), 69.6 (1 C, d,
2JP-C 5.6, CH2), 69.4 (1 C, d, 2JP-C 5.3, CH2), 69.3 (1 C, d, 2JP-C 5.5, CH2), 17.7 (1 C, d,
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1JP-C 67.8, CH3), 16.7 (1 C, d, 1JP-C 71.9, CH3); δP (121 MHz, CDCl3) 58.8, 0.2, 0.0, −0.1;
HRMS m/z (ES+) [Found: (M+Na)+ 1239.3330. C64H68O16NaP4 requires M+ 1239.3356];
m/z (ES+) 1239 ([M+Na]+, 100%).
(±)-4-Dimethylphosphinyl-myo-inositol 1,3,5-trisphosphate hexakis-sodium salt
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Palladium black (39 mg, 0.36 mmol, 20 equiv.) and sodium bicarbonate (9 mg, 0.11
mmol, 6 equiv.) were added to a solution of (±)-2,6-bis-O-benzyl-4-dimethylphosphinyl-
1,3,5-tris(dibenzylphosphate)-myo-inositol 107 (22 mg, 0.018 mmol, 1 equiv.) in t-
butanol (3.0 mL) and water (0.5 mL) under nitrogen. The mixture was then placed under
hydrogen and stirred for 5 h. The organic phase removed and water (1 mL) was added
to the black residue. The palladium was removed by filtration and washed with water.
The aqueous filtrate was freeze-dried to give (±)-4-dimethylphosphinyl-myo-inositol
1,3,5-trisphosphate hexakis-sodium salt 108 (11 mg, 100% yield) as a colourless solid.
δH (300 MHz, D2O) 4.52 (1 H, dd, J 2.2, 2.2, inositol ring 2-H), 4.26 (1 H, ddd, J 10.0,
10.0, 10.0, inositol ring), 3.94-3.75 (4 H, m, 4 × inositol ring), 1.62 (3 H, s, POCH3), 1.57
(3 H, s, POCH3); δC (75 MHz, D2O) 76.2 (CH), 75.3 (1C, d, 2JP-C 6.9, CH), 73.9 (1C, d,
2JP-C 5.0, CH), 72.3 (1C, d, 2JP-C 7.2, CH), 72.0 (CH), 70.0 (CH), 16.5 (CH3), 15.2 (CH3);
δP (121 MHz, D2O) 66.6, 3.7, 3.0, 2.9; HRMS m/z (FAB) [Found: (M−6Na+5H)−
494.9625. C8H19O16P4 requires M− 494.9629]; m/z (ES-) 247 (100%), 495
([M−6Na+5H]−, 18%); 517 ([M−5Na+4H]−, 18%); 539 ([M−4Na+3H]−, 7%).
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(±)-2,6-bis-O-Benzyl-1,3,5-tris(dibenzylphosphate)-4-sulfate-myo-inositol sodium
salt 109
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A solution of (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzylphosphate)-myo-inositol 106 (30 mg,
0.026 mmol, 1.0 equiv.), sulfur trioxide pyridine complex (41 mg, 0.263 mmol, 10 equiv.)
and triethylamine (10.5 mg, 15 μL, 0.104 mmol, 4.0 equiv.) in DMF (1 mL) was heated to
50 °C for 24 h. After this time, the reaction was adjudged to have completed by TLC
analysis. Triethylamine (1 mL) and methanol (2 mL) was added and the solvent was
removed in vacuo. The residue was adsorbed onto silica gel and subjected to silica gel
column chromatography eluting with ethyl acetate/hexane (60:40, 70:30, 80:20 then 100
% ethyl acetate) then methanol/chloroform (5:95). The product was dissolved in
methanol and stirred with Dowex Marathon C sodium form resin for 20 min. The resin
was removed by filtration and washed with methanol. Water (5 mL) was added to the
filtrate which was freeze-dried overnight to give (±)-2,6-bis-O-benzyl-1,3,5-
tris(dibenzylphosphate)-4-sulfate-myo-inositol sodium salt 109 (14 mg, 44% yield) as a
colourless, hygroscopic solid. Rf 0.28 (methanol/chloroform 10:90); δH (400 MHz,
CD3OD) 7.42-7.15 (40 H, m, 8 × Ph), 5.25-4.82 (14 H, m, CH2Ph), 4.96 (1 H, d, J 11.1,
CH2Ph), 4.75 (1 H, d, J 11.1, CH2Ph), 4.62-4.53 (5 H, m, 5 × inositol ring), 4.06 (1 H, dd,
J 8.8, 8.8, inositol ring); δC (101 MHz, CD3OD) 139.6 (C), 139.5 (C), 137.8-136.9 (6 C,
m, 6 × ArC), 129.64 (CH), 129.60 (CH), 129.57 (CH), 129.5 (CH), 129.48 (CH), 129.41
(CH), 129.35 (CH), 129.33 (CH), 129.3 (CH), 129.2 (CH), 129.17 (CH), 129.0 (CH),
128.8 (CH), 128.7 (CH), 128.6 (CH), 128.4 (CH), 79. 5 (1 C, d, 2JP-C 6.1, CH), 78.6 (CH),
78.3 (1 C, d, 2JP-C 5.9, CH), 78.0 (CH), 77.0 (1 C, dd, 3JP-C 6.1, CH), 76.6 (1 C, d, 2JP-C
5.6, CH), 76.4 (CH2), 75.5 (CH2), 76.4 (1 C, d, 2JP-C 5.2, CH2), 71.33 (1 C, d, 2JP-C 5.2,
CH2), 71.3 (1 C, d, 2JP-C 5.2, CH2), 71.2 (1 C, d, 2JP-C 5.8, CH2), 71.1 (2 C, d, 2JP-C 6.6,
CH2), 70.8 (1 C, d, 2JP-C 6.2, CH2); δP (162 MHz, CD3OD) −2.4, −3.0, −3.3; HRMS m/z
(FAB) [Found: (M−Na)− 1219.2866. C62H62O18P3S requires M− 1219.2875]; m/z (ES−)
1219 ([M−Na]−, (100%).
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(±)-myo-Inositol 4-sulfate-1,3,5-trisphosphate heptakis-sodium salt 110
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Palladium black (24 mg, 0.23 mmol, 20 equiv.) and sodium bicarbonate (6.2 mg, 0.07
mmol, 6.5 equiv.) were added to a solution of (±)-2,6-bis-O-benzyl-1,3,5-
tris(dibenzylphosphate)-4-sulfate-myo-inositol sodium salt 109 (14 mg, 0.011 mmol, 1
equiv.) in t-butanol (3.0 mL) and water (0.5 mL) under nitrogen. The mixture was then
placed under hydrogen and stirred for 2.5 h. The organic phase was decanted by pipette
and water added to the black residue. The palladium was removed by filtration, washed
with water and the aqueous filtrate was freeze-dried to give (±)-myo-inositol 4-sulfate-
1,3,5-trisphosphate heptakis-sodium salt 110 (7 mg, 99% yield) as a colourless solid. δH
(300 MHz, D2O) 4.47 (1 H, br s, inositol ring 2-H), 4.37 (1 H, ddd, J 9.3, 9.3, 9.3, inositol
ring), 3.89-3.72 (4 H, m, 4 × inositol ring); δC (75 MHz, D2O) 79.1 (CH), 75.9 (1 C, d, 2JP-
C 4.0, CH), 73.8 (1 C, d, 2JP-C 5.0, CH), 72.5 (1 C, d, 2JP-C 6.8, CH), 71.9 (CH), 69.9
(CH); δP (121 MHz, D2O) 4.0, 3.1, 3.0; HRMS m/z (FAB) [Found: (M−7Na+6H)−
498.9113. C6H14O18P3S requires M− 498.9119]; m/z (ES-) 123 (100%), 499
([M−7Na+6H]−, 11%).
(±)-myo-Inositol 4-sulfate-1,3,5-trisphosphate tetrakis-sodium salt 111
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Palladium black (42 mg, 0.39 mmol, 20 equiv.) and sodium bicarbonate (5.0 mg, 0.06
mmol, 3.0 equiv.) were added to a solution of (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzyl
phosphate)-4-sulfonato-myo-inositol sodium salt 109 (24.5 mg, 19.7 μmol, 1 equiv.) in t-
butanol (3.0 mL) and water (0.5 mL) under nitrogen. The mixture was then placed under
hydrogen and stirred for 3 h. The organic phase was decanted by pipette and water (2
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mL) added to the black residue. The palladium was removed by filtration, washed with
water (5 mL) and the aqueous filtrate was freeze-dried to give (±)-myo-inositol 4-sulfate-
1,3,5-trisphosphate tetrakis-sodium salt 110 (11 mg, 97% yield) as a colourless solid. δH
(300 MHz, D2O) 4.59 (1 H, dd, J 9.7, 9.7, inositol ring), 4.41 (1 H, dd, J 2.5, 2.5, inositol
ring 2-H), 4.12-3.94 (3 H, m, 3 × inositol ring), 3.87 (1 H, dd, J 9.4, 9.4, inositol ring); δC
(75 MHz, D2O) 79.2 (1 C, dd, 3JP-C 5.8, 4.5 CH), 76.9 (1 C, d, JP-C 5.8, CH), 74.5 (1 C, d,
JP-C 5.5, CH), 73.1 (1 C, d, JP-C 5.3, CH), 71.0 (1 C, d, JP-C 5.8, CH), 69.9 (CH); δP (121
MHz, D2O) 0.4, -0.3, -0.5; HRMS m/z (FAB) [Found: (M−3Na+2H)− 520.8937.
C6H13O18NaP3S requires M− 520.8939]; m/z (ES-) 499 ([M−4Na+3H]−, 100%); 521
([M−3Na+2H]−, 30%); 543 ([M−2Na+H]−, 10%).
(±)-2,6-bis-O-Benzyl-4-phenoxyacetyl-1,3,5-tris(dibenzylphosphate)-myo-inositol
112
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To a solution of (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzylphosphate)-myo-inositol 106 (86
mg, 0.075 mmol, 1 equiv.), triethylamine (38 mg, 53 µL, 0.377 mmol, 5.0 equiv.) and
DMAP (catalytic amount) in THF (2 mL) was added phenoxyacetyl chloride (51 mg, 42
μL, 0.302 mmol, 4.0 equiv.) at 0 °C. The mixture was allowed to warm to RT and stirred
for 3 h, after which time the reaction was adjudged to be incomplete by TLC analysis.
Triethylamine (38 mg, 53 µL, 0.377 mmol, 5.0 equiv.) and phenoxyacetyl chloride (51
mg, 42 μL, 0.302 mmol, 4.0 equiv.) were added at 0 °C. The mixture was stirred for a
further 1.5 h, then diluted with diethyl ether (6 mL). Water (5 mL) was added and the
layers separated. The aqueous phase was extracted with diethyl ether (3 × 8 mL) and
the combined organic extracts were washed with saturated aqueous sodium bicarbonate
solution (15 mL) and brine (15 mL), dried (MgSO4), filtered and concentrated. The crude
product was immediately adsorbed onto silica gel and purification by silica gel column
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chromatography eluting with ethyl acetate/petroleum ether (50:50 then 60:40) gave (±)-
2,6-bis-O-benzyl-4-phenoxyacetyl-1,3,5-tris(dibenzylphosphate)-myo-inositol 112
(51 mg, 53% yield), as a colourless gum. Rf 0.41 (ethyl acetate/petroleum ether 70:30);
νmax (thin film)/cm-1 3034 (m), 2953 (m), 1773 (s), 1497 (s), 1456 (s), 1272 (s), 1011 (s);
δH (300 MHz, CDCl3) 7.35-7.14 (40 H, m, Ph), 7.09-7.05 (2 H, m, Ph), 6.94-6.88 (1 H, m,
Ph), 6.82-6.79 (2 H, m, Ph), 5.79 (1 H, dd, J 9.8, 9.8, inositol ring 4-H), 4.98-4.75 (14 H,
m, CH2Ph), 4.70 (2 H, s, CH2Ph), 4.60 (1 H, d, J 16.3, C(O)CHHOPh), 4.48 (1 H, d, J
16.3, C(O)CHHOPh), 4.46 (1 H, dd, J 2.4, 2.4, inositol ring 2-H), 4.40 (1 H, ddd, J 9.2,
9.2, 9.2, inositol ring), 4.33-4.24 (2 H, m, 2 × inositol ring), 4.10 (1 H, dd, J 9.5, 9.5,
inositol ring); δC (101 MHz, CDCl3) 168.5 (C=O), 157.7 (C), 138.0 (C), 137.7 (C), 135.6-
135.2 (6 C, m, 6 × ArC), 129.4 (CH), 128.73 (CH), 128.7 (CH), 128.6 (CH), 128.58 (CH),
128.55 (CH), 128.5 (CH), 128.45 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 128.04
(CH), 128.0 (CH), 127.9 (CH), 127.84 (CH), 127.82 (CH), 127.7 (CH), 127.6 (CH), 127.5
(CH), 121.4 (CH), 114.8 (CH), 77.8 (CH), 77.7 (CH), 77.4 (CH), 76.8 (1 C, d, 2JP-C 5.3,
CH), 76.0 (CH2), 75.2 (CH2), 75.0 (1 C, d, 2JP-C 5.3, CH), 71.3 (1 C, d, 2JP-C, 4.4, CH),
70.0 (1 C, d, 2JP-C 5.7, CH2), 69.8 (1 C, d, 2JP-C 5.6, CH2), 69.7 (1 C, d, 2JP-C 5.7, CH2),
69.6 (1 C, d, 2JP-C 5.6, CH2), 69.5 (1 C, d, 2JP-C 5.6, CH2), 69.4 (1 C, d, 2JP-C 5.7, CH2),
64.9 (CH2); δP (162 MHz, CDCl3) −1.6, −1.7, −1.8; HRMS m/z (ES+) [Found: (M+Na)+
1297.3665. C70H69O17NaP3 requires M+ 1297.3645], m/z (ES+) 1297 ([M+Na]+, 100%).
(±)-2,6-bis-O-Benzyl-4-phenylcarbamate-1,3,5-tris(dibenzylphosphate)-4-
phenylcarbamate-myo-inositol 114
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To a solution of (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzylphosphate)-myo-inositol 106
(83 mg, 0.073 mmol, 1.0 equiv.) and 4-dimethylaminopyridine (catalytic amount) in
pyridine (1 mL) and dichloromethane (0.2 mL) at 0 °C was added phenylisocyanate (173
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mg, 158 μL, 1.46 mmol, 20 equiv.). Precipitate was immediately formed, and the mixture
was allowed to warm to RT. After 2 h stirring, the reaction was adjudged to be complete
by TLC analysis. The reaction mixture was transferred directly onto a silica gel
chromatography column. Elution with ethyl acetate and hexane (50:50, 60:40, then
80:20) followed by ethyl acetate (100 %) gave (±)-2,6-bis-O-benzyl-1,3,5-
tris(dibenzylphosphate)-4-phenylcarbamate-myo-inositol 114 (74 mg, 80% yield), as a
colourless gum. Rf 0.26 (ethyl acetate); νmax (thin film)/cm-1 3449 (m), 3065 (m), 3034
(m), 2956 (m), 1738 (s), 1602 (m), 1542 (m), 1456 (m), 1268 (s), 1221 (s), 1016 (s); δH
(400 MHz, CDCl3) 7.33-7.07 (40 H, m, 8 × Ph), 6.99-6.96 (5 H, m, Ph), 5.64 (1 H, dd, J
9.9, 9.9, inositol ring 4-H), 4.95-4.62 (16 H, m, CH2Ph), 4.52 (1H, ddd, J 9.4, 9.4, 9.4,
inositol ring), 4.46 (1 H, dd, J 2.5, 2.5, inositol ring 2-H), 4.40-4.31 (2 H, m, 2 × inositol
ring), 4.13 (1 H, dd, J 9.6, 9.6, inositol ring); δC (101 MHz, CDCl3) 152.6 (C=O), 138.2
(C), 137.9 (C), 137.8 (C), 135.7-135.3 (6 C, m, 6 × C), 128.9 (CH), 128.6 (CH), 128.59
(CH), 128.56 (CH), 128.52 (CH), 128.5 (CH), 128.4 (CH), 128.33 (CH), 128.29 (CH),
128.28 (CH), 128.2 (CH), 127.89 (CH), 127.87 (CH), 127.8 (CH), 127.7 (CH), 127.6
(CH), 127.57 (CH), 127.5 (CH), 127.4 (CH), 127.36 (CH), 123.2 (CH), 118.6 (CH), 78.02
(CH), 77.95 (CH), 77.9 (CH), 77.0 (1 C, d, 2JP-C 5.4, CH), 75.9 (CH2), 75.6 (1 C, d, 2JP-C
5.2, CH), 74.9 (CH2), 71.7 (CH), 69.7-69.2 (6 C, m, 6 × CH2); δP (162 MHz, CDCl3) -1.3,
-1.7, -1.8; HRMS m/z (FAB) [Found: (M+Na)+ 1282.3644. C69H68O16NNaP3 requires M+
1282.3643]; m/z (ES+) 1282 ([M+Na]+, 100%).
(±)-4-Phenylcarbamate-myo-inositol-1,3,5-trisphosphate hexakis-sodium salt 115
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Palladium black (121 mg, 1.14 mmol, 20 equiv.) and sodium bicarbonate (29 mg, 0.343
mmol, 6 equiv.) were added to a solution of (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzyl
phosphate)-4-phenylcarbamate-myo-inositol 114 (72 mg, 57 μmol, 1 equiv.) in t-butanol
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(3.0 mL) and water (0.5 mL) under nitrogen. The mixture was then placed under
hydrogen and stirred for 3 h. The organic phase was decanted by pipette and water
added to the black residue. The palladium was removed by filtration and the aqueous
filtrate was freeze-dried to give (±)-4-phenylcarbamate-myo-inositol-1,3,5-trisphosphate
hexakis-sodium salt 115 (32 mg, 84% yield) as a colourless solid. δH (400 MHz, D2O)
7.29-7.27 (2 H, m, Ph), 7.23-7.19 (2 H, m, Ph), 6.99-6.94 (1 H, m, Ph), 4.89 (1 H, dd, J
9.7, 9.7, inositol ring 4-H), 4.41 (1 H, dd, J 2.4, 2.4, inositol ring 2-H), 3.95 (1 H, ddd, J
11.1, 8.6, 2.4, inositol ring), 3.90-3.72 (3 H, m, 3 × inositol ring); δC (75 MHz, D2O) 155.8
(C=O), 137.7 (C), 129.2 (CH), 124.0 (CH), 120.0 (CH), 76.1 (1 C, d, 2JP-C 5.2, CH
inositol ring), 74.3 (1 C, d, 2JP-C 5.2, CH inositol ring), 72.9 (CH, inositol ring), 72.6 (1 C,
d, 2JP-C 4.5, inositol ring), 71.8 (CH, inositol ring); δP (121 MHz, D2O) 2.4, 2.0, 1.1;
HRMS m/z (FAB) [Found: (M−6Na+5H)− 537.9916. C13H19O16NP3 requires M−
537.9922]; m/z (ES-) 97 (100%), 538 ([M−6Na+5H]−, 62%); 560 ([M−5Na+4H]−, 50%);
582 ([M−4Na+3H]−, 21%).
(±)-2,6-bis-O-Benzyl-1,3,5-tris(dibenzylphosphate)-4-(4'-benzyloxy)phenyl
carbamate-myo-inositol 116
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To a solution of (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzylphosphate)-myo-inositol 106 (72
mg, 0.063 mmol, 1.0 equiv.) and 4-dimethylaminopyridine (catalytic amount) in pyridine
(1 mL) and dichloromethane (0.2 mL) at 0 °C was added 4-(benzyloxy)phenyl
isocyanate (245 mg, 1.09 mmol, 17 equiv.). A precipitate was immediately formed, and
the mixture was allowed to warm to RT. After 7 h, the reaction was adjudged to be
complete by TLC analysis. The reaction mixture was transferred directly onto a silica gel
chromatography column. Elution with ethyl acetate and hexane (50:50, 60:40 then
80:20) followed by ethyl acetate (100 %) gave a mixture of two products. Ethyl acetate
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was added to the product mixture and the solids removed by filtration. The filtrate was
concentrated to give (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzylphosphate)-4-(4'-
benzyloxy)phenyl carbamate-myo-inositol 116 (65 mg, 76% yield), as a colourless gum.
Rf 0.48 (ethyl acetate); νmax (thin film)/cm-1 3279 (m), 3064 (m), 1734 (s), 1539 (s), 1268
(s), 1218 (s); δH (400 MHz, CDCl3) 7.51-7.16 (43 H, m, Ar), 7.10-7.03 (4 H, m, Ar), 6.84-
6.82 (2 H, d, J 9.1, NHC2H4OBn), 5.77 (1 H, dd, J 9.8, 9.8, inositol ring 4-H), 5.07 (2 H,
s, CH2Ar), 5.02-4.72 (16 H, m, 16 × CH2Ar), 4.66 (1 H, ddd, J 9.5, 9.5, 9.5, inositol ring
5-H), 4.57 (1 H, dd, J 2.5, 2.5, inositol ring 2-H), 4.42-4.49 (2 H, m, 2 × inositol ring 1-H
and 3-H), 4.22 (1 H, ddd, J 9.5, 9.5, 9.5, inositol ring 6-H); δC (101 MHz, CDCl3) 154.9
(C), 152.9 (C=O), 138.2 (C), 137.9 (C), 135.7-135.4 (6 C, m, 6 × C), 131.3 (C), 128.60
(CH), 128.58 (CH), 128.55 (CH), 128.51 (CH), 128.49 (CH), 128.4 (CH), 128.33 (CH),
128.30 (CH), 128.0 (CH), 127.89 (CH), 127.87 (CH), 127.8 (CH), 127.7 (CH), 127.6
(CH), 127.56 (CH), 127.5 (CH), 127.4, 127.3 (CH), 120.3 (CH), 115.2 (CH), 78.04 (CH),
78.00 (CH), 77.9 (CH), 77.0 (1 C, d, 2JP-C 5.1, CH), 75.9 (CH2), 75.6 (1 C, d, 2JP-C 5.1,
CH), 74.9 (CH2), 71.6 (CH), 70.3 (CH2), 69.7 (1 C, d, 2JP-C 6.1, CH2), 69.6 (1 C, d, 2JP-C
5.5, CH2), 69.5 (1 C, d, 2JP-C 5.3, CH2), 69.46 (1 C, d, 2JP-C 6.1, CH2), 69.4 (1 C, d, 2JP-C
5.7, CH2), 69.2 (1 C, d, 2JP-C 5.3, CH2); δP (162 MHz, CDCl3) −1.3,−1.6, −1.7; HRMS m/z
(FAB+) [Found: (M+Na)+ 1388.4074. C76H74O17NNaP3 requires M+ 1388.4062]; m/z
(ES+) 1384 ([M+NH4]+, 100%).
(±)-4-(4'-Carbamoyl-N-phenolate)-myo-inositol 1,3,5-trisphosphate heptakis-
sodium salt 118
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Palladium black (78 mg, 0.74 mmol, 20 equiv.) and sodium bicarbonate (21.9 mg, 0.26
mmol, 7 equiv.) were added to a solution of (±)-2,6-bis-O-benzyl-1,3,5-tris(dibenzyl
phosphate)-4-dimethylphosphinyl myo-inositol 116 (51 mg, 37 μmol, 1 equiv.) in t-
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butanol (3.0 mL) and water (0.5 mL) under nitrogen. The mixture was then placed under
hydrogen and stirred for 3 h. The organic phase removed and water (1 mL) was added
to the black residue. The palladium was removed by filtration and washed with water.
The aqueous filtrate was freeze-dried to (±)-4-(4'-carbamoyl-N-phenolate)-myo-
inositol 1,3,5-trisphosphate heptakis-sodium salt 118 (24 mg, 92% yield) as a colourless
solid. δH (400 MHz, D2O) 7.21 (2 H, d, J 9.0, NHC6H4OBn), 6.79 (2 H, d, J 9.0,
NHC6H4OBn), 5.01 (1 H, dd, J 9.9, 9.9, inositol ring 4-H), 4.41 (1 H, dd, J 2.5, 2.5,
inositol ring 2-H), 4.10 (1 H, ddd, J 9.9, 9.6, 2.5, inositol ring), 4.05-3.86 (3 H, m, 3 ×
inositol ring); δC (75 MHz, D2O) 156.4 (C=O), 152.2 (C), 130.3 (C), 122.9 (CH), 115.7
(CH), 76.2 (1 C, d, 2JP-C 5.4, CH), 74.3 (1 C, d, 2JP-C 5.4, CH), 72.9 (1 C, d, 2JP-C 5.4,
CH), 72.8 (1 C, d, 2JP-C 5.3, CH), 71.7 (1 C, d, 2JP-C 5.3, CH), 70.17 (CH); δP (162 MHz,
D2O) 1.9, 1.6, 0.6; HRMS m/z (FAB) [Found: (M−7Na+6H)− 553.9865. C62H62O18P3S
requires M− 553.9871]; m/z (ES−) 576 ([M−6Na+5H]−, 100%); 598 ([M−5Na+4H]−, 65%).
(-)-1D-5-O-Allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-endo-4-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-119
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O
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Triisopropylsilyl triflate (7.15 g, 6.20 mL, 23.3 mmol, 2.2 equiv.) was added to a stirred
solution of (-)-1D-5-O-allyl-2,6-di-O-benzyl-3-O-endo-4-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-41 (5.66 g, 10.60 mmol, 1.0 equiv.)
and 2,6-lutidine (3.40 g, 3.70 mL, 31.8 mmol, 3.0 equiv.) in dry dichloromethane (50 mL)
at 0 °C. The mixture was allowed to warm to RT and stirred for 18 h. Water (50 mL) was
added to the mixture and the organic and aqueous phases separated. The organic
phase was collected and the aqueous portion extracted with dichloromethane (3 × 50
mL). The combined organic extracts were washed with brine (100 mL), then dried
(MgSO4), filtered and concentrated under reduced pressure. Purification by silica gel
column chromatography, eluting with ethyl acetate and petroleum ether (5:95), gave (-)-
1D-5-O-allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-endo-4-O-exo-(L-1',7',7'-
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trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-119 (6.20 g, 85% yield) as a
colourless gum. Rf 0.62 (ethyl acetate/petroleum ether 10:90); 20D[α] -2.91, (c 1.1 in
CHCl3); νmax (thin film)/cm-1 3386 (w), 2944 (s), 2867 (s), 1455 (m), 1098 (s); δH (400
MHz, CDCl3) 7.34-7.15 (10 H, m, 2 × Ph), 5.83 (1 H, dddd, J 17.2, 10.4, 5.6, 5.6,
CH=CH2), 5.20 (1 H, dddd, J 17.2, 1.8, 1.7, 1.7, CHC=CHH), 5.03 (1 H, dddd, J 10.4,
1.8, 1.2, 1.2, CHC=CHH), 4.90 (1 H, d, JAB 11.5, OCHAHB-Ph), 4.88 (1 H, d, JA'B' 11.1,
OCHA'HB'-Ph), 4.70 (1 H, d, JA'B' 11.1, OCHA'HB'-Ph), 4.64 (1 H, d, JAB 11.5, OCHAHB-
Ph), 4.29 (1 H, dddd, J 12.7, 5.6, 1.7, 1.2, CHHCH=CH2), 4.11 (1 H, dd, J 2.8, 1.6,
inositol ring 2-H), 4.05 (1 H, dddd, J 12.7, 5.6, 1.7, 1.2, CHHCH=CH2), 3.95 (1 H, dd, J
9.7, 9.7, inositol ring), 3.84 (1 H, dd, J 9.3, 2.8, inositol ring), 3.67 (1 H, dd, J, 8.5, 8.5,
inositol ring), 3.45 (1 H, dd, J 9.5, 8.5, inositol ring), 3.22 (1 H, dd, J 9.7, 1,6, inositol
ring), 2.08 (1 H, dt, J 13.5, 3.8, camphor ring), 1.84 (1 H, ddd, J 12.9, 9.6, 3.8, camphor
ring), 1.68-1.62 (2 H, m, camphor ring), 1.37-1.29 (1 H, m, camphor ring),1.19-1.12 (2 H,
m, camphor ring), 0.98-0.96 (21 H Si[CH(CH3)2]3), 0.94 (3 H, s, CH3), 0.78 (3 H, s, CH3
camphor bridge), 0.74 (3 H, s, CH3 camphor bridge); δC (75 MHz, CDCl3) 139.5 (C),
138.9 (C), 135.4 (CH), 128.1 (CH), 128.0 (CH), 127.6 (CH), 127.5 (CH), 127.3 (CH),
127.1 (CH), 120.4 (C), 116.5 (CH2), 83.3 (CH), 81.6 (CH), 77.5 (CH), 76.8 (CH), 76.0
(CH), 75.9 (CH2), 74.9 (CH), 73.8 (CH2), 71.7 (CH2), 52.9 (C), 48.3 (C), 46.3 (CH2), 45.0
(CH), 28.9 (CH2), 26.8 (CH2), 20.3 (CH3), 20.2 (CH3), 18.2 (CH3), 12.9 (CH), 9.7 (CH3);
HRMS m/z (ES+) [Found: (M+H)+ 691.4394. C42H63O6Si requires M+ 691.4388]; m/z
(ES+) 691 ([M+H]+, 100%).
(-)-1D-5-O-Allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol (-)-70
OBn
OAll
BnO
HO
OH
OTIPS
(-)-70
Acetyl chloride (211 mg, 191 μl, 2.69 mmol, 0.3 equiv.) was added to a solution of (-)-
1D-5-O-allyl-2,6-di-O-benzyl-1-O-triisopropylsilyl-3-O-endo-4-O-exo-(L-1',7',7'-
trimethylbicyclo[2.2.1]hept-2'-ylidine)-myo-inositol (-)-119 (6.19 g, 8.97 mmol, 1 equiv.) in
dichloromethane (80 mL) and methanol (40 mL) and the solution was stirred for 3.5 h.
The reaction mixture was quenched by the addition of triethylamine (2 mL), and all
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volatile components were removed in vacuo. The residue was partitioned between
dichloromethane (30 mL) and water (30 mL), and the aqueous phase was extracted with
dichloromethane (3 × 30 mL). The combined organic extracts were washed with brine,
dried (MgSO4), filtered and concentrated under reduced pressure. Purification by silica
gel column chromatography, eluting with ethyl acetate/petroleum ether (20/80 then
30/70) gave (-)-1D-5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol (-)-70
(4.01 g, 80% yield) as a colourless gum. 20D[α] -16.9, (c 1.7 in CHCl3); δH (300 MHz,
CDCl3) 7.38-7.24 (10 H, m, 2 × Ph), 5.87 (1 H, dddd, J 17.3, 10.4, 5.7, 5.7, CH=CH2)
5.22 (1 H, dddd, J 17.3, 1.7, 1.6, 1.6, CH=CHH), 5.13-5.07 (1 H, m, CH=CHH), 5.11 (1
H, d, JAB 11.4, OCHAHB-Ph), 4.92 (1 H, d, J A'B' 11.7, OCHA'HB'-Ph), 4.86 (1 H, d, JA'B'
11.7, OCHA'HB'-Ph), 4.76 (1 H, d, JAB 11.4, OCHAHB-Ph), 4.31 (1 H, dddd, J 12.4, 5.7,
1.6, 1.3, CHHCH=CH2), 4.24 (1 H, dddd, J 12.4, 5.7, 1.6, 1.3, CHHCH=CH2), 4.02-3.99
(1 H, m, inositol ring 2-H), 3.87-3.79 (3 H, m, 3 × inositol ring 1-H, 4-H, 6-H), 3.48 (1 H,
dd, J 9.6, 2.6, inositol ring 3-H), 3.26-3.15 (1 H, m, inositol ring 5-H), 2.64 (1 H, br s,
OH), 2.44 (1 H, br s, OH), 1.10-1.07 (21 H, m, 3 × SiCH, 18 × SiCHCH3). The data are in
agreement with the values reported for (±)-70.
(+)-1D-3-O-Benzoyl-5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol (-)-
73
OBn
OAll
BnO
BzO
OH
OTIPS
(-)-73
A mixture of 5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol (-)-70 (3.90 g,
7.01 mmol, 1.0 equiv.) and dibutyltin oxide (5.24 g, 21.03 mmol, 3.0 equiv.) in dry
toluene (40 mL) was heated under reflux for 16 h with Dean-Stark apparatus. The
mixture was then reacted with benzoyl chloride (1.08 g, 900 μL, 7.71 mmol, 3.0 equiv.)
using the procedure described for compound (±)-73 to give (+)-1D-3-O-benzoyl-5-O-allyl-
2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol (-)-73 (3.43 g, 74% yield) as a
colourless solid. 20D[α] +26.0, (c 1.6 in CHCl3); mp 94-96 °C (dichloromethane/petroleum
ether); δH (300 MHz, CDCl3) 8.10-8.06 (2 H, m, C6H5C(O)CH), 7.63-7.59 (1 H, m,
C6H5C(O)CH), 7.47-7.42 (2 H, m, C6H5C(O)CH), 7.39-7.25 (10 H, m, 2 × Ph), 5.89 (1 H,
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dddd, J 17.1, 10.4, 5.6, 5.6, CH=CH2), 5.22 (1 H, dddd, J 17.1, 1.7, 1.6, 1.6, CH=CHH),
5.10 (1 H, dddd, J 10.4, 1.7, 1.2, 1.2, CH=CHH), 5.02 (1 H, dd, J 10.2, 2.3, inositol ring
3-H), 4.90 (2 H, s, OCH2-Ph), 4.86 (1 H, d, J AB 11.5, OCHAHB-Ph), 4.76 (1 H, d, JAB
11.5, OCHAHB-Ph), 4.38 (1 H, dddd, J 12.4, 5.6, 1.7, 1.3, CHHCH=CH2), 4.33-4.25 (2 H,
m, 1 × inositol ring 4-H, 1 × CHHCH=CH2), 4.16 (1 H, dd, J 2.1, 2.1 inositol ring 2-H),
4.00-3.92 (2 H, m, inositol ring 1-H and 6-H), 3.35 (1 H, dd, J 9.0, 9.0, inositol ring 5-H),
2.34 (1 H, d, J 2.8, OH), 1.10-1.07 (21 H, m, 3 × SiCH, 18 × SiCHCH3). The data are in
agreement with the values reported for (±)-73.
1D-3-O-Benzoyl-5-O-allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-
triisopropylsilyl-myo-inositol 74
OBn
OAll
BnO
BzO
OPMB
OTIPS
74
To a solution of 4-methoxybenzyltrichloroacetimidate (2.81 g, 9.94 mmol, 2.0 equiv.) and
(+)-1D-3-O-benzoyl-5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol (-)-73
(3.28 g, 4.97 mmol, 1.0 equiv.) and 4 Å molecular sieves in toluene (100 mL) was added
yttrium (III) triflate (53 mg, 0.099 mmol, 0.02 equiv.) at -78 °C. The mixture was stirred at
-78 °C for 30 min, then the temperature was raised to -40 °C and the progress of the
reaction was monitored by TLC analysis. After 3 h at this temperature 4-
methoxybenzyltrichloroacetimidate (702 mg, 520 μL, 2.49 mmol, 0.5 equiv.) was added
to the mixture. The temperature was raised to -20 °C and allowed to slowly warm to RT
overnight. The reaction mixture was quenched by the addition of saturated aqueous
sodium bicarbonate solution (1 mL) and filtered through a pad of Celite. The filtrate was
concentrated under reduced pressure, and the residue partitioned between ethyl acetate
(50 mL) and water (50 mL). The aqueous phase was extracted with ethyl acetate (3 × 50
mL) and the combined organic fractions were washed with saturated aqueous sodium
bicarbonate solution (70 mL) and brine (70 mL), dried (MgSO4), filtered and
concentrated under reduced pressure. Exhaustive purification by silica gel column
chromatography eluting with ethyl acetate/petroleum ether (2.5:97.5 then 5:95) gave 1D-
3-O-benzoyl-5-O-allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-
myo-inositol 74 (2.49 g, 64% yield) as an impure, colourless gum which was used
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without further purification. Rf 0.47 (ethyl acetate/petroleum ether 25:75); δH (300 MHz,
CDCl3) 8.02-7.92 (2 H, m, C6H5C(O)CH), 7.64-7.58 (1 H, m, C6H5C(O)CH) 7.49-7.43 (2
H, m, C6H5C(O)CH), 7.41-7.25 (10 H, m, 2 × Ph), 7.10 (2 H, d, J 8.7, C6H4OCH3), 6.71
(2 H, d, J 8.7, C6H4OCH3) 5.92 (1 H, dddd, J 17.0, 10.5, 5.6, 5.6, CH=CH2), 5.23 (1 H,
dddd, J 17.0, 1.8, 1.6, 1.6, CH=CHH), 5.13 (1 H, dddd, J 10.5, 1.8, 1.1, 1.1, CH=CHH),
5.03 (1 H, dd, J 10.0, 2.3, inositol ring), 4.93 (1 H, d, J AB 11.3, OCHAHB-Ph), 4.90 (1 H,
d, JA'B' 11.4, OCHA'HB'-Ph), 4.89 (1 H, d, J AB 11.3, OCHAHB-Ph), 4.72 (1 H, d, JAB 10.5,
OCHAHBC6H4OCH3), 4.71 (1 H, d, JA'B' 11.4, OCHA'HB'-Ph), 4.65 (1 H, d, JAB 10.5,
OCHAHBC6H4OCH3), 4.42-4.27 (2 H, m, CH2CH=CH2), 4.18 (1 H, dd, J 10.0, 9.3, inositol
ring) 4.12-4.09 (1 H, m, inositol ring), 3.99-3.89 (2 H, m, inositol ring), 3.72 (3 H, s,
OCH3), 3.44-3.40 (1 H, m, inositol ring), 1.09-1.04 (21 H, m, 3 × SiCH, 18 × SiCHCH3).
The data are in agreement with the values reported for (±)-74.
(+)-1D-5-O-Allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-myo-
inositol (+)-75
OBn
OAll
BnO
HO
OPMB
OTIPS
(+)-75
1D-3-O-Benzoyl-5-O-allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-
myo-inositol 74 (2.47 g, 3.17 mmol, 1 equiv.) was reacted with 2 M aqueous sodium
hydroxide solution (2 mL, 4.96 mmol, 1.25 equiv.) in diethyl ether (14 mL) and methanol
(7 mL) using the procedure described for compound (±)-75 to give (+)-1D-5-O-allyl-2,6-
bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl myo-inositol (+)-75 (1.72 g,
80% yield) as a colourless oil. 20D[α] +24.3, (c 1.0 in CHCl3); δH (300 MHz, CDCl3) 7.37-
7.20 (12 H, m, 10 × C6H5, 2 × C6H4OCH3), 6.87 (2 H, d, J 8.7, C6H4OCH3) 5.88 (1 H,
dddd, J 17.1, 10.4, 5.7, 5.7, CH=CH2), 5.23 (1 H, dddd, J 17.1, 1.7, 1.6, 1.6, CH=CHH),
5.13 (1 H, dddd, J 10.4, 1.7, 1.3, 1.3, CH=CHH), 5.00 (1 H, d, J AB 11.3, OCHAHB-Ph),
4.88 (1 H, d, JA'B' 11.5, OCHA'HB'-Ph), 4.86 (1 H, d, JA'B' 11.5, OCHA'HB'-Ph), 4.83 (1 H, d,
JAB 10.7, OCHAHBC6H4OCH3), 4.77 (1 H, d, J AB 11.3, OCHAHB-Ph), 4.67 (1 H, d, JAB
10.7, OCHAHBC6H4OCH3), 4.30 (2 H, m, CH2CH=CH2), 3.98 (1 H, dd, J 2.4, 2.4, inositol
ring 2-H), 3.88 (1 H, dd, J 9.2, 9.2, inositol ring 6-H), 3.81-3.77 (1 H, m, inositol ring 1-H),
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3.80 (3 H, s, OCH3), 3.75 (1 H, dd, J 9.2, 9.2, inositol ring 4-H), 3.51-3.48 (1 H, m,
inositol ring 3-H), 3.32 (1 H, dd, J 9.2, 9.2 inositol ring 5-H), 2.20 (1 H, br s, OH), 1.09-
1.05 (21 H, m, 3 × SiCH, 18 × SiCHCH3). The data are in agreement with the values
reported for (±)-75.
(+)-1D-2,6-bis-O-Benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-myo-inositol
(+)-68
OBn
OH
BnO
HO
OPMB
OTIPS
(+)-68
A stirred solution of (+)-1D-5-O-allyl-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-
triisopropylsilyl-myo-inositol (+)-75 (1.63 g, 2.41 mmol, 1 equiv.), Wilkinson’s catalyst
(557 mg, 0.60 mmol, 0.25 equiv.) and diisopropylethyl amine (342 mg, 461 μL,
2.65 mmol, 1.1 equiv.) in absolute ethanol (25 mL) was heated under reflux for 3 h.
Analysis by 1H NMR showed that full isomerisation of the allyl double bonds had
occurred. The reaction mixture was then filtered through a pad of Celite and
concentrated under reduced pressure. The residue was dissolved in methanol (8 mL)
and dichloromethane (5 mL) and acetyl chloride (57 mg, 52 μL, 0.72 mmol, 0.3 equiv.)
was added. The mixture was stirred for 4 h after which the reaction was quenched with
triethylamine (2 mL). All volatile components were removed in vacuo and the residue
partitioned between ethyl acetate (20 mL) and water (20 mL). The aqueous phase was
extracted with ethyl acetate (3 × 20 mL) and the combined organic extracts were
washed with aqueous saturated sodium bicarbonate solution (40 mL) and brine (40 mL),
dried (MgSO4), filtered and concentrated in vacuo. Purification of the crude product by
silica gel column chromatography, eluting with ethyl acetate and petroleum ether (15:85,
25:75 then 40:60) gave the desired product (+)-1D-2,6-bis-O-benzyl-4-O-(4'-
methoxybenzyl)-1-O-triisopropylsilyl-myo-inositol (+)-68 (74 mg, 5% yield) as a
colourless gum, and 2,6-bis-O-benzyl-1-O-triisopropylsilyl myo-inositol (+)-120 (658 mg)
as an undesired by-product. Data for compound (+)-68: 20D[α] +28.6, (c 0.9 in CHCl3); δH
(300 MHz, CDCl3) 7.39-7.25 (10 H, m, 2 × Ph), 7.26 (2 H, d, J 8.6, C6H4OCH3), 6.87 (2
H, d, J 8.6, C6H4OCH3), 5.02 (1 H, d, J AB 11.3, OCHAHB-Ph), 4.99 (1 H, d, JA'B' 11.6,
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OCHA'HB'-Ph), 4.83 (1 H, d, JAB 10.8, OCHAHBC6H4OCH3), 4.80 (1 H, d, J AB 11.3,
OCHAHB-Ph), 4.73 (1 H, d, JA'B' 11.6, OCHA'HB'-Ph) 4.67 (1 H, d, JAB 10.8,
OCHAHBC6H4OCH3), 3.98 (1 H, dd, J 2.0, 2.0, inositol ring 2-H), 3.89-3.78 (2 H, m,
inositol ring 3-H, 4-H), 3.81 (3 H, s, OCH3), 3.67-3.65 (1 H, m, inositol ring 6-H), 3.58-
3.47 (2 H, m, inositol ring 1-H, 5-H), 2.34 (1 H, br s, OH), 2.28 (1 H, d, J 4.7, OH), 1.11-
1.09 (21 H, m, 3 × SiCH, 18 × SiCHCH3). The data are in agreement with the values
reported for (±)-68. Data for compound (+)-120: 20D[α] +14.1 (c 1.1 in CHCl3) δH (300
MHz, CDCl3) 7.37-7.27 (10 H, m, 2 × Ph), 5.09 (1 H, d, J AB 11.1, OCHAHB-Ph), 4.96 (1
H, d, JA'B' 11.7, OCHA'HB'-Ph), 4.78 (1 H, d, JA'B' 11.7, OCHA'HB'-Ph) 4.78 (1 H, d, JAB
11.1, OCHAHB-Ph), 4.00 (1 H, dd, J 2.1, 2.1, inositol ring 2-H), 3.89 (1 H, dd, J 9.4, 2.1,
inositol ring 1-H), 3.78 (1 H, dd, J 9.0, 9.0, inositol ring 6-H), 3.73 (1 H, dd, J 9.0, 9.0,
inositol ring 4-H), 3.50-3.47 (1 H, m, inositol ring 3-H), 3.37-3.34 (1 H, m, inositol ring 5-
H), 2.99 (1 H, br s, OH), 2.58 (2 H, br s, 2 × OH), 1.14-1.10 (21 H, m, 3 × SiCH, 18 ×
SiCHCH3). The data are in agreement with the values reported for the synthesis of 2,6-
bis-O-benzyl-1-O-triisopropylsilyl myo-inositol (+)-120 below.
(-)-1D-2,6-bis-O-Benzyl-4-O-(4'-methoxybenzyl)-1,3,5-tris(dibenzylphosphate)-myo-
inositol (-)-105
OBn
O
BnO
O
OPMB
O
P P
OBn
BnO
O O
P
O
OBn
OBn
OBn
OBn
(-)-105
To a solution of (+)-1D-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-1-O-triisopropylsilyl-
myo-inositol (+)-68 (71 mg, 0.11 mmol, 1.0 equiv.) in THF (2 mL) was added
tetrabutylammonium fluoride (1 M in THF, 134 μL, 1.2 equiv.). The mixture was stirred
for 2.5 h after which the reaction was adjudged to be complete by TLC analysis. The
mixture was diluted with diethyl ether (5 mL). Water (5 mL) was added and the layers
separated and the aqueous phase was extracted with diethyl ether (3 × 5 mL). The
combined organic extracts were washed with aqueous saturated bicarbonate solution
(10 mL) and brine (10 mL), dried (MgSO4), filtered and concentrated. The crude product
was passed through a silica plug, eluting with ethyl acetate/hexane (35:75, then 70:30).
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The inositol material obtained was then dissolved in dichloromethane (1 mL). This
solution was added to a stirred mixture of 1H-tetrazole (3 % w/v in acetonitrile, 1.0 mL,
0.45 mmol, 6.0 equiv.) and bis(benzyloxy)-N,N-diisopropylamino phosphine (155 mg,
0.45 mmol, 6.0 equiv.) in dichloromethane (2 mL). After 18 h, bis(benzyloxy)-N,N-
diisopropylamino phosphine (52 mg, 0.15 mmol, 2 equiv.) in dichloromethane (1 mL)
was added via cannula, followed by 1H-tetrazole in acetonitrile (3% w/v, 350 μL, 0.15
mmol, 2 equiv.), and the mixture was stirred for 3 h. The mixture was cooled to -78 °C
and 3-chloroperbenzoic acid (assume 60 %, 173 mg, 0.60 mmol, 8.0 equiv.) was added.
The temperature was raised to RT and the mixture stirred for 2 h. The 3-
chloroperbenzoic acid was quenched with a 10 % aqueous solution of sodium bisulfite
(3 mL). The mixture was stirred for 10 min and the organic and aqueous phases were
separated. The aqueous layer was extracted with dichloromethane (3 × 5 mL). The
combined organic extracts were washed with saturated aqueous sodium bicarbonate
solution (10 mL), brine (10 mL), dried (MgSO4), filtered and concentrated under reduced
pressure. Purification by silica gel chromatography, eluting with ethyl acetate and
hexane (40:60, 50:50 then 60:40) gave (-)-1D-2,6-bis-O-benzyl-4-O-(4'-methoxybenzyl)-
1,3,5-tris(dibenzylphosphate)-myo-inositol (-)-105 (56 g, 40% yield over two steps) as a
colourless gum. 20D[α] -1.3 (c 1.1 in CHCl3); δH (400 MHz, CDCl3) 7.42-7.40 (2 H, m, Ph),
7.37-7.15 (36 H, m, 34 × Ph, 2 × C6H4OCH3), 7.10-7.05 (4 H, m, Ph), 6.76 (2 H, d, J 8.7,
C6H4OCH3), 5.00-4.71 (18 H, m, 16 × OCH2Ph, 2 × OCH2C6H4OCH3), 4.59 (1 H, dd, J
2.4, 2.4, inositol ring 2-H), 4.42 (1 H, ddd, J 9.2, 9.2, 9.2, inositol ring 5-H), 4.34-4.26 (2
H, m, inositol ring 1-H and 3-H), 4.10 (2 H, dd, J 9.5, 9.5, inositol ring 4-H and 6-H), 3.70
(3 H, s, OCH3); δP (121 MHz, CDCl3) -1.4, -1.6 (2 P). The data are in agreement with the
values reported for (±)-105.
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(-)-1D-2,6-bis-O-Benzyl-1,3,5-tris(dibenzylphosphate)-myo-inositol (-)-106
OBn
O
BnO
O
OH
O
P P
OBn
BnO
O O
P
O
OBn
OBn
OBn
OBn
(-)-106
(-)-1D-2,6-bis-O-Benzyl-4-O-(4'-methoxybenzyl)-1,3,5-tris(dibenzylphosphate)-myo-
inositol (-)-105 (55 mg, 0.044 mmol, 1.equiv.) was reacted with ceric ammonium nitrate
(1.10 g, 2.02 mmol, 2.5 equiv.) in acetonitrile (20 mL) and water (5 mL) using the
procedure described for compound (±)-106 to give (-)-1D-2,6-bis-O-benzyl-1,3,5-
tris(dibenzylphosphate)-myo-inositol (-)-106 (36 mg, 72% yield) as a colourless gum.
20
D[α] -5.1, (c 1.8 in CHCl3); δH (300 MHz, CDCl3) 7.35-7.14 (40 H, m, Ph), 5.13 (1 H, s,
OCH2Ph), 5.11 (1 H, s, OCH2Ph), 5.05-4.99 (4 H, m, OCH2Ph), 4.98-4.85 (6 H, m,
OCH2Ph), 4.72 (2 H, s, OCH2Ph), 4.68 (2 H, s, OCH2Ph), 4.57 (1 H, br s, OH), 4.34-4.33
(1 H, m, inositol ring), 4.27-4.16 (4 H, m, 4 × inositol ring), 3.99 (1 H, dd, J 9.3, 9.3,
inositol ring); δP (121 MHz, CDCl3) 0.2, -1.1, -1.8. The data are in agreement with the
values reported for (±)-106.
(±)-2,6-bis-O-Benzyl-1-O-triisopropylsilyl-myo-inositol 120
OBn
OH
BnO
HO
OH
OTIPS
120
A stirred solution of (±)-5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-inositol 70
(1.82 g, 3.27 mmol, 1 equiv.), Wilkinsons catalyst (303 g, 0.33 mmol, 0.1 equiv.) and
diisopropylethyl amine (422 mg, 569 μL, 3.33 mmol, 1.0 equiv.) in absolute ethanol (25
mL) was heated under reflux for 3 h. Analysis by 1H NMR showed that full isomerisation
of the allyl double bond had occurred. The reaction mixture was then filtered through a
pad of Celite and concentrated under reduced pressure. The residue was dissolved in
methanol (20 mL) and 4-toluenesulfonic acid (186 mg, 0.98 mmol, 0.3 equiv.) was
added. The mixture was stirred for 2 h after which 4-toluenesulfonic acid (124 mg, 0.65
mmol, 0.2 equiv.) was again added. The mixture was stirred for a further 2 h and the
reaction was then quenched with triethylamine (3 mL). All volatile components were
removed in vacuo and the residue partitioned between ethyl acetate (30 mL) and water
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(20 mL). The aqueous phase was extracted with ethyl acetate (3 × 30 mL) and the
combined organic extracts were washed with aqueous saturated sodium bicarbonate
solution (50 mL) and brine (50 mL), dried (MgSO4), filtered and concentrated in vacuo.
Purification of the crude product by silica gel column chromatography, eluting with ethyl
acetate and hexane (25:75, 30:70 then 40:60) gave (±)-2,6-bis-O-benzyl-1-O-
triisopropylsilyl-myo-inositol 120 (902 mg, 53%) as a colourless oil. Rf 0.14 (ethyl
acetate/petroleum ether 50:50); δH (300 MHz, CDCl3) 7.38-7.28 (10 H, m, 2 × Ph), 5.09
(1 H, d, JAB 11.1, OCHAHB-Ph), 4.96 (1 H, d, JA'B' 11.7, OCHA'HB'-Ph), 4.78 (1 H, d, JA'B'
11.7, OCHA'HB'-Ph) 4.77 (1 H, d, JAB 11.1, OCHAHB-Ph), 4.00 (1 H, dd, J 2.2, 2.2, inositol
ring 2-H), 3.88 (1 H, dd, J 9.4, 2.2, inositol ring 1-H), 3.78 (1 H, dd, J 9.0, 9.0, inositol
ring 6-H), 3.73 (1 H, dd, J 9.0, 9.0, inositol ring 4-H), 3.49-3.47 (1 H, m, inositol ring 3-H),
3.36 (1 H, ddd, J 9.0, 9.0, 1.9, inositol ring 5-H), 2.99 (1 H, d, J 1.8, OH), 2.59 (1 H, d, J
1.9, OH), 2.55 (1 H, d, J 7.6, OH), 1.16-1.08 (21 H, m, 3 × SiCH, 18 × SiCHCH3). The
data are in agreement with the values reported for (+)-120.
(±)-2,6-bis-O-Benzyl-1-O-triisopropylsilyl-3,4,5-tris(dibenzylphosphate)-myo-
inositol 124
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(±)-2,6-bis-O-Benzyl-1-O-triisopropylsilyl-3,4,5-tris(dibenzylphosphate)-myo-inositol 124
(1.46 g, 74% yield) was obtained from (±)-2,6-bis-O-benzyl-1-O-triisopropylsilyl-myo-
inositol 120 (783 mg, 1.51 mmol) using the procedure described for (+)-124. Rf 0.68
(ethyl actate/petroleum ether 60:40); δH (400 MHz, CDCl3) 7.41-7.11 (38 H, m, Ph),
6.90-6.88 (2 H, m, Ph), 5.15-4.74 (15 H, m, 14 × CH2Ph, 1 × inositol ring 4-H), 4.81 (1 H,
dd, J 11.8, 7.4, CHAHBPh), 4.61 (1 H, ddd, J 9.4, 9.4, 9.4, inositol ring 5-H), 4.56 (1 H,
dd, J 11.8, 8.6, CHAHBPh), 4.44 (1 H, dd, J 1.9, 1.9, inositol ring 2-H), 4.30 (1 H, ddd, J
9.4, 7.1, 1.9, inositol ring 3-H), 4.03 (1 H, dd, J 9.4, 9.4, inositol ring 6-H), 3.91 (1 H, dd,
J 9.4, 1.9, inositol ring 1-H), 1.07-1.04 (21 H, m, 3 × SiCH, 18 × SiCHCH3); δP (121 MHz,
CDCl3) -1.3 (2 P), -1.7; HRMS m/z (ES+) [Found: (M+NH4)+ 1314.5063. C71H87O15NP3Si
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requires M+ 1314.5052], m/z (ES+) 1297 ([M+H]+, 100%). The data are in agreement
with the values reported for (+)-124.
(±)-2,6-bis-O-Benzyl-3,4,5-tris(dibenzylphosphate)-myo-inositol 125183
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(±)-2,6-bis-O-Benzyl-3,4,5-tris(dibenzylphosphate)-myo-inositol 125 (953 g, 80% yield)
was obtained from (±)-2,6-bis-O-benzyl-1-O-triisopropylsilyl-3,4,5-
tris(dibenzylphosphate)-myo-inositol 124 (1.36 g, 1.05 mmol) using the procedure
described for compound (-)-125. Rf 0.24 (ethyl acetate/petroleum ether 60:40); δH (400
MHz, CDCl3) 7.35-7.14 (40 H, m, Ph), 5.15-4.95 (12 H, m, 11 × CH2Ph, 1 × inositol ring
4-H), 4.89-4.79 (3 H, m, CH2Ph), 4.70-4.64 (2 H, m, CH2Ph), 4.47 (1 H, ddd, J 9.5, 9.5,
9.5, inositol ring 5-H), 4.30 (1 H, dd, J 2.5, 2.5, inositol ring 2-H), 4.26 (1 H, ddd, J 9.5,
7.7, 2.5, inositol ring 3-H), 3.84 (1 H, dd, J 9.5, 9.5, inositol ring 6-H), 3.52 (1 H, ddd, J
9.5, 6.2, 2.5, inositol ring 1-H), 1.94 (1 H, d, J 6.2, OH); δP (162 MHz, CDCl3) -1.2, -1.3, -
1.9; m/z (ES+) [Found: (M+NH4)+ 1158.3702. C62H67O15NP3 requires M+ 1158.3718],
m/z (ES+) 1141 (M+, 100%). The data are in agreement with the values reported in the
literature.183
(±)-2,6-bis-O-Benzyl-3,4,5-tris(dibenzylphosphate)-1-sulfate-myo-inositol sodium
salt 126
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A solution of (±)-2,6-bis-O-benzyl-3,4,5-tris(dibenzylphosphate)-myo-inositol 125 (96 mg,
0.084 mmol, 1.0 equiv.) and sulfur trioxide pyridine complex (131 mg, 0.84 mmol, 10
equiv.) in DMF (1 mL) was heated to 50 °C for 8 h. After this time, the reaction was
adjudged to be complete by TLC analysis. Triethylamine (1 mL) and methanol (2 mL)
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was added and the solvent was removed in vacuo. The residue was subjected to silica
gel column chromatography eluting with ethyl acetate/hexane (80:20 then 100 % ethyl
acetate) then methanol/chloroform (5:95). The purified product was dissolved in
methanol (5 mL) and stirred with Dowex Marathon C sodium form resin for 20 min. The
resin was removed by filtration and washed with methanol (3 mL) and methanol/water (3
mL). Water (2 mL) was added to the filtrate which was freeze-dried to give (±)-2,6-bis-O-
benzyl-3,4,5-tris(dibenzylphosphate)-1-sulfate-myo-inositol sodium salt 126 (46 mg, 44%
yield) as a hygroscopic, colourless solid. δH (300 MHz, CD3OD) 7.56 (2 H, d, J 7.6, Ph),
7.42 (2 H, d, J 7,6, Ph), 7.31-7.08 (36 H, m, Ph), 516-4.55 (21 H, m, 16 × CH2Ph, 5 ×
inositol ring), 4.07 (1 H, dd, J 9.8, 9.8, inositol ring); δC (75 MHz, CD3OD) 140.2 (C),
139.7 (C), 137.3-136.9 (6 C, m, 6 × ArC), 130.1 (CH), 129.7 (CH), 129.6 (CH), 129.51
(CH), 129.49 (CH), 129.47 (CH), 129.43 (CH), 129.36 (CH), 129.3 (CH), 129.2 (CH),
129.15 (CH), 129.1 (CH), 129.0 (CH), 128.8 (CH), 128.5 (CH), 128.4 (CH), 80.0 (1 C, d,
2JP-C 4.9, CH), 79.2 (CH), 78.5-78.7 (1 C, m, CH), 78.4 (CH), 78.2 (CH), 77.0 (CH2), 76.8
(CH), 75.2 (CH2), 71.4 (1 C, d, 2JP-C 6.0, CH2), 71.2-70.9 (4 C, m, 4 × CH2), 70.7 (1 C, d,
2JP-C 5.6, CH2); δP (121 MHz, CD3OD) −2.4, −2.8, −3.0. The data are in agreement with
the values reported for (+)-126.
(±)-2,6-bis-O-Benzyl-1-(dibenzyl)methylenephosphonate-3,4,5-
tris(dibenzylphosphate)-myo-inositol 133
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Dibenzyl phosphonomethyl triflate 131 (160 mg, 0.38 mmol, 3.0 equiv.) in THF (1 mL)
was added to a solution of (±)-2,6-bis-O-benzyl-3,4,5-tris(dibenzylphosphate)-myo-
inositol 125 (145 mg, 0.127 mmol, 1.0 equiv.) in THF (1 mL). The mixture was cooled to
-78 °C and sodium hydride (60 % dispersion in mineral oil, 8 mg, 1.6 equiv.) was added,
and the reaction monitored by TLC analysis. After stirring at -78 °C for 1 h, the mixture
was allowed to warm to -15 °C and the mixture was stirred at this temperature for 1 h.
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The reaction temperature was then raised to RT and stirred for a further 2 h. After this
time, the reaction was observed to be incomplete by TLC analysis. The mixture was
cooled to -78 °C and sodium hydride (60 % dispersion in mineral oil, 8 mg, 1.6 equiv.)
was added. The mixture was allowed to warm to RT and stirred for a further 2 h. After
this time, the reaction was adjudged to be complete by TLC analysis. The mixture was
diluted with diethyl ether (5 mL) and quenched by the addition of aqueous saturated
sodium bicarbonate solution (3 mL). The layers were separated and the aqueous phase
was extracted with diethyl ether (3 × 5 mL). the combined organic extracts were washed
with brine, dried (MgSO4), filtered and concentrated. Repeated silica gel column
chromatography, eluting with ethyl acetate and hexane (50:50, 60:40, 70:30 then 80:20)
gave (±)-2,6-bis-O-benzyl-1-(dibenzyl)methylenephosphonate-3,4,5-
tris(dibenzylphosphate)-myo-inositol 133 (43 mg, 24% yield) as a colourless gum. Rf
0.24 (ethyl acetate/petroleum ether 60:40); νmax (thin film)/cm-1 3475 (m), 3065 (m), 3034
(m), 2956 (m), 1456 (s), 1274 (s), 1019 (s); δH (300 MHz, CDCl3) 7.44-7.20 (48 H, m,
Ph), 7.07-7.04 (2 H, m, Ph), 5.19-4.69 (21 H, m, 20 × CH2Ph, 1 × inositol ring 4-H), 4.51
(1 H, ddd, J 9.5, 9.5, 9.5, inositol ring 5-H), 4.50 (1 H, dd, J 2.3, 2.3, inositol ring 2-H),
4.24 (1 H, ddd, J 9.6, 7.3, 2.3, inositol ring 3-H), 4.07 (1 H, dd, J 9.5, 9.5, inositol ring 6-
H), 3.85 (1 H, dd, J 13.6, 9.2, CH2P), 3.77 (1 H, dd, J 13.6, 8.6, CH2P), 3.34 (1 H, dd, J
9.5, 2.5, inositol ring 1-H); δC (75 MHz, CDCl3) 138.4 (C), 138.3 (C), 136.3-135.5 (8 C,
m, P(O)OCH2Ph), 128.6 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 128.1
(CH), 128.11 (CH), 128.07 (CH), 128.0 (CH), 127.95 (CH), 127.9 (CH), 127.6 (CH),
127.5 (CH), 127.4 (CH), 127.2 (CH), 82.8 (CH, inositol ring), 82.6 (CH, inositol ring),
78.5 (CH, inositol ring), 76.4 (CH, inositol ring), 75.8 (CH, inositol ring), 75.4 (CH, inositol
ring), 75.3 (CH2), 74.7 (CH2), 69.8 (1 C, d, 2JP-C 5.7, CH2Ph), 69.7 (1 C, d, 2JP-C 5.7,
CH2Ph), 69.6 (1 C, d, 2JP-C 5.5, CH2Ph), 69.5 (1 C, d, 2JP-C 5.0, CH2Ph), 69.4 (1 C, d, 2JP-
C 5.6, CH2Ph), 69.2 (1 C, d, 2JP-C 5.2, CH2Ph), 68.0 (1 C, d, 2JP-C 6.6, CH2Ph), 67.8 (1 C,
d, 2JP-C 6.6, CH2Ph), 66.4 (1 C, d, 1JP-C 167.1, CH2P(O)(OBn)2); δP (121 MHz, CDCl3)
22.6, -0.0, -0.2, -0.8; HRMS m/z (FAB) [Found: (M+NH4)+ 1432.4498. C77H82O18NP4
requires M+ 1432.4477]; m/z (ES+) 1432 ([M+NH4]+, 100%).
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(±)-1-Methylenephosphonate-myo-inositol 3,4,5-trisphosphate octakis-sodium salt
134
OH
O
HO
O
O
O
P
O-Na+
PO O-Na+
O
O-Na+P
O
+Na-O O-Na+
O-Na+
P
O
O-Na+
O-Na+
134
Palladium black (65 mg, 0.68 mmol, 20 equiv.) and sodium bicarbonate (20.4 mg, 0.24
mmol, 8 equiv.) were added to a solution of (±)-2,6-bis-O-benzyl-1-
(dibenzyl)methylenephosphonate-3,4,5-tris(dibenzylphosphate)-myo-inositol 133
(43 mg, 30.4 μmol, 1 equiv.) in t-butanol (3.0 mL) and water (0.5 mL) under nitrogen.
The mixture was then placed under hydrogen and stirred for 3 h. The organic phase was
removed and water (1 mL) was added to the black residue. The palladium was removed
by filtration and washed with water. The aqueous filtrate was freeze-dried to give (±)-1-
methylenephosphonate-myo-inositol 3,4,5-trisphosphate octakis-sodium salt 134 (19.6
mg, 93% yield) as a colourless solid. δH (300 MHz, D2O) 4.40 (1 H, d, J 2.6, inositol ring
2-H), 4.36 (1 H, ddd, J 9.4, 9.4, 9.4, inositol ring 4-H), 4.04 (1 H, ddd, J 9.4, 9.4, 2.6,
inositol ring 3-H), 3.95 (1 H, ddd, J 9.2, 9.2, 9.2 inositol ring 5-H), 3.82 (1 H, dd, J 9.5,
9.5, inositol ring 6-H), 3.77 (1 H, dd, J 12.7, 9.8, CH2P), 3.57 (1 H, dd, J 12.7, 9.8,
CH2P), 3.37 (1 H, dd, J 9.5, 2.6, inositol ring 1-H); δC (75 MHz, D2O) 80.3 (1 C, d, 2JP-C
13.5, CH), 78.3 (CH), 76.1 (CH), 74.5 (CH), 70.9 (CH), 67.2 (CH), 66.7 (1 C, d, 1JP-C
155.3, CH2); δP (162 MHz, D2O) 15.7, 1.0, 0.8, 0.3; HRMS m/z (FAB) [Found:
(M−8Na+7H)− 512.9369. C7H17O18P4 requires M− 512.9371]; m/z (ES−) 170 (100%), 513
([M−8Na+7H]−, 1%), 535 ([M−7Na+6H]−, 2%), 557 ([M−6Na+5H]−, 3%), 579
([M−5Na+6H]−, 2%).
Dibenzyl(hydroxymethyl)phosphonate 129175
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A mixture of dibenzyl phosphite (85 %, 8.26 g, 26.8 mmol, 1.0 equiv.),
paraformaldehyde (0.83 g, 26.8, mmol, 1.0 equiv.) and triethylamine (270 mg, 373 μL,
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2.7 mmol, 0.1 equiv.) was heated to 130 °C for 10 min until the mixture became clear.
The mixture was allowed to cool to RT and directly purified by silica gel column
chromatography eluting with diethyl ether then diethyl ether/ethanol (99:1) to give
dibenzyl (hydroxymethyl)phosphonate 129 (2.40 g, 31%) as a colourless oil. Rf 0.27
(diethyl ether); δH (400 MHz, CDCl3) 7.40-7.35 (10 H, m, 2 × Ph), 5.15 (2 H, dd, J 11.8,
8.8, PhCH2), 5.08 (2 H, dd, J 11.8, 8.2, CH2Ph), 3.92 (2 H, app t, J 6.3, PCH2OH), 3.17
(1 H, br s, OH); δC (75 MHz, D2O) 136.1 (C), 136.0 (C), 128.7 (CH), 128.6 (CH), 128.1
(CH), 68.1 (CH2), 68.0 (CH2), 58.6 (1 C, d, 1JP-C 160, CH2); δP (162 MHz, CDCl3) 24.8.
The data are in good agreement with literature values.175
Dibenzyl phosphonomethyl triflates 131175
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2,6-Lutidine (301 mg, 308 μL, 3.8 mmol, 1.2 equiv.) was added to a solution of dibenzyl
(hydroxymethyl)phosphonate 129 (927 mg, 3.2 mmol, 1.0 equiv.) in dichloromethane (8
mL) at -78 °C. Triflic anhydride (993 mg, 592 μL, 3.5 mmol, 1.1 equiv.) was added
dropwise and the mixture stirred at -78 °C for 1 h. The temperature was raised to -40 °C
and stirred for 1 h, then stirred at -10 °C for 1 h. The mixture was diluted with diethyl
ether (50 mL) and the precipitate was removed by filtration. The filtrate was washed with
water, 1 M HCl then brine, dried (MgSO4), filtered and concentrated. The crude oil was
purified by silica gel column chromatography, eluting with ethyl acetate/hexane (3:1).
The product obtained was again subjected to silica gel column chromatography, eluting
with diethyl ether/hexane (1:1) to give dibenzyl phosphonomethyl triflate 131 (358 mg,
26% yield) as a colourless oil. Rf 0.56 (diethyl ether); δH (400 MHz, CDCl3) 7.42-7.36 (10
H, m, 2 × Ph), 5.18 (2 H, dd, J 11.9, 9.5, CH2Ph), 5.13 (2 H, dd, J 11.6, 9.7, CH2Ph),
4.53 (2 H, d, J 9.0, PCH2OTf); δP (162 MHz, CDCl3) 13.3; δF (375 MHz, CDCl3) −73.9.
The data are in good agreement with literature values.175
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(+)-1D-2,6-bis-O-Benzyl-1-O-triisopropylsilyl myo-inositol (+)-120
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A stirred solution of (-)-1D-5-O-allyl-2,6-bis-O-benzyl-1-O-triisopropylsilyl myo-inositol (-)-
70 (1.58 g, 2.84 mmol, 1 equiv.), Wilkinsons catalyst (263 g, 0.28 mmol, 0.1 equiv.) and
diisopropylethyl amine (403 mg, 544 μL, 3.13 mmol, 1.1 equiv.) in absolute ethanol (25
mL) was heated under reflux for 3 h. Analysis by 1H NMR showed that full isomerisation
of the allyl double bond had occurred. The reaction mixture was then filtered through a
pad of Celite and concentrated under reduced pressure. The residue was dissolved in
methanol (5 mL) and dichloromethane (8 mL) and acetyl chloride (89 mg, 81 μL, 1.14
mmol, 0.4 equiv.) was added. The mixture was stirred for 4 h after which the reaction
was quenched with triethylamine (3 mL). All volatile components were removed in vacuo
and the residue partitioned between ethyl acetate (20 mL) and water (20 mL). The
aqueous phase was extracted with ethyl acetate (3 × 20 mL) and the combined organic
extracts were washed with aqueous saturated sodium bicarbonate solution (50 mL) and
brine (50 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification of the
crude product by silica gel column chromatography, eluting with ethyl acetate and
hexane (25:75, 30:70 then 40:60) gave (+)-1D-2,6-bis-O-benzyl-1-O-triisopropylsilyl
myo-inositol (+)-120 (789 mg, 54%) as a colourless oil. Rf 0.14 (ethyl acetate/petroleum
ether 50:50); 20D[α] +15.4, (c 1.8 in CHCl3); νmax (thin film)/cm
-1 3405 (s), 2943 (s), 1455
(s), 1150 (s), 1061 (s); δH (300 MHz, CDCl3) 7.38-7.28 (10 H, m, 2 × Ph), 5.09 (1 H, d, J
AB 11.1, OCHAHB-Ph), 4.96 (1 H, d, JA'B' 11.7, OCHA'HB'-Ph), 4.78 (1 H, d, JA'B' 11.7,
OCHA'HB'-Ph) 4.77 (1 H, d, JAB 11.1, OCHAHB-Ph), 4.00 (1 H, dd, J 2.2, 2.2, inositol ring
2-H), 3.89 (1 H, dd, J 9.4, 2.2, inositol ring 1-H), 3.78 (1 H, dd, J 9.0, 9.0, inositol ring 6-
H), 3.73 (1 H, dd, J 9.0, 9.0, inositol ring 4-H), 3.50-3.47 (1 H, m, inositol ring 3-H), 3.36
(1 H, ddd, J 9.0, 9.0, 1.9, inositol ring 5-H), 2.99 (1 H, d, J 1.8, OH), 2.59 (1 H, d, J 1.9,
OH), 2.55 (1 H, d, J 7.6, OH), 1.15-1.09 (21 H, m, 3 × SiCH, 18 × SiCHCH3); δC (75
MHz, CDCl3) 139.3 (C), 139.2 (C), 128.82 (CH), 128.8 (CH), 128.1 (CH), 128.0 (CH),
127.8 (CH), 82.2 (CH), 81.7 (CH), 75.8 (CH2), 75.5 (CH2), 75.3 (CH), 74.9 (CH), 74.4
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(CH), 72.7 (CH), 18.7 (CH3), 13.2 (CH); HRMS m/z (ES+) [Found: (M+H)+ 517.2978.
C29H45O6Si requires M+ 517.2980], m/z (ES+) 517 ([M+H]+, 100%).
(+)-1D-2,6-bis-O-Benzyl-1-O-triisopropylsilyl-3,4,5-tris(dibenzylphosphate)-myo-
inositol (+)-124
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1H-Tetrazole in acetonitrile (3 % w/v, 21 mL, 9.17 mmol, 6.0 equiv.) was added to a
solution of bis(benzyloxy)-N,N-diisopropylamino phosphine (3.17 g, 9.17 mmol, 6.0
equiv.) in dichloromethane (10 mL) and the mixture stirred for 10 min. A solution of (+)-
1D-2,6-bis-O-benzyl-1-O-triisopropylsilyl myo-inositol (+)-120 (789 mg, 1.53 mmol, 1.0
equiv.) in dichloromethane (10 mL) was added via cannula and the resulting mixture
stirred for 5 h. After this time, bis(benzyloxy)-N,N-diisopropylamino phosphine (1.06 g,
3.06 mmol, 2 equiv.) in dichloromethane (10 mL) was added via cannula, followed by
1H-tetrazole in acetonitrile (3% w/v, 7.00 mL, 3.06 mmol, 2 equiv.), and the mixture was
stirred for 16 h. The mixture was cooled to -78 °C and 3-chloroperbenzoic acid (assume
60%, 3.52 g, 12.25 mmol, 8.0 equiv.) was added. The temperature was raised to RT and
the mixture stirred for 2 h. The 3-chloroperbenzoic acid was quenched with a 10%
aqueous solution of sodium bisulfite (30 mL). The mixture was stirred for 10 min and the
organic and aqueous phases were separated. The aqueous layer was extracted with
dichloromethane (3 × 30 mL). The combined organic extracts were washed with
saturated aqueous sodium bicarbonate solution (50 mL), brine (50 mL), dried (MgSO4),
filtered and concentrated under reduced pressure. Purification by silica gel
chromatography, eluting with ethyl acetate and petroleum ether (15:85, 20:80, 25:75
then 35:65) gave (+)-1D-2,6-bis-O-benzyl-1-O-triisopropylsilyl-3,4,5-
tris(dibenzylphosphate)-myo-inositol (+)-124 (1.71 g, 86% yield) as a colourless gum. Rf
0.67 (ethyl acetate/petroleum ether 60:40); 20D[α] +5.5, (c 1.3 in CHCl3); νmax (thin
film)/cm-1 3033 (m), 2945 (s), 1954 (w), 1456 (s), 1278 (s), 1016 (s); δH (400 MHz,
CDCl3) 7.41-7.15 (38 H, m, Ph), 6.90-6.88 (2 H, m, Ph), 5.15-4.73 (15 H, m, 14 ×
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CH2Ph, 1 × inositol ring 4-H), 4.82 (1 H, dd, J 11.8, 7.4, CHAHBPh), 4.62 (1 H, ddd, J
9.4, 9.4, 9.4, inositol ring 5-H), 4.56 (1 H, dd, J 11.8, 8.6, CHAHBPh), 4.44 (1 H, dd, J 1.9,
1.9, inositol ring 2-H), 4.30 (1 H, ddd, J 9.5, 7.1, 1.9, inositol ring 3-H), 4.03 (1 H, dd, J
9.4, 9.4, inositol ring 6-H), 3.91 (1 H, dd, J 9.4, 1.9, inositol ring 1-H), 1.07-1.04 (21 H, m,
3 × SiCH, 18 × SiCHCH3); δC (75 MHz, CDCl3) 139.2 (C), 139.1 (C), 136.7 (1 C, d, 2JP-C
7.7, C), 136.6 (1 C, d, 2JP-C 7.1, C), 136.5 (1 C, d, 2JP-C 8.2, C), 136.2 (1 C, d, 2JP-C 7.2,
C), 136.1 (1 C, d, 2JP-C 7.3, C), 136.0 (1 C, d, 2JP-C 8.2, C), 129.0 (CH), 128.8 (CH),
128.7 (CH), 128.66 (CH), 128.6 (CH), 128.56 (CH), 128.5 (CH), 128.4 (CH), 128.37
(CH), 128.3 (CH), 128.2 (CH), 127.9 (CH), 127.7 (CH), 127.0 (CH), 126.7 (CH), 80.5
(CH), 79.8 (CH), 77.4-77.2 (CH), 76.8 (CH), 75.9 (CH2), 75.2 (CH2), 73.9 (CH), 70.2
(1 C, d, 2JP-C 5.7, CH2), 70.0-69.8 (3 C, m, CH2), 69.8 (1 C, d, 2JP-C 5.9, CH2), 69.4 (1
C, d, 2JP-C 5.0, CH2), 18.6 (CH3), 13.1 (CH); δP (121 MHz, CDCl3) -1.4, -1.5, -1.9; HRMS
m/z (FAB) [Found: (M+H)+ 1297.4777. C71H84O15P3Si requires M+ 1297.4787], m/z
(ES+) 149 (100%), 1298 ([M+H]+, 40%); Anal. calcd for C71H83O15P3Si: C, 65.73%; H
6.45%. Found: C, 65.49%; H, 6.67%.
(-)-1D-2,6-bis-O-Benzyl-3,4,5-tris(dibenzylphosphate)-myo-inositol (-)-125183
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To a solution (+)-1D-2,6-bis-O-benzyl-1-O-triisopropylsilyl-3,4,5-tris(dibenzylphosphate)-
myo-inositol (+)-124 (1.71 g, 1.32 mmol, 1.0 equiv.) in THF (20 mL) was added
tetrabutylammonium fluoride (1 M solution in THF, 1.6 mL, 1.58 mmol, 1.2 equiv.) and
the solution was stirred for 1.5 h. The solution was diluted with ether (50 mL) and water
was added (40 mL). The layers were separated and the aqueous phase was extracted
with ether (3 × 50 mL). The combined extracts were washed with brine (80 mL), dried
(MgSO4) and filtered. The crude product was adsorbed onto silica and purified by silica
gel column chromatography, eluting with ethyl acetate and petroleum ether (40:60,
60:40 then 80:20) to give (-)-1D-2,6-bis-O-benzyl-3,4,5-tris(dibenzylphosphate)-myo-
inositol (-)-125 (1.22 g, 81% yield) as a colourless gum. Rf 0.24 (ethyl acetate/petroleum
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ether 60:40); 20D[α] −8.9 (c 1.1 in CHCl3), [Lit.,
183 20
D[α] −8.2, (c 1.0 in CHCl3)]; νmax (thin
film)/cm-1 3379 (s), 3065 (m), 3034 (m), 2954 (m), 1456 (s), 1273 (s), 1017 (s); δH (400
MHz, CDCl3) 7.40-7.19 (40 H, m, Ph), 5.18-4.99 (12 H, m, 11 × CH2Ph, 1 × inositol ring
4-H), 4.93-4.84 (3 H, m, CH2Ph), 4.75-4.70 (2 H, m, CH2Ph), 4.51 (1 H, ddd, J 9.5, 9.5,
9.5, inositol ring 5-H), 4.35 (1 H, dd, J 2.5, 2.5, inositol ring 2-H), 4.31 (1 H, ddd, J 10.0,
7.6, 2.5, inositol ring 3-H), 3.89 (1 H, dd, J 9.5, 9.5, inositol ring 6-H), 3.58 (1 H, dd, J
9.5, 2.5, inositol ring 1-H); δC (101 MHz, CDCl3) 138.24 (C), 138.23 (C), 136.2 (1 C, d,
2JP-C 7.3, C), 136.1 (1 C, d, 2JP-C 6.8, C), 136.0 (1 C, d, 2JP-C 7.3, C), 135.9 (1 C, d, 2JP-C
7.3, C), 135.7 (1 C, d, 2JP-C 6.8, C), 135.5 (1 C, d, 2JP-C 7.3, C), 128.6 (CH), 128.5 (CH),
128.4 (CH), 128.3 (CH), 128.25 (CH), 128.17 (CH), 128.15 (CH), 128.1 (CH), 128.0
(CH), 127.80 (CH), 127.78 (CH), 127.76 (CH), 79.6 (CH), 78.5 (CH), 77.8 (CH), 76.3
(CH), 76.2 (CH), 75.6 (CH2), 74.8 (CH2), 71.4 (CH), 69.8 (1 C, d, 2JP-C 5.8, CH2), 69.7 (1
C, d, 2JP-C 5.8, CH2), 69.63 (1 C, d, 2JP-C 5.8, CH2), 69.57 (1 C, d, 2JP-C 5.8, CH2), 69.5 (1
C, d, 2JP-C 5.3, CH2), 69.4 (1 C, d, 2JP-C 5.3, CH2); δP (162 MHz, CDCl3) -1.2, -1.3, -1.9;
HRMS m/z (ES+) [Found: (M+Na)+ 1163.3290. C62H63O15NaP3 requires M+ 1163.3272],
m/z (ES+) 1163 ([M+Na]+, 100%); Anal. calcd for C62H63O15P3: C, 65.26 %; H 5.56%.
Found: C, 65.09%; H, 5.42%. The data are in agreement with the literature values.183
(-)-1D-2,6-bis-O-Benzyl-1-(dibenzyl)methylenephosphonate-3,4,5-
tris(dibenzylphosphate)-myo-inositol (-)-133
OBn
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(-)-133
Dibenzyl phosphonomethyl triflate 131 (195 mg, 0.46 mmol, 3.0 equiv.) in THF (1 mL)
was added to a solution of (-)-1D-2,6-bis-O-benzyl-3,4,5-tris(dibenzylphosphate)-myo-
inositol (-)-125 (175 mg, 0.153 mmol, 1.0 equiv.) in THF (1 mL). The mixture was cooled
to -15 °C and sodium hydride (60 % dispersion in mineral oil, 9 mg, 1.5 equiv.) was
added. After stirring at -15 °C for 1.5 h, the mixture was allowed to warm to RT and
stirred for a further 1 h. After this time, the reaction was adjudged to be complete by TLC
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analysis. The mixture was diluted with diethyl ether (5 mL) and quenched by the addition
of aqueous saturated sodium bicarbonate solution (3 mL). The layers were separated
and the aqueous phase was extracted with diethyl ether (3 × 5 mL). the combined
organic extracts were washed with brine, dried (MgSO4), filtered and concentrated.
Repeated silica gel column chromatography, eluting with ethyl acetate and hexane
(50:50, 60:40, 70:30 then 80:20) gave (-)-1D-2,6-bis-O-benzyl-1-
(dibenzyl)methylenephosphonate-3,4,5-tris(dibenzylphosphate)-myo-inositol (-)-133 (61
mg, 28% yield) as a colourless gum. Rf 0.24 (ethyl acetate/petroleum ether 60:40); 20D[α]
−6.6 (c 1.2 in CHCl3); νmax (thin film)/cm-1 3476 (m), 3065 (m), 3034 (m), 2956 (m), 1456
(s), 1274 (s), 1019 (s), 737 (s), 697 (s); δH (400 MHz, CDCl3) 7.40-7.23 (48 H, m, Ph),
7.05-7.03 (2 H, m, Ph), 5.13-4.80 (21 H, m, 20 × CH2Ph, 1 × inositol ring 4-H), 4.52-4.45
(2 H, m, inositol ring 2-H, 5-H), 4.25-4.23 (1 H, m, inositol ring 3-H), 4.04 (1 H, dd, J 9.5,
9.4, inositol ring 6-H), 3.85-3.75 (2 H, m, CH2P), 3.35 (1 H, m, inositol ring 1-H); δC (75
MHz, CDCl3) 138.8 (C), 138.7 (C), 136.6-136.0 (8 C, m, P(O)OCH2Ph), 129.0 (CH),
128.9 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 128.54 (CH), 128.5 (CH), 128.4 (CH),
128.34 (CH), 128.3 (CH), 128.0 (CH), 127.8 (CH), 127.6 (CH), 83.2 (CH, inositol ring),
83.0 (CH, inositol ring), 78.9 (CH, inositol ring), 76.7 (CH, inositol ring), 76.2 (CH, inositol
ring), 75.8 (CH, inositol ring), 75.7 (CH2), 75.1 (CH2), 70.2-69.6 (6 C, m, CH2Ph), 68.4 (1
C, d, 2JP-C 6.3, CH2Ph), 68.2 (1 C, d, 2JP-C 6.3, CH2Ph), 66.8 (1 C, d, 1JP-C 166.9,
CH2P(O)(OBn)2); δP (121 MHz, CDCl3) 21.4, -1.20, -1.4, -2.0; HRMS m/z (FAB) [Found:
(M+Na)+ 1437.4019. C77H78O18NaP4 requires M+ 1437.4031]; m/z (ES+) 1437 ([M+Na]+,
100%).
(+)-1D-2,6-bis-O-Benzyl-3,4,5-tris(dibenzylphosphate)-1-sulfate-myo-inositol
sodium salt (+)-126
OBn
O
BnO
O
O
O
P
P
O
OBn
OBn
O
BnO OBn PO
OBn
OBn
S
O-Na+O
O
(+)-126
A solution of (-)-1D-2,6-bis-O-benzyl-3,4,5-tris(dibenzylphosphate)-myo-inositol (-)-125
(89 mg, 0.078 mmol, 1.0 equiv.) and sulfur trioxide pyridine complex (122 mg, 0.781
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mmol, 10 equiv.) in DMF (2 mL) was heated to 50 °C for 20 h. After this time, the
reaction was adjudged to be complete by TLC analysis. Triethylamine (1 mL) and
methanol (2 mL) was added and the solvent was removed in vacuo. Silica gel column
chromatography, eluting with ethyl acetate/hexane (70:30, 80:20 then 100% ethyl
acetate) then methanol/chloroform (5:95), gave a colourless gum. The gum was
dissolved in methanol (6 mL) and stirred with Dowex Marathon C sodium form resin for 1
h. The resin was removed by filtration and washed with methanol (5 mL) and
methanol/water (2 mL). Water (2 mL) was added to the filtrate which was freeze-dried to
give (+)-1D-2,6-bis-O-benzyl-3,4,5-tris(dibenzylphosphate)-1-sulfate-myo-inositol sodium
salt (+)-126 (66 mg, 68% yield) as a hygroscopic, colourless solid. Rf 0.25
(methanol/chloroform 10:90); 20D[α] +8.8 (c 1.2 in MeOH); νmax (thin film)/cm
-1 3463 (m),
3034 (m), 1456 (m), 1264 (s), 1016 (s); δH (300 MHz, CD3OD) 7.58 (2 H, d, J 7.6, Ph),
7.45 (2 H, d, J 7.6, Ph), 7.32-7.11 (36 H, m, Ph), 5.18-4.56 (21 H, m, 16 × CH2Ph, 5 ×
inositol ring), 4.09 (1 H, dd, J 9.8, 9.8, inositol ring); δC (75 MHz, CD3OD) 140.2 (C),
139.7 (C), 137.3-136.9 (6 C, m, 6 × ArC), 130.1 (CH), 129.7 (CH), 129.6 (CH), 129.51
(CH), 129.49 (CH), 129.47 (CH), 129.43 (CH), 129.36 (CH), 129.3 (CH), 129.2 (CH),
129.15 (CH), 129.1 (CH), 129.0 (CH), 128.8 (CH), 128.5 (CH), 128.4 (CH), 80.0 (1 C, d,
2JP-C 4.9, CH), 79.2 (CH), 78.5-78.7 (1 C, m, CH), 78.4 (CH), 78.2 (CH), 77.0 (CH2), 76.8
(CH), 75.2 (CH2), 71.4 (1 C, d, 2JP-C 6.0, CH2), 71.2-70.9 (4 C, m, 4 × CH2), 70.7 (1 C, d,
2JP-C 5.6, CH2); δP (121 MHz, CD3OD) −2.1, −2.68, −2.72; HRMS m/z (FAB) [Found:
(M−Na+2H)+ 1221.3041. C62H62O18P3S requires M+ 1221.3021]; m/z (ES+) 1238
([M−Na+H+NH4]+, 100%).
(-)-1D-myo-Inositol-1-sulfate-3,4,5-trisphosphate tetrakis-sodium salt (-)-135
OH
O
HO
O
O
O
P
OH
PO O-Na+
S
O-Na+O
O
O
O-Na+P
O
O-Na+HO
OH
(-)-135
Palladium black (67 mg, 0.628 mmol, 20 equiv.) and sodium bicarbonate (7.9 mg, 94.2
μmol, 3 equiv.) were added to a solution of (+)-1D-2,6-bis-O-benzyl-1,3,5-tris(dibenzyl
phosphate)-4-sulfonato-myo-inositol sodium salt (+)-126 (39 mg, 31.4 μmol, 1 equiv.) in
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t-butanol (3.0 mL) and water (0.5 mL) under nitrogen. The mixture was then placed
under hydrogen and stirred for 3 h. The organic phase was decanted by pipette and
water (2 mL) added to the black residue. The palladium was removed by filtration and
the aqueous filtrate was freeze-dried to give (-)-1D-myo-inositol-1-sulfate-3,4,5-
trisphosphate tetrakis-sodium salt (-)-135 (14.8 mg, 80% yield) as a colourless solid.
20
D[α] −8.0 (c 1.3 in H2O); δH (300 MHz, D2O) 4.44 (1 H, dd, J 2.7, 2.7, inositol ring 2-H),
4.35 (1 H, ddd, J 9.4, 9.4, 9.4, inositol ring 4-H), 4.22 (1 H, dd, J 9.9, 2.7, inositol ring 1-
H), 4.06 (1 H, ddd, J, 9.9, 9.9, 2.7, inositol ring 3-H), 4.00 (1 H, ddd, J 9.2, 9.2, 9.2,
inositol ring 5-H), 3.84 (1 H, dd, J 9.5, 9.5, inositol ring 6-H); δC (75 MHz, D2O) 78.1
(CH), 77.8 (CH), 75.9 (CH), 74.3 (1 C, d 2JP-C 5.0, CH), 69.8 (1 C, d, 2JP-C 2.3, CH), 69.4
(CH); δP (121 MHz, D2O) 1.1, 0.8, 0.2; HRMS m/z (ES-) [Found: (M−3Na+2H)−
520.8933. C6H13O18NaP3S requires M− 520.8939]; m/z (ES-) 499 ([M−4Na+3H]−, 100
%); 521 ([M−3Na+2H]−, 52%).
Benzyloxycarbonylmethyl trifluoromethanesulfonate184
OBn
O
OTf
Dry pyridine (262 mg, 268 μL, 3.31 mmol, 1.1 equiv.) was added to a solution of benzyl
glycolate (500 mg, 3.31 mmol, 1.0 equiv.) in dichloromethane (12 mL) at -15 °C. Triflic
anhydride (934 mg, 557 μL, 3.31 mmol, 1.1 equiv.) was added dropwise and the mixture
stirred at -10 °C for 20 min. The temperature was raised to RT and stirred for 30 min,
after which time the reaction was adjudged to be complete by TLC analysis. The mixture
was concentrated in vacuo and the crude product was purified by silica gel column
chromatography, eluting with dichloromethane/hexane (1:1) to give
benzyloxycarbonylmethyl trifluoromethanesulfonate (590 mg, 66% yield) as an unstable,
colourless solid. Rf 0.51 (dichloromethane/hexane 1:1); δH (300 MHz, CDCl3) 7.40-7.42
(5 H, m, Ph), 5.13 (2 H, s, CH2OPh), 4.96 (2 H, s, CH2OTf); δF (375 MHz, CDCl3) −74.5.
The data are in good agreement with literature values.184
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Appendix 2 – Crystallographic Data
Crystal structure of compound 73
Crystal data and structure refinement for 73
Empirical formula C39 H52 O7 Si
Theta range for data
collection 2.16 to 25.35°.
Formula weight 660.90 Index ranges
-19<=h<=23, -
9<=k<=11, -
24<=l<=21
Temperature 93(2) K Reflections collected 25664
Wavelength 0.71073 Å Independent reflections 6536 [R(int) = 0.0707]
Crystal system Monoclinic Completeness to theta =25.35° 98.7 %
Space group P2(1)/c Absorption correction Multiscan
Unit cell dimensions
a = 19.7899(19) Å = 
90°.
b = 9.5638(9) Å = 
107.923(4)°.
c = 20.0909(19) Å  = 
90°.
Max. and min.
transmission 1.0000 and 0.9598
Volume 3618.0(6) Å3 Refinement method Full-matrix least-squares on F2
Z 4 Data / restraints /parameters 6536 / 1 / 429
Density (calculated) 1.213 Mg/m3 Goodness-of-fit on F2 1.220
Absorption
coefficient 0.113 mm
-1 Final R indices
[I>2sigma(I)]
R1 = 0.0792, wR2 =
0.1144
F(000) 1424 R indices (all data) R1 = 0.1071, wR2 =0.1215
Crystal size 0.01 x 0.01 x 0.150mm3
Largest diff. peak and
hole 0.357 and -0.279 e.Å
-3
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Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103)
for 73. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
x y z U(Eq)
C(1) 2113(2) 3191(3) 7665(2) 14(1)
O(1) 2694(1) 3934(2) 8126(1) 16(1)
C(2) 1697(2) 2440(3) 8090(2) 14(1)
O(2) 2142(1) 1404(2) 8531(1) 16(1)
C(3) 1063(2) 1710(3) 7581(2) 16(1)
O(3) 662(1) 954(2) 7966(1) 17(1)
C(4) 1274(2) 632(3) 7125(2) 15(1)
O(4) 658(1) 131(2) 6601(1) 20(1)
C(5) 1762(2) 1285(3) 6752(2) 15(1)
O(5) 2039(1) 178(2) 6430(1) 17(1)
C(6) 2385(2) 2106(3) 7246(2) 14(1)
O(6) 2746(1) 2757(2) 6809(1) 17(1)
Si(1) 2706(1) 5607(1) 8377(1) 14(1)
C(7) 1990(2) 5958(3) 8813(2) 18(1)
C(8) 2150(2) 7236(4) 9306(2) 28(1)
C(9) 1241(2) 6116(4) 8289(2) 24(1)
C(10) 3603(2) 5788(4) 9050(2) 21(1)
C(11) 3682(2) 4792(4) 9670(2) 33(1)
C(12) 4237(2) 5593(4) 8766(2) 31(1)
C(13) 2579(2) 6827(3) 7611(2) 17(1)
C(14) 2875(2) 8288(3) 7870(2) 22(1)
C(15) 2887(2) 6322(4) 7039(2) 22(1)
C(16) 2315(2) 1662(4) 9261(2) 23(1)
C(17) 2954(2) 788(4) 9645(2) 20(1)
C(18) 3475(2) 485(4) 9331(2) 20(1)
C(19) 4057(2) -329(4) 9676(2) 24(1)
C(20) 4132(2) -837(4) 10341(2) 25(1)
C(21) 3618(2) -514(4) 10658(2) 26(1)
C(22) 3030(2) 288(4) 10312(2) 21(1)
C(23) 182(2) 1710(4) 8163(2) 17(1)
O(23) 61(1) 2929(2) 8007(1) 22(1)
C(24) -172(2) 876(4) 8587(2) 17(1)
C(25) 21(2) -502(4) 8777(2) 20(1)
C(26) -322(2) -1242(4) 9177(2) 24(1)
C(27) -855(2) -610(4) 9380(2) 25(1)
C(28) -1050(2) 765(4) 9192(2) 26(1)
C(29) -713(2) 1510(4) 8794(2) 20(1)
C(30) 1932(2) 342(4) 5696(2) 20(1)
C(31) 1184(2) 55(4) 5258(2) 23(1)
C(32) 812(2) 842(4) 4736(2) 27(1)
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C(33) 3509(2) 2822(4) 7121(2) 19(1)
C(34) 3862(2) 1408(3) 7178(2) 17(1)
C(35) 3790(2) 603(4) 6589(2) 24(1)
C(36) 4119(2) -696(4) 6636(2) 31(1)
C(37) 4535(2) -1185(4) 7283(2) 32(1)
C(38) 4619(2) -386(4) 7877(2) 29(1)
C(39) 4281(2) 902(4) 7824(2) 24(1)
Bond lengths [Å] and angles [°] for 73
C(1)-O(1) 1.424(3) C(28)C(29) 1.385(5) C(9)-C(7)-Si(1) 113.5(2)
C(1)-C(6) 1.533(4) C(30)C(31) 1.496(4) C(8)-C(7)-Si(1) 113.5(2)
C(1)-C(2) 1.536(4) C(31)C(32) 1.317(5) C(11)-C(10)-C(12) 109.5(3)
O(1)-Si(1) 1.675(2) C(33)C(34) 1.511(5) C(11)-C(10)-Si(1) 111.4(2)
C(2)-O(2) 1.435(4) C(34)C(35) 1.382(5) C(12)-C(10)-Si(1) 114.7(2)
C(2)-C(3) 1.521(4) C(34)C(39) 1.393(5) C(15)-C(13)-C(14) 109.9(3)
O(2)-C(16) 1.423(4) C(35)C(36) 1.392(5) C(15)-C(13)-Si(1) 115.6(2)
C(3)-O(3) 1.458(4) C(36)C(37) 1.390(5) C(14)-C(13)-Si(1) 110.1(2)
C(3)-C(4) 1.521(4) C(37)C(38) 1.383(5) O(2)-C(16)-C(17) 109.1(3)
O(3)-C(23) 1.347(4) C(38)C(39) 1.391(5) C(22)-C(17)-C(18) 119.3(3)
C(4)-O(4) 1.425(3) O(1)-C(1)-C(6) 110.2(2) C(22)-C(17)-C(16) 120.5(3)
C(4)-C(5) 1.526(4) O(1)C-(1)-C(2) 109.6(2) C(18)-C(17)-C(16) 120.1(3)
C(5)-O(5) 1.434(4) C(6)C-(1)C-(2) 109.1(3) C(19)-C(18)-C(17) 120.4(3)
C(5)-C(6) 1.539(4) C(1)O-(1)Si-(1) 127.35(19) C(18)-C(19)-C(20) 120.3(3)
O(5)-C(30) 1.432(4) O(2)C-(2)C-(3) 108.7(3) C(19)-C(20)-C(21) 119.2(3)
C(6)-O(6) 1.434(4) O(2)C-(2)C-(1) 109.4(2) C(22)-C(21)-C(20) 120.8(3)
O(6)-C(33) 1.446(3) C(3)C-(2)C-(1) 108.3(2) C(17)-C(22)-C(21) 119.9(3)
Si(1)-C(10) 1.879(3) C(16)O-(2)C-(2) 115.1(2) O(23)-C(23)-O(3) 122.8(3)
Si(1)-C(13) 1.885(3) O(3)-C(3)C-(4) 106.2(2) O(23)-C(23)-C(24) 124.9(3)
Si(1)-C(7) 1.911(3) O(3)-C(3)C-(2) 110.0(2) O(3)-C(23)-C(24) 112.3(3)
C(7)-C(9) 1.538(4) C(4)-C(3)C-(2) 113.2(2) C(25)-C(24)-C(29) 119.9(3)
C(7)-C(8) 1.544(5) C(23)-O(3)C-(3) 116.0(2) C(25)-C(24)-C(23) 121.8(3)
C(10)-C(11) 1.536(5) O(4)-C(4)C-(3) 110.1(2) C(29)-C(24)-C(23) 118.4(3)
C(10)-C(12) 1.541(4) O(4)-C(4)C-(5) 107.5(2) C(24)-C(25)-C(26) 119.9(3)
C(13)-C(15) 1.536(4) C(3)-C(4)C-(5) 110.6(3) C(27)-C(26)-C(25) 119.9(3)
C(13)-C(14) 1.543(4) O(5)-C(5)C-(4) 107.9(3) C(26)-C(27)-C(28) 120.5(3)
C(16)-C(17) 1.513(4) O(5)-C(5)C-(6) 109.0(2) C(29)-C(28)-C(27) 120.1(3)
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C(17)-C(22) 1.387(4) C(4)-C(5)C-(6) 113.2(2) C(28)-C(29)-C(24) 119.7(3)
C(17)-C(18) 1.396(4) C(30)-O(5)C-(5) 115.3(2) O(5)-C(30)-C(31) 113.1(3)
C(18)-C(19) 1.385(5) O(6)-C(6)-C(1) 111.5(3) C(32)-C(31)-C(30) 125.0(3)
C(19)-C(20) 1.387(5) O(6)-C(6)-C(5) 106.1(2) O(6)-C(33)-C(34) 113.0(3)
C(20)-C(21) 1.390(5) C(1)-C(6)-C(5) 110.7(2) C(35)-C(34)-C(39) 118.6(3)
C(21)-C(22) 1.388(5) C(6)-O(6)-C(33) 113.8(2) C(35)-C(34)-C(33) 120.7(3)
C(23)-O(23) 1.212(4) O(1)-Si(1)-C(10) 103.16(13) C(39)-C(34)-C(33) 120.7(3)
C(23)-C(24) 1.490(4) O(1)-Si(1)-C(13) 111.06(13) C(34)-C(35)-C(36) 121.1(3)
C(24)-C(25) 1.392(5) C(10)-Si(1)-C(13) 112.94(15) C(37)-C(36)-C(35) 119.6(3)
C(24)-C(29) 1.402(4) O(1)-Si(1)-C(7) 111.19(13) C(38)-C(37)-C(36) 120.0(3)
C(25)-C(26) 1.392(5) C(10)-Si(1)-C(7) 108.89(14) C(37)-C(38)-C(39) 119.7(3)
C(26)-C(27) 1.383(5) C(13)-Si(1)-C(7) 109.47(14) C(38)-C(39)-C(34) 120.9(3)
C(27)-C(28) 1.389(5) C(9)-C(7)-C(8) 109.0(3)
Anisotropic displacement parameters (Å2x 103) for 73. The anisotropic
displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ]
U11 U22 U33 U23 U13 U12
C(1) 14(2) 13(2) 14(2) -3(1) 1(1) -2(1)
O(1) 16(1) 15(1) 18(1) -1(1) 4(1) -3(1)
C(2) 15(2) 13(2) 14(2) -2(1) 4(1) 3(1)
O(2) 21(1) 14(1) 13(1) 1(1) 3(1) 2(1)
C(3) 15(2) 18(2) 16(2) 4(1) 7(1) 1(1)
O(3) 17(1) 16(1) 21(1) -1(1) 9(1) -3(1)
C(4) 15(2) 14(2) 16(2) -1(1) 4(1) -3(1)
O(4) 18(1) 24(1) 18(1) -4(1) 6(1) -9(1)
C(5) 19(2) 12(2) 13(2) 2(1) 5(1) 4(1)
O(5) 19(1) 18(1) 14(1) -3(1) 6(1) 2(1)
C(6) 14(2) 15(2) 14(2) -1(1) 5(1) 0(1)
O(6) 14(1) 19(1) 19(1) 2(1) 8(1) -1(1)
Si(1) 15(1) 13(1) 14(1) 0(1) 4(1) -1(1)
C(7) 23(2) 13(2) 19(2) 0(1) 10(1) 0(1)
C(8) 34(2) 25(2) 29(2) -8(2) 17(2) -2(2)
C(9) 21(2) 27(2) 26(2) 1(2) 10(2) 4(2)
C(10) 20(2) 18(2) 20(2) -4(2) 0(1) -5(1)
C(11) 31(2) 40(2) 21(2) 5(2) -2(2) -2(2)
C(12) 15(2) 46(3) 28(2) 2(2) 0(1) 2(2)
C(13) 17(2) 19(2) 14(2) 0(1) 3(1) 0(1)
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C(14) 28(2) 16(2) 24(2) 0(2) 10(2) 1(2)
C(15) 29(2) 21(2) 19(2) 2(2) 9(2) 0(2)
C(16) 27(2) 26(2) 18(2) 2(2) 10(2) 5(2)
C(17) 24(2) 18(2) 16(2) 1(1) 4(1) -2(1)
C(18) 24(2) 24(2) 13(2) 1(2) 6(1) -3(2)
C(19) 19(2) 30(2) 25(2) -3(2) 7(1) -3(2)
C(20) 19(2) 23(2) 28(2) 3(2) -3(2) 0(2)
C(21) 30(2) 29(2) 19(2) 3(2) 5(2) -2(2)
C(22) 27(2) 22(2) 16(2) 0(2) 9(1) 0(2)
C(23) 14(2) 21(2) 14(2) -4(2) 2(1) -1(1)
O(23) 25(1) 18(1) 25(1) 2(1) 12(1) 3(1)
Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 73
x y z U(eq)
H(1A) 1792 3865 7335 17
H(2A) 1531 3129 8381 17
H(3A) 748 2426 7275 19
H(4A) 1522 -167 7421 18
H(4O) 423(18) -580(30) 6803(18) 48(12)
H(5A) 1477 1931 6379 18
H(6A) 2714 1443 7576 17
H(7A) 1977 5123 9108 21
H(8A) 1765 7357 9512 42
H(8B) 2188 8075 9041 42
H(8C) 2598 7085 9679 42
H(9A) 901 6296 8545 36
H(9B) 1110 5253 8017 36
H(9C) 1236 6899 7973 36
H(10A) 3634 6762 9238 25
H(11A) 4154 4910 10011 49
H(11B) 3626 3824 9501 49
H(11C) 3318 5007 9892 49
H(12A) 4682 5705 9148 47
H(12B) 4213 6294 8404 47
H(12C) 4219 4654 8565 47
H(13A) 2055 6936 7387 20
H(14A) 2805 8915 7469 33
H(14B) 3384 8215 8123 33
H(14C) 2626 8663 8184 33
H(15A) 2792 7021 6664 34
H(15B) 2665 5433 6847 34
H(15C) 3401 6190 7239 34
200
H(16A) 1907 1418 9425 27
H(16B) 2424 2666 9358 27
H(18A) 3431 839 8877 24
H(19A) 4406 -539 9456 29
H(20A) 4529 -1398 10577 30
H(21A) 3670 -846 11116 32
H(22A) 2680 494 10532 26
H(25A) 385 -937 8634 24
H(26A) -189 -2180 9310 29
H(27A) -1090 -1119 9650 30
H(28A) -1414 1194 9337 31
H(29A) -849 2448 8663 25
H(30A) 2254 -301 5554 24
H(30B) 2059 1309 5606 24
H(31A) 960 -758 5364 27
H(32A) 1017 1663 4614 32
H(32B) 338 590 4481 32
H(33A) 3619 3236 7595 23
H(33B) 3709 3447 6837 23
H(35A) 3510 941 6145 29
H(36A) 4059 -1244 6227 37
H(37A) 4762 -2070 7318 38
H(38A) 4907 -716 8319 35
H(39A) 4336 1444 8233 28
Torsion angles [°] for 73
C(6)-C(1)-O(1)-Si(1) 147.1(2) C(13)-Si(1)-C(10)-C(12) -55.7(3)
C(2)-C(1)-O(1)-Si(1) -92.8(3) C(7)-Si(1)-C(10)-C(12) -177.6(3)
O(1)-C(1)-C(2)-O(2) -64.1(3) O(1)-Si(1)-C(13)-C(15) -32.7(3)
C(6)-C(1)-C(2)-O(2) 56.7(3) C(10)-Si(1)-C(13)-C(15) 82.7(3)
O(1)-C(1)-C(2)-C(3) 177.5(2) C(7)-Si(1)-C(13)-C(15) -155.8(2)
C(6)-C(1)-C(2)-C(3) -61.7(3) O(1)-Si(1)-C(13)-C(14) -157.9(2)
C(3)-C(2)-O(2)-C(16) -127.7(3) C(10)-Si(1)-C(13)-C(14) -42.5(3)
C(1)-C(2)-O(2)-C(16) 114.3(3) C(7)-Si(1)-C(13)-C(14) 79.0(2)
O(2)-C(2)-C(3)-O(3) 59.8(3) C(2)-O(2)-C(16)-C(17) -162.0(3)
C(1)-C(2)-C(3)-O(3) 178.6(2) O(2)-C(16)-C(17)-C(22) -148.1(3)
O(2)-C(2)-C(3)-C(4) -58.7(3) O(2)-C(16)-C(17)-C(18) 32.3(4)
C(1)-C(2)-C(3)-C(4) 60.1(3) C(22)-C(17)-C(18)-C(19) 1.2(5)
C(4)-C(3)-O(3)-C(23) -152.8(2) C(16)-C(17)-C(18)-C(19) -179.2(3)
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C(2)-C(3)-O(3)-C(23) 84.4(3) C(17)-C(18)-C(19)-C(20) -0.8(5)
O(3)-C(3)-C(4)-O(4) 67.1(3) C(18)-C(19)-C(20)-C(21) -0.3(5)
C(2)-C(3)-C(4)-O(4) -172.2(2) C(19)-C(20)-C(21)-C(22) 1.0(5)
O(3)-C(3)-C(4)-C(5) -174.3(2) C(18)-C(17)-C(22)-C(21) -0.5(5)
C(2)-C(3)-C(4)-C(5) -53.5(3) C(16)-C(17)-C(22)-C(21) 180.0(3)
O(4)-C(4)-C(5)-O(5) -69.7(3) C(20)-C(21)-C(22)-C(17) -0.6(5)
C(3)-C(4)-C(5)-O(5) 170.2(2) C(3)-O(3)-C(23)-O(23) 3.3(4)
O(4)-C(4)-C(5)-C(6) 169.6(2) C(3)-O(3)-C(23)-C(24) -176.7(2)
C(3)-C(4)-C(5)-C(6) 49.4(3) O(23)-C(23)-C(24)-C(25) -176.6(3)
C(4)-C(5)-O(5)-C(30) 125.8(3) O(3)-C(23)-C(24)-C(25) 3.4(4)
C(6)-C(5)-O(5)-C(30) -110.9(3) O(23)-C(23)-C(24)-C(29) 3.5(5)
O(1)-C(1)-C(6)-O(6) -62.7(3) O(3)-C(23)-C(24)-C(29) -176.5(3)
C(2)-C(1)-C(6)-O(6) 176.9(2) C(29)-C(24)-C(25)-C(26) -0.4(5)
O(1)-C(1)-C(6)-C(5) 179.4(2) C(23)-C(24)-C(25)-C(26) 179.6(3)
C(2)-C(1)-C(6)-C(5) 59.0(3) C(24)-C(25)-C(26)-C(27) 0.4(5)
O(5)-C(5)-C(6)-O(6) 65.4(3) C(25)-C(26)-C(27)-C(28) -0.5(5)
C(4)-C(5)-C(6)-O(6) -174.5(2) C(26)-C(27)-C(28)-C(29) 0.5(5)
O(5)-C(5)-C(6)-C(1) -173.4(2) C(27)-C(28)-C(29)-C(24) -0.5(5)
C(4)-C(5)-C(6)-C(1) -53.4(3) C(25)-C(24)-C(29)-C(28) 0.5(5)
C(1)-C(6)-O(6)-C(33) 95.4(3) C(23)-C(24)-C(29)-C(28) -179.6(3)
C(5)-C(6)-O(6)-C(33) -144.0(2) C(5)-O(5)C-(30)-C(31) -75.2(3)
C(1)-O(1)-Si(1)-C(10) 174.1(2) O(5)-C(30)-C(31)-C(32) 134.4(3)
C(1)-O(1)-Si(1)-C(13) -64.6(3) C(6)-O(6)-C(33)-C(34) 70.1(3)
C(1)-O(1)-Si(1)-C(7) 57.6(3) O(6)-C(33)-C(34)-C(35) 58.4(4)
O(1)Si(1)C(7)C(9) -78.0(3) O(6)-C(33)-C(34)-C(39) -123.0(3)
C(10)-Si(1)-C(7)-C(9) 169.0(2) C(39)-C(34)-C(35)-C(36) 0.7(5)
C(13)-Si(1)-C(7)-C(9) 45.1(3) C(33)-C(34)-C(35)-C(36) 179.4(3)
O(1)-Si(1)-C(7)-C(8) 156.8(2) C(34)-C(35)-C(36)-C(37) -0.8(5)
C(10)-Si(1)-C(7)-C(8) 43.8(3) C(35)-C(36)-C(37)C(38) 0.2(5)
C(13)-Si(1)-C(7)-C(8) -80.1(3) C(36)-C(37)-C(38)-C(39) 0.5(5)
O(1)-Si(1)-C(10)-C(11) -60.8(3) C(37)-C(38)-C(39)-C(34) -0.6(5)
C(13)-Si(1)-C(10)-C(11) 179.2(2) C(35)-C(34)-C(39)-C(38) 0.0(5)
C(7)-Si(1)-C(10)-C(11) 57.4(3) C(33)-C(34)-C(39)-C(38) -178.7(3)
O(1)-Si(1)-C(10)-C(12) 64.2(3)
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Hydrogen bonds for 73 [Å and °]
D-H...A d(D-H) d(H...A) d(D...A) <(DHA)
O(4)-H(4O)...O(23)#1 0.9799(10) 1.823(9) 2.788(3) 168(3)
Symmetry transformations used to generate equivalent atoms: #1 -x,y-1/2,-z+3/2
